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Introduction
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I. Malawi
Malawi (Figure 1) is a small land-locked country in south-eastern Africa. It is one of the most 
densely populated countries in the area and the population has grown steadily to more than 13 
million in 2005. The capital Lilongwe is located in the Central Region, while the largest city Blan-
tyre is the commercial center and is situated in the Southern Region. It has a subtropical climate. 
Malawi became independent in 1963 after having been a British colony since 1891. A multi-party 
democracy was established in 1993. Malawi is amongst the poorest countries in Africa and the 
world. The gross domestic product per capita is less than 600 USD per year [Wickipedia]. Sixty-
five percent of the population lives below the poverty line on less than 1 USD per day. Episodes of 
food insecurity are common. Women are more affected by poverty than men, and more than 50% 
of women in Malawi are illiterate [1]. The economy is dependent on agriculture; the most important 
crops are tobacco, tea and sugar.
II. Health, health care and HIV/AIDS in Malawi
The public health in Malawi is far from satisfactory. Health indicators such as the infant, under-five, 
and maternal mortality rates are among the worst in the world (Table 1). This may be explained 
by poverty, the long-term poor state of the health care infrastructure and the HIV/AIDS epidemic; 
these factors are interwoven and negatively impact on each other. The public expenditure on health 
per capita is only 11 USD per annum and there is a profound human resource crisis in the health 
care sector. The life expectancy at birth of a Malawian has dropped to 36.3 years, mainly as a result 
of the HIV/AIDS epidemic [2]. Forty-six percent of the population is under the age of 15 years [3]. 
The first case of AIDS in Malawi was diagnosed in 1985 and the number of HIV infected persons 
rose steeply until halfway through the 1990s, after which the HIV prevalence gradually stabilized 
to around 14% in adults. The total number of HIV infected persons is estimated to be 900,000. 
Around eight percent are children and seven percent are adults over 50 years [1]. The number of 
deaths per year from AIDS is estimated to be 70,000. The HIV prevalence is higher among women, 
in urban areas, and in the Southern Region. It is very high in the area in and around Blantyre.
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Figure 1. Map of Malawi
(www.sas.upenn.edu)
Table 1. Selected Health Indicators (1999-2003)
Infant mortality rate per 1,000 live births  104
Under-five mortality rate per 1,000 live births  189
Life expectancy at birth (years) 36,3 
Crude birth rate per 1,000 population  46
Population growth rate  1.9
Maternal mortality rate/100,000 live births  1,120
Antenatal care coverage (%)  91,4
Attendance at birth by trained personnel (%) 55
Low birth weight babies (%) 13,1
Children < 5 years chronically malnourished (%)  49
Children 12-23 months fully immunized (%) 70
Immunization BCG (%) 89.2
Immunization measles (%) 64.2
Population per physician  101,000
Public health expenditure (USD/capita /annum)  11
Adapted from ref 1
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III. Study sites: Queen Elizabeth Central Hospital and Ndirande Health Cen-
ter in Blantyre
Ndirande Health Center is situated in a large township on the outskirts of Blantyre. The popula-
tion of Ndirande is not exactly known, but approximates 100,000 inhabitants of different ethnic 
backgrounds. This shanty town has a vibrant small-scale business community, much of the busi-
ness takes place in a huge market area. In 2000-2001 a clinical research facility was developed on 
the premises of Ndirande Health Center that contained a Voluntary HIV Counseling and Testing 
Center. The studies of chapters 2 to 5 were based in this research facility.
The remainder of the studies were performed in Queen Elizabeth Central Hospital, a government 
hospital located in the center of Blantyre with around 1200 beds. It is the only public hospital that 
offers free medical care in Blantyre and although it should function as a tertiary center it mainly 
provides primary and secondary health care. The medical wards of QECH admit around 10,000 
patients per year, the bed occupancy rate is greater than 100 percent and 75 percent of the adult 
patients admitted in the medical wards are HIV infected. QECH is the teaching hospital of the Col-
lege of Medicine of the University of Malawi, the only medical school in the country; the clinical 
departments of the College of Medicine are based in the hospital and provide most of the specialist 
staff for in-patient and out-patient medical care.
Thesis outline
I. In the first part of this thesis (chapters 2 to 6) we present descriptive studies of aspects of the 
natural history of HIV infection. These studies were done when antiretroviral therapy was not 
accessible to most patients in the Blantyre area due to the prohibitive costs. At the same time 
trimethoprim-sulfamethoxazole (TS) prophylaxis had not yet been introduced, because of concerns 
about low benefit and potential disadvantages in Malawi. Hardly any of the patients enrolled in 
these studies were therefore receiving antiretroviral therapy or TS prophylaxis.
In chapter two we addressed the question of the potential impact of TS prophylaxis in HIV infected 
persons in Malawi and the bacterial resistance among pathogenic bacterial strains cultured during 
disease episodes in this population. To this effect we conducted a large community based cohort 
study in a township of Blantyre. This would enable us to describe the natural history of HIV infec-
tion in Malawi in detail. 
In chapter three we investigated the incidence and clinical aspects of Pneumocystis jiroveci pneu-
monia (PcP) in an attempt to resolve the debate about whether or not PcP is less common in Afri-
cans than in HIV infected persons in western settings, where it had been the most common oppor-
tunistic infection in patients with AIDS.
We studied the association of malaria with HIV associated immune suppression in chapter four 
using the comprehensive information we obtained concerning all febrile episodes to distinguish 
malaria from other HIV related infections and the outcome of the management of these episodes. 
To investigate the association between the efficacy of malaria treatment with SP and HIV associ-
ated immune suppression in chapter five we used the CD4 counts recorded at regular intervals 
during follow-up, and the outcome of the malaria episodes.
In chapter six we studied an aspect of tuberculosis, probably the most important HIV related 
infection in sub-Saharan Africa. We investigated the hypothesis that adrenal insufficiency, caused 
by tuberculosis and/or HIV and exacerbated by rifampicin treatment, contributes to the very high 
case-fatality rate of tuberculosis. 
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II. In the second part of the thesis (chapters 7 to 14) we present studies concerning antiretroviral 
therapy. The character of the studies is mostly descriptive and operational and focuses on experi-
ence in the antiretroviral therapy clinic of Queen Elizabeth Central Hospital in Blantyre. Initially 
ART was restricted to few who could afford it but in 2004 an ambitious nation-wide scale-up cam-
paign of free ART started.
In chapter seven we evaluated the results of the fee paying ART clinic in QECH, which had started 
operating in 2000, looking at retention in care, virological and immunological results, adherence 
and nevirapine drug levels. At the time of this cross sectional study study (2003) hardly any data 
were available concerning antiretroviral therapy in Malawi.
 
In chapter eight we wanted to document a history of antiretroviral therapy in QECH from 2000 to 
2007 to demonstrate the major achievements of the Malawi ART scale-up programme since 2004 
and to discuss future challenges.
Chapter nine we studied a small group of patients in detail who started ART shortly after treat-
ment for pulmonary tuberculosis was initiated. In preparation for a large trial of the timing of ART 
during tuberculosis treatment we wanted to provide information about side effects, drug interac-
tions between nevirapine and rifampicin, adherence and immune reconstitution disease of the two 
treatments in combination.
Early mortality during ART is emerging as one of the main challenges of ART in sub-Saharan 
Africa and because a low body mass is an independent risk factor, food supplementation is widely 
used; in Malawi food supplementation for wasted persons with HIV infection has become standard 
of care. There is however no evidence base for this policy in adults. In chapter ten we wanted to 
compare two different food supplements and their effect on nutritional recovery, mortality and 
severe morbidity, immune reconstitution, adherence to ART and quality of life in wasted adults 
starting ART. A control group was not included in this clinical trial. In chapter eleven we therefore 
compared data from chapter ten with those from a cohort study done earlier at the ART clinic of 
QECH serving as a historical control group without food supplementation. 
In chapter twelve we audited the provision of post exposure prophylaxis (PEP) for HIV after occu-
pational injuries in QECH from 2003 to 2005, and conducted interviews with nurses to investigate 
the incidence and nature of their occupational injuries.
Efforts to make expensive laboratory tests for monitoring of ART more accessible in resource poor 
settings are increasing. In chapter thirteen we studied whether fingertip blood samples could be 
used instead of venous blood samples for CD4 count measurements.
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Abstract 
The benefits of trimethoprim-sulfamethoxazole (TS) prophylaxis reported for persons living with 
HIV in Cote D’Ivoire are difficult to extrapolate to sub-Saharan countries, where bacterial resis-
tance to TS is higher and where cross-resistance between TS and sulfadoxine-pyrimethamine (SP) 
may impair SP efficacy for malaria treatment. We conducted a community based cohort study to 
measure the incidence of potentially TS preventable illnesses in Blantyre, Malawi. We found a 
high incidence of malaria, invasive bacterial infections and probable bacterial pneumonias but low 
rates of PcP, isosporiasis, and Toxoplasma encephalitis. Most bacterial isolates were resistant to TS 
but sensitive to azithromycin, a possible alternative to TS. Clinical trials are needed to determine 
the role of TS or alternative regimens for prophylaxis against secondary infections among people 
living with HIV in sub-Saharan Africa. These should also assess benefit in patients receiving anti-
retroviral therapy.
080356 Oosterhout BW.indd   18 11-11-2008   15:48:41
19
Introduction
Two randomized controlled trials in HIV-infected adults in Abidjan, Cote D’Ivoire, provided evi-
dence of benefit from trimethoprim-sulfamethoxazole (TS) prophylaxis. In one study, TS pro-
phylaxis reduced the incidence of serious adverse events in persons with WHO stage II or III of 
HIV disease, including pneumonia, isosporiasis, malaria, and acute unexplained fever, but did 
not significantly reduce mortality [1]. In a second study, TS prophylaxis in HIV-positive patients 
co-infected with tuberculosis reduced mortality by 46% as well as reducing hospital admission 
rates, particularly for enteritis, non-typhoidal Salmonella (NTS) sepsis and isosporiasis [2]. The 
incidences of Pneumocystis jiroveci pneumonia (PcP) and Toxoplasma encephalitis (TE) were low 
in both studies, with the exception of TE in the group with CD4 counts below 100/mm3. Based on 
these two studies, WHO and UNAIDS made a provisional recommendation of TS prophylaxis for 
all HIV-infected adults and children in Africa who are symptomatic, or asymptomatic with a CD4 
cell count below 500/mm3, as well as for all infants born to HIV-infected mothers [3].
These recommendations have not been widely implemented throughout the region for a number of 
reasons. There are logistical and financial barriers to their introduction in resource-poor settings, 
and the potential drawbacks of TS prophylaxis have not been adequately assessed. Concerns have 
been raised that the prophylactic efficacy of TS may be lower elsewhere in sub-Saharan Africa than 
was reported in Cote D’Ivoire because of much higher levels of bacterial resistance to TS [4, 5]. 
An additional concern is that widespread TS prophylaxis may accelerate the development of malaria 
parasites resistant to antifolate anti-malarial drugs, such as sulfadoxine-pyrimethamine (SP). High 
rates of chloroquine failure have led several African countries to move to SP as the first-line anti-
malarial drug, and in 1993 Malawi became the first African country to make this change. We 
have recently shown that SP retains about 80% clinical efficacy against Plasmodium falciparum in 
Malawi [6]. In vitro studies have demonstrated evidence of P. falciparum cross-resistance between 
trimethoprim and pyrimethamine (conferred by mutations in Plasmodium falciparum dihydrofo-
late reductase [DHFR]) and between sulfamethoxazole and sulphadoxine (conferred by mutations 
in dihydropteroate synthase [DHPS]) [7, 8]. TS prophylaxis may therefore increase the spread of 
SP resistance in populations. If individuals on TS prophylaxis develop malaria, the risk SP resistant 
parasites may be higher. Due to these concerns, health policymakers in Malawi do not recommend 
routine TS prophylaxis for HIV-infected individuals, and have called for further research into the 
risks and benefits of TS prophylaxis. 
Little is known about the disease burden of TS-preventable infections and the associated antibiotic 
resistance patterns in persons living with HIV in Malawi and other settings with relatively high 
rates of bacterial resistance to TS. One non-randomized study reported a mortality benefit for TS 
prophylaxis, but the comparison group had significantly higher CD4 cell counts and less advanced 
HIV disease than the prophylaxis group [9]. Another study using historical controls observed lower 
mortality among Malawian tuberculosis patients offered voluntary counseling and testing for HIV 
and TS prophylaxis [10]. One prospective, controlled trial did not show benefit from TS prophylaxis 
in Malawian adults with tuberculosis and symptomatic AIDS, but this trial was stopped prema-
turely after results from the Cote D’Ivoire studies were presented [11]. 
To assess the potential role of TS prophylaxis for people living with HIV in Malawi, we con-
ducted a prospective, observational cohort study in Blantyre, the commercial center of the country. 
Outcomes of interest were the incidence of severe events (hospitalizations and deaths) and the 
incidence of clinical illness episodes that could potentially be prevented by TS prophylaxis: bacte-
remia/sepsis, isosporiasis, bacterial enteritis, bacterial pneumonia, PcP, otitis media, sinusitis, bac-
terial meningitis, Toxoplasma encephalitis, urinary tract infection, skin and soft tissue infections, 
and malaria. We determined the prevalence of TS resistance in bacterial isolates and the in vivo 
efficacy of SP for treating falciparum malaria.




The study was conducted at Ndirande Health Centre, which is situated in a large township on 
the outskirts of Blantyre, from September 2002 through December 2003. Approximately 100,000 
inhabitants of various Malawian ethnic backgrounds populate the township. Other than private 
dispensaries and traditional medical practitioners, the Health Centre is the only source of medical 
care serving this relatively poor population. At the time of this study, anti-retroviral drugs were 
not readily available in Malawi. The study staff provided basic medical care at the health center; 
patients needing hospitalization were referred to the Queen Elizabeth Central Hospital, a large pub-
lic teaching hospital in Blantyre, affiliated with the University of Malawi College of Medicine. 
Study subjects
Following voluntary HIV counseling and testing (VCT) at the Ndirande Health Centre, informed 
consent was sought from any HIV infected person aged 16 years or older if they were willing to 
have their HIV test results disclosed to study investigators and intended to remain in the study area 
for at least 8 months. Chronic prophylaxis and treatment with anti-folate drugs were the only exclu-
sion criteria. A full history and physical examination were carried out on recruitment, with staging 
of HIV infection and AIDS according to WHO classifications [12]. Clinical evaluations were per-
formed at scheduled monthly follow up visits. Participants were encouraged to report to the clinic 
whenever they developed symptoms. If they missed a monthly appointment, study nurses actively 
traced them at work or home. If they did not attend on two consecutive scheduled visits, they were 
considered lost to follow up.
Laboratory investigations
Determine HIV rapid diagnostic strips (Abbott Laboratories, Abbott Park IL) and UniGold (Trin-
ity Biotech, Wicklow, Ireland) were used for HIV testing. Discrepancies were resolved by a third 
rapid test (Hemostrip HIV, Saliva Diagnostics, Vancouver, WA). On recruitment, a CD4 and CD8 
count (FacsCount, Becton-Dickinson), measurements of hemoglobin concentrations (HemoCue, 
HemoCue AB, Angelholm, Sweden), IgG antibody titers against Toxoplasma (Captia Toxoplasma 
gondii IgG, Trinity Biotech, Ireland) and blood films for malaria (thick and thin films, stained with 
Fields stain) were conducted. CD4 and CD8 counts were repeated every four months, to help guide 
diagnostic evaluations for opportunistic infections associated with specific CD4 count ranges. 
Hemoglobin concentration and blood films for malaria were repeated monthly. Blood for aerobic 
bacterial culture (BacT/Alert 3D, BioMerieux) and malaria smears was obtained for all febrile epi-
sodes. All pathogens recovered by culture of blood, cerebrospinal fluid or pus were tested for anti-
microbial susceptibility by the Standardized Disc Diffusion Testing Method [13]. SP therapeutic 
efficacy was assessed in patients with uncomplicated falciparum malaria according to a standard 
WHO protocol [14]. Sputum induction by ultrasonic nebulizer was performed and immunofluo-
rescent staining for Pneumocystis jiroveci cysts was done for suspected cases of PcP. Nested PCR 
for P. jiroveci was performed on sputum samples from the probable PcP cases (those with clini-
cal suspicion and good response to PcP treatment, but with negative immunofluorescence stain-
ing of induced sputum samples) [15]. Stool examinations were performed with epifluorescence 
microscopy for Isospora belli, auramine staining for Isospora belli and Cryptosporidium species 
oocysts, and modified Ziehl-Neelsen stains for Cryptosporidium species and Isospora belli oocysts 
[16,17,18]. Other diagnostic tests were performed, including basic biochemistry, hematological, 
microbiological and radiological investigations.
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Clinical diagnoses
Detailed, standardized case definitions and diagnostic and treatment guidelines were designed 
for this study and followed by study clinicians at the Ndirande Health Centre and in Queen 
Elizabeth Central Hospital. A chest x-ray consistent with pneumonia was required for diagno-
ses of bacterial pneumonia. Diagnoses of confirmed bacterial pneumonia, confirmed bacterial 
enteritis and bacteremia/sepsis were assigned when pathogenic bacteria were isolated from the 
blood culture. A diagnosis of PcP was considered in patients on the basis of a consistent clini-
cal picture, a chest X-ray, a positive 02 saturation exercise test [19] and a recent CD4 count 
<200/mm3. Each case was reviewed by one of the senior clinicians. The diagnosis of Toxo-
plasma encephalitis was considered in any patient with new onset convulsions, focal neurologi-
cal deficits, lowered consciousness or signs of raised intracranial pressure, who had a positive 
Toxoplasma IgG and for whose illness there was no other identifiable explanation. Support-
ive evidence included a low CD4 count (<200/mm3), compatible findings on a CT scan with 
contrast of the brain (when available) and a clinical response to toxoplasmosis treatment. 
Ethical review
This study was approved by the Institutional Review Boards of the University of Malawi 
College of Medicine, the University of Maryland, and the Michigan State University and 
the study was conducted in accordance with the ethical standards of these review commit-
tees and the Helsinki Declaration of 1975, as revised in 1983. Written informed consent 
was obtained from all participants in their preferred language (Chichewa or English).
Statistical considerations
For each event, an incidence rate of all episodes during the study period (including first and follow-
ing episodes in one individual) per person-year of follow-up was calculated with 95% confidence 
intervals based on Poisson distribution. The incidence rates of severe events were stratified by CD4 
count and WHO clinical HIV stage. 
Results
4,739 persons underwent VCT, of whom 1,267 (27%) were found to be HIV-1 seropositive. 660 
participants were enrolled in the study and accumulated 4,082 person-months of follow-up. The 
majority was female (66 %). This proportions was consistent with that observed in the population 
presenting for VCT (data not shown). One hundred fifty-five patients (24 %) were withdrawn from 
the study (48 migrated, 17 withdrew consent, 17 started TS prophylaxis elsewhere and 73 were lost 
to follow-up), and 52 participants died during the follow-up period. Data collected prior to death or 
withdrawal were included in the analysis.
On enrollment, 284 of the subjects (43 %) had a CD4 count below 200/mm3 and 156 (24 %) had a 
WHO clinical stage of III or IV (Table 1). 
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Table 2. The incidence of HIV-related events and potentially TS preventable infections (indicated 
by bold type).
 Diagnosis No. of Events  (in no. of patients)
Incidence Rates
/ 100 person-years
 Acute fever of unknown origin 89  (80) 26.2
 Bacteremia / sepsis 55  (48) 16.2
 Uncomplicated malaria 115  (89) 33.8
 Severe malaria 1   (1) 0.3
  
 Confirmed PCP 1  (1) 0.3
 Probable PCP 4  (4) 1.2
 Confirmed bacterial pneumonia 13  (12) 3.8
 Probable bacterial pneumonia 56  (43) 16.5
 Unspecified respiratory illness 99  (81) 29.1
 Pulmonary tuberculosis 41  (38) 12.1
 Extra-pulmonary tuberculosis 11  (11) 3.2
  
 Probable bacterial acute otitis 27  (24) 7.9
 Probable bacterial sinusitis 2  (2) 0.6
  
 Confirmed bacterial meningitis 1  (1) 0.3
 Probable bacterial meningitis 1  (1) 0.3
 Confirmed cryptococcal meningitis 5  (4) 1.5
 Probable tuberculous meningitis 3  (3) 0.9
 Toxoplasma encephalitis 0  (0) 0.0
  
 Non-specific diarrhea 126 (92) 37.0
 Confirmed bacterial enteritis 3   (3) 0.9
 Isosporiasis 1   (1) 0.3
 Other confirmed parasitic enteritis 25  (21) 7.3
 Probable bacterial dysentery 15  (15) 4.4
 Probable bacterial enteritis 21  (21) 6.2
  
 Probable lower urinary tract infection 39  (29) 11.5
 Probable upper urinary tract infection 3  (3) 0.9
  
 Soft tissue abscess 29  (25) 8.5
  
 Urethral discharge (men) 13  (10) 3.8
 Vaginal discharge – cervicitis 19  (17) 5.6
 Vaginal discharge - no cervicitis 15  (14) 4.4
 Genital ulcers 39  (32) 11.5
  
 Oral candidiasis 125 (82) 36.7
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 Oesophageal candidiasis 12  (10) 3.5
  
 Kaposi’s sarcoma 13  (13) 5.0
 Non Hodgkin Lymphoma 3  (3) 0.9
  
 Herpes zoster (shingles) 25 (22) 7.3
































































There were 260 severe events (208 hospitalizations, 52 deaths), and the associated incidence rate 
was 76 per 100 person years of follow-up. Severe events correlated with the initial WHO clinical 
stage and CD4 count (Table 1). Only 34 persons (5 %) received antiretroviral therapy (ART) at any 
time during the study period, as this was only available in the Blantyre area at a price that was 
prohibitive for most participants. The incidence of potentially TS preventable infections and the 
incidence rates of other HIV related events are shown in Table 2. 
Severe and invasive bacterial infections were common. The bacteria cultured most often were non-
typhoidal salmonellae and Streptococcus pneumoniae (Table 3), and rates of in vitro resistance to 
TS (Figure 1) were high. 
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Figure 1.  In vitro resistance of cultured bacterial isolates to trimethoprim-sulfamethoxazole and 
azithromycin. NTS, non-typhoidal Salmonella; GNR, other gram-negative rods; S. 
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There were 57 episodes that were clinically suspicious for PcP, and induced sputum samples were 
collected and analyzed. In one case, who died despite being treated with TS and prednisolone, 
P. jiroveci cysts were detected using immunofluorescent staining. An additional four patients 
were treated for PcP on clinical grounds, despite negative stains of induced sputum samples, and 
improved. Subsequent nested PCR testing for P. jiroveci was negative for these patients, making 
the diagnosis of PcP doubtful.
The overall seroprevalence of Toxoplasma in this patient population was 28 %. We suspected Toxo-
plasma encephalitis in two individuals with unexplained focal neurological deficits, but the diag-
noses were rejected because of negative Toxoplasma IgG titers and normal CT scans of the brain. 
The majority (74 %) of cases of non-specific diarrhea were acute, self-limited episodes. Among the 
confirmed cases of parasitic enteritis were giardiasis (n=14), strongyloidiasis (n=6), cryptosporidi-
osis (n=1), and isosporiasis (n=1). 
SP therapeutic efficacy was assessed in 73 clinical episodes of uncomplicated falciparum malaria. 
Fifty-three (73 %) completed the therapeutic efficacy study. Seventy-seven percent had an adequate 
clinical response to SP and early and late treatment failures occurred in 17 % and 6 % of the popula-
tion, respectively. One patient was hospitalized because of hyperparasitemia (>10% of circulating 
erythrocytes infected), but none met other criteria for severe malaria [20]. 
Discussion
This study represents a comprehensive evaluation of opportunistic infections and other AIDS-
related syndromes affecting a large population of persons living with HIV in sub-Saharan Africa. 
Malaria was the most commonly diagnosed illness, highlighting both the vulnerability of this pop-
ulation to any decrease in anti-malarial drug efficacy and the potential benefit of a prophylactic 
regimen that prevents malaria. The therapeutic efficacy of SP for the treatment of malaria in our 
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cohort was 77%, slightly lower than that recently reported for children at Ndirande Health Centre 
during the period of 1998 through 2002 [6]. In Malawi, where most P. falciparum infections carry 
multiple resistance-conferring DHFR and DHPS mutations [21], TS would be likely to select for 
the most highly resistant parasites, increasing the individual risk of SP treatment failure and the 
overall rate of antifolate-resistant malaria in the population. In addition to impairing SP efficacy, 
widespread TS prophylaxis may threaten the efficacy of chlorproguanil-dapsone, a new, inexpen-
sive, and effective antifolate anti-malarial [22]. Clinical trials of the impact of TS prophylaxis on SP 
efficacy are needed. If it is shown to impair SP efficacy, alternative anti-malaria therapy will need 
to be made available to persons taking TS prophylaxis.
Seventy-six percent of all the cultured pathogenic bacteria were resistant to TS. In the most serious 
infections, with positive blood cultures, the rate of TS resistance was even higher. Our community-
based resistance results are comparable to those found in studies from the tertiary level hospital in 
Blantyre [23]. While these data raise concerns about the efficacy of TS for prophylaxis of bacterial 
infections in HIV infected persons in Malawi, it is possible that the in vivo efficacy of TS in pre-
venting infection may not be accurately reflected in the in vitro susceptibility results. 
Experience in Cote D’Ivoire after the introduction of TS prophylaxis indicates that despite increas-
ing bacterial resistance, TS seemed to maintain its prophylactic efficacy [24]. In a recent report 
from Uganda, morbidity and mortality decreased in a cohort of adults with HIV infection after they 
began TS prophylaxis, despite bacterial resistance to TS that was higher than in the Cote d’Ivoire 
studies but generally lower than we report here [25].
Many clinical events could not be precisely diagnosed: episodes of non-specific diarrhea unspeci-
fied respiratory illnesses and acute fevers of unknown etiology were all common. These episodes 
generally resolved spontaneously or after empirical therapy with antibiotics not active against PcP, 
and reflect a variety of viral and unidentified bacterial infections and other syndromes. Acute fever 
of unknown etiology and non-specific diarrhea were among the events that appeared to be pre-
vented by TS prophylaxis in the Cote D’Ivoire studies [1, 2]. 
PcP is now recognized as a common problem in African children under the age of one year [26]. 
The situation in adults is uncertain: the reported incidence of PcP in African adult populations var-
ies greatly [27]. The unavailability of broncho-alveolar lavage could have resulted in underestimat-
ing the true incidence of PcP in our study. The sensitivity of induced sputum samples compared 
to broncho-alveolar lavage is reported to be 67 % [28]. Thus, even with a conservative estimate of 
50% sensitivity, the incidence of PcP would still be low in our cohort. 
We diagnosed no cases of Toxoplasma encephalitis, consistent with the low incidence rates found 
in most other African studies [29]. The incidence of Isospora belli infection was also low in this 
community-based cohort, in contrast to earlier data generated from selected patient groups in ter-
tiary hospitals [30, 31]. 
Are there other antibiotics that might offer better prophylactic efficacy than TS without compromis-
ing SP resistance? Azithromycin, a macrolide antibiotic drug, is available in generic formulations, 
safe and well tolerated in AIDS patients [32], active against PcP, Toxoplasma [33] and Salmonella 
typhi [34] and effective as malaria prophylaxis [35]. In our study, azithromycin had good in vitro 
activity against the gram-positive organisms, Salmonella and other gram-negative rods, with an 
overall sensitivity of 73 %. This in vitro activity may underestimate the in vivo efficacy for intra-
cellular pathogens such as Salmonella species, because the drug achieves levels up to 100 times 
serum levels in phagocytes [36]. It acts outside of the folate pathway, and is therefore not expected 
to interfere with the therapeutic efficacy of SP. An important concern is that widespread use of 
azithromycin would accelerate the development of bacterial resistance to macrolide drugs [37], 
including erythromycin, which is frequently prescribed for respiratory illnesses in Malawi. 
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Many countries in sub-Saharan Africa have started antiretroviral treatment (ART) programs and 
are preparing to treat large numbers of patients. The benefits and risks of TS prophylaxis need to 
be assessed in persons receiving ART, with careful attention to potential impact on adherence and 
the ability to assess side effects common to both interventions. 
With increasingly clear evidence for the benefit of TS even in areas with relatively high bacterial 
resistance [25,38] the question of the impact of TS prophylaxis on SP efficacy for treating malaria 
needs to be settled definitively.
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Abstract
In a prospective study of 660 HIV-positive Malawian adults, we diagnosed Pneumocystis jirovecii 
pneumonia (PcP) using clinical features, induced sputum for immunofluorescent staining, real-
time PCR, and post-treatment follow up. PcP incidence was highest in patients with the lowest CD4 
counts, but PcP is uncommon compared with incidences of pulmonary tuberculosis and bacterial 
pneumonia.
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Introduction
The incidence of Pneumocystis jirovecii pneumonia (PcP) in HIV-infected adults in the sub-Saha-
ran African region remains uncertain. That PcP is common in African children <1 year of age is 
well documented (1), but reported prevalence and incidence rates in adult African populations vary 
widely (2). Many of these reports were cross-sectional studies in selected populations from tertiary 
hospitals (3–5), and therefore might contain selection bias that favors identifying higher rates of 
PcP.
To our knowledge, no large prospective studies have been done by using broncho-alveolar lavage 
(BAL) in combination with immunofluorescent (IF) staining for P.jirovecii cysts, the diagnostic 
procedures of choice. Real-time PCR performed on sputum samples has high sensitivity but low 
specificity for PcP (6,7). The few studies in African adults that used PCR assays for Pneumocystis 
did not distinguish sub-clinical colonization from infection, mainly because of limited follow-up 
after diagnosis (3,4).
We describe here the incidence of PcP from a large cohort study of HIV-infected Malawian adults 
that used a comprehensive diagnostic approach that included induced sputum with IF staining, real-
time PCR, and follow-up after diagnosis and treatment.
The Study
HIV-infected adults (>15 years of age), who sought treatment at a government health center in the 
township of Ndirande, Blantyre, Malawi, were enrolled in a prospective, community-based study 
to determine the incidence of infections that were preventable by trimethoprim-sulfamethoxazole 
prophylaxis (8). Clinical evaluations were performed monthly and at sick visits occurring between 
the scheduled monthly evaluations. CD4 counts were determined every 4 months. Standardized 
diagnostic and treatment guidelines and case definitions were used. At the time of the study, in 
Malawi, antiretroviral therapy (ART) was rarely used, and trimethoprim-sulfamethoxazole pro-
phylaxis was not recommended.
Cases of suspected PcP were identified by patients’ clinical signs and symptoms, chest x-ray results, 
oxygen desaturation exercise test results (9), CD4 count, and failure to improve with antimicrobial 
treatment without activity against P. jirovecii. Patients’ sputum production was induced by an 
ultrasonic nebulizer with hypertonic saline, followed by IF staining for P. jirovecii cysts. A case 
was classified as clinical PcP when the IF staining for P. jirovecii cysts was positive or the partici-
pant had strong clinical evidence of PcP and negative IF. Clinical follow up data were collected 
after the episode of suspected PcP.
After the study, real-time PCR for the P. jirovecii dihydropteroate synthase and human RNAase P 
(control DNA) was performed on DNA extracted from the stored induced sputum slides (10). Clini-
cians were not aware of the PCR results during the study, and laboratory staff performing the PCR 
was blinded to clinical information and IF results. A final diagnosis of confirmed PcP was made 
for any episode with a positive IF result, positive PCR result, or both, unless recovery (defined as 
resolution of respiratory symptoms present at the start of the episode) without PcP treatment was 
observed with a minimum of 4 weeks of follow-up. If the PCR results were positive but the patient 
recovered without active treatment against PcP, the result was interpreted as Pneumocystis coloni-
zation. A negative PCR result ruled out PcP diagnosis in patients who had received PcP treatment 
on the basis of clinical evidence alone.
Incidence rates of respiratory diagnoses per 100 person-years of follow-up were calculated with 
95% confidence intervals (CI’s) based on Poisson distribution. First and subsequent episodes in the 
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same person were counted separately, except for PcP, because patients with PcP received secondary 
prophylaxis and exited the study. The CD4 count at the time of the episode or within the previous 6 
months was used for analysis. We used Χ2, Mann-Whitney, and Student t tests for analysis of age, 
sex, and CD4 counts among diagnoses, respectively, using SPSS version 12 software (SPSS Inc., 
Chicago, IL, USA). The study was approved by the Institutional Review Boards of the University 
of Malawi College of Medicine, the University of Maryland, and Michigan State University.
Results
Beginning in September 2002, 660 adults were enrolled in the study and followed up through 
August 2004. Baseline CD4 and World Health Organization stage data are shown in Table 1. Mean 
age was 31.7 years (range 16–66); 437 (66%) were female. Mean duration of follow up was 10.7 
months (95% CI 10.4–11.5) per person. Eighty-six (13%) participants died, and 37 (6%) were with-
drawn from the study because they started lifelong trimethoprim-sulfamethoxazole prophylaxis. 
Sixty-three participants (9.5%) left the area, 20 (3%) withdrew consent, and 119 (17%) were lost to 
follow up. 
A smaller proportion of patients from the lower CD4 strata exited the study than from the higher 
CD4 content group.
Ninety-five episodes of suspected PcP occurred in 75 persons. Outcomes of these episodes are 
given in Table 2. A final diagnosis of confirmed PcP was made in 6 episodes, and 9 episodes of 
Pneumocystis colonization were recorded, with a mean follow up of 26 weeks (range 4–48 weeks). 
Table 3 shows the incidence rates of PcP and other respiratory conditions in the cohort. With full 
diagnostic workup including post treatment follow up as the gold standard for the diagnosis of PcP; 
the sensitivity of PCR alone was 100%, the specificity 88%, and the positive predictive value 31%. 
Among episodes in which PcP was suspected, the mean CD4 count in patients with confirmed PcP 
cases (42.5 cells/mm3, range 1–103) was not significantly lower than in those with Pneumocystis 
colonization (89.1 cells/mm3, range 7–194;  p=0.28), but was significantly lower than in those with 
other diagnoses (97.0 cells/mm3, range 1–311; p = 0.03). Mean age and sex distribution of confirmed 
PcP, Pneumocystis colonization, and other diagnoses were not significantly different. The case-
fatality rate of confirmed PcP was 50%.
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Table 1. Baseline characteristics of study participants at enrolment. 
 
    n   pyo  
    
 
CD4 (cells/ml) 
0 – 99    125  83 
100 – 199   159  145 
200 – 499   271  268 
>500    77  75 




I    267  255 
II    191  190 
III    160  120 
IV    42  25 
 
 
Total    660  591 
 
 
pyo = person years of observation (based on the enrolment characteristics)  
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Table 3. The incidence of PcP and other respiratory illnesses
Diagnosis All CD4 counts CD4 0-99 /mm3 CD4 100-199 /mm3





































1 Diagnosis based on new consolidations on a chest x-ray and response to antibiotics 
Conclusions
This is the first community-based prospective study of PcP in a developing country. We found an 
incidence of PcP in Malawian HIV-infected adults of 1.0/100 person-years, similar to the rates 
observed in studies that used less comprehensive diagnostic approaches in South African miners 
(0.5/100 person-years) (11) and the placebo arms of trials of trimethoprim-sulfamethoxazole pro-
phylaxis in Côte d’Ivoire (12,13). The incidence in persons with CD4 counts <200/mm3 (2.5/100 
person-years) was clearly lower than in AIDS patients in the United States before the introduction 
of routine trimethoprim-sulfamethoxazole prophylaxis and highly active ART (10/100 person-years 
[14]). In the lowest CD4 count range (<100/mm3), PcP was common, although the incidence was low 
compared with that of bacterial pneumonia and pulmonary tuberculosis.
We believe it is unlikely that we missed many PcP cases among other diagnoses or losses to follow-up 
because of the intensive active and passive follow-up and because our facility provided expeditious, 
high-quality care free of charge. 
Allowing for reduced sensitivity of induced sputum compared to BAL (7) and considering cases 
with diagnostic uncertainty, as PcP cases would still leave the PcP incidence low in the HIV-infected 
population in general.
We found that Pneumocystis colonization and confirmed PcP were equally common among patients 
with suspected PcP. More sensitive molecular detection methods would possibly have detected higher 
rates of colonization. It remains uncertain why certain HIV-infected persons clear Pneumocystis 
colonization while others develop PcP. The level of immune suppression as indicated by the CD4 
count is a possible explanation, although our data do not support this. Genetic differences between P. 
jirovecii strains may be relevant (15). Variation in worldwide distribution of strains, as well as differ-
ences in host genetics and shorter survival of patients in low CD4 count ranges, are possible causes 
of the lower PcP incidence in Africa than in developed countries.
The incidence of PcP in HIV-infected Malawian adults, diagnosed clinically and confirmed with molec-
ular analysis, was low compared with the incidence of bacterial pneumonia and pulmonary tuberculo-
sis at all levels of immunosuppression. PcP rarely occurred with CD4 cell counts >100 mm3. Among the 
most immuno-compromised patients, PcP is an important diagnostic consideration.
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Abstract
Background. Human immunodeficiency virus (HIV) infection and malaria coexist in much of 
Africa. Previous studies differ in their findings on the interactions between the 2 infections.
Methods. Adults living with HIV infection in Blantyre, Malawi, were enrolled in a longitudinal 
observational study from September 2002 to August 2004. Malaria blood smears were obtained 
monthly and for any illness suggestive of malaria. Complete evaluations of all illness episodes were 
conducted, regardless of malaria smear results.
Results. The incidence of clinical malaria episodes was higher in participants with CD4 cell counts 
200 cells/mm3 than in those with CD4 cell counts 1500 cells/mm3. The trend was preserved when 
increasingly specific definitions of malaria disease were used. The prevalence of malaria infection 
was not associated with CD4 cell count. In per-visit analysis, lower CD4 cell counts were asso-
ciated with higher incidences of pneumonia, sepsis, and tuberculosis but not of malaria. Severe 
malaria was rare, with only 3 cases in 591 person-years of observation. Parasite density and CD4 
cell count were independent risk factors for fever.
Conclusions. Profoundly immunosuppressed adults with HIV infection require more-frequent 
treatment for uncomplicated malaria, but malaria infection and disease are less strongly associated 
with HIV-associated immunosuppression than are other opportunistic infections. Where malaria is 
common, the high incidence of fever found among immunosuppressed adults may lead to misclas-
sification of illness episodes as malaria.
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Introduction
HIV infection and Plasmodium falciparum malaria are 2 of the gravest health threats in sub-Saha-
ran Africa. Efforts to control the spread of both of these deadly infections have failed [1, 2]. HIV 
infection and malaria coexist in large populations in Africa, so even a small interaction between the 
2 infections may have important public health consequences. Although the relationship between 
HIV infection and malaria has been investigated in a variety of settings, no consistent relationship 
has emerged.
Early studies of the interactions between HIV infection and P. falciparum malaria in infants and 
young children in Zaire and Uganda found no increased rates of malaria infection in HIV-infected 
children, compared with those in HIV-uninfected control individuals [3–5]. In studies in Zambia 
and Burundi, HIV infection was not found to be associated with cerebral malaria [6, 7]. In 1998, a 
comprehensive meta-analysis concluded that, among children and non-pregnant adults, there was 
no evidence of an interaction between HIV infection and malaria [8]. In a malaria epidemic in 
South Africa, where transmission of and immunity to malaria are low, HIV infection has been 
found to be associated with more severe malaria disease among both adults and children [9, 10]. 
Increased morbidity due to malaria among HIV-infected pregnant women has been demonstrated 
in several sites in Africa, and HIV-infected women have a higher incidence of placental malaria 
[11]. Most of these earlier studies did not measure the degree of immunosuppression. Two recent 
studies examined the interaction between malaria and HIV infection among adults in malaria-
endemic regions of Uganda, with precise assessment of immunosuppression.
Whitworth et al. conducted a longitudinal cohort study of HIV infected and -uninfected adults in a 
rural area in Uganda [12]. In that study, increased immunosuppression was found to be associated 
with increased odds of clinical malaria being detected during routine active surveillance visits, 
which occurred every 3 months, and a trend toward an increased incidence of clinical malaria was 
observed during interim passive surveillance visits by participants seeking treatment for illness. 
In that study, clinical malaria was defined as fever or history of fever accompanied by significant 
parasitemia, but other potential causes of fever were not reported. Among HIV-infected adults par-
ticipating in a pneumococcal vaccine trial in Entebbe, Uganda, an increased rate of malarial fever 
was observed among individuals with lower CD4 cell counts [13]. These study participants were 
followed every 6 months, and many sought antimalarial treatment outside of the study.
We conducted a longitudinal study of people living with HIV infection in an urban community in 
Blantyre, Malawi, where malaria is holo-endemic with seasonal peaks. We followed the partici-
pants monthly and performed a comprehensive investigation into every illness experienced within 
the cohort. Here, we report our findings regarding the interaction between HIV immunosuppres-
sion and malaria.
Subjects and methods
Subjects. In collaboration with the Malawi National AIDS Control Programme and the District 
Health Office, we established a Voluntary HIV Counseling and Testing Center at the Blantyre 
Malaria Project research clinic at the Ndirande Health Centre, on the outskirts of Blantyre, the 
largest city in Malawi. Free voluntary counseling and testing for HIV was offered as a community 
service. HIV infection was diagnosed by testing with 2 rapid tests: Determine HIV rapid diagnostic 
strips (Abbott Laboratories) and UniGold (Trinity Biotech). Hemostrip HIV (Saliva Diagnostics) 
was used as a third test if the results of the first 2 tests conflicted, in accordance with the Malawi 
National AIDS Control Programme protocol. Individuals ≥16 years of age who were found to be 
infected with HIV were invited to participate in the study. Inclusion criteria included HIV infec-
tion and residence in the study area. The only exclusion criterion was long-term prophylaxis with 
trimethoprim-sulfamethoxazole (TS), because, at the time of this study, TS prophylaxis was not 
recommended for people living with HIV infection in Malawi, and the principle objectives of our 
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study were to describe the baseline epidemiology of opportunistic infections and assess the poten-
tial role of TS prophylaxis in this setting. Since this was the first community-based study of people 
living with HIV infection in Malawi, we had no data on which to base a sample size calculation. 
Our aim was to recruit 500–800 participants to be followed for 1–2 years to characterize the 
important infections in the population.
The study protocol was reviewed and approved by the Institutional Review Boards of the Uni-
versity of Maryland and Michigan State University and by the University of Malawi College of 
Medicine Research and Ethics Committee. Informed consent was obtained from all participants 
before enrollment in the study. 
Participants were free to withdraw from the study at any time and continue to receive care at the 
District Health Center. Participants who volunteered for the study were evaluated on the day of 
enrollment and every month thereafter. In addition, participants were instructed to return to the 
study clinic for evaluation any time they were ill. The clinic was located at the District Health 
Center serving the area, and the study clinicians under the supervision of physicians provided free, 
complete, and expeditious care for all illnesses. Diagnostic evaluation of each illness was under-
taken in accordance with standardized diagnostic guidelines and case definitions.
Specimen collection. CD4 cell counts were measured at enrollment and every 4 months thereafter 
(FacsCount; Becton Dickinson). Malaria smears were obtained at enrollment; at every scheduled 
visit, regardless of symptoms; and at any sick visits when the participant had fever or any other 
signs or symptoms of malaria disease.
Malaria thick smears were stained with Field’s stain, and parasites were counted against 200 white 
blood cells. Parasite density was calculated on the basis of an estimated white blood cell count of 
8000 cells/mm3. For smears with high parasite density, thin smears were obtained to measure the 
percentage of parasitized red blood cells, and parasite density was calculated on the basis of the 
measured hemoglobin level (HemoCue; HemoCue AB). Extensive evaluation of potential causes 
of intercurrent fever and illness were conducted as described elsewhere [14].
Case definitions. Because there is no reference standard method for diagnosis of malaria disease 
in a malaria-endemic area in which individuals may have asymptomatic infection and symptoms 
caused by a different illness, increasingly specific definitions were applied to categorize malaria 
disease. Clinical malaria was a diagnosis made at the time of the clinic visit and refers to any 
level of parasitemia with symptoms associated with malaria, including fever documented on physi-
cal examination or history of fever during the previous 48 hours, myalgia, weakness, pallor, and 
headache. When a clear additional cause of symptomatic disease was found at the same time as 
parasitemia, the diagnosis of clinical malaria was not made if the parasite density was <1 parasite/
high-power microscope field and the study physician determined that the non-malaria illness could 
account for all observed symptoms. Clinical malaria with significant parasitemia included cases 
of clinical malaria that had a parasite density >2790 parasites/μL, the parasite density at which 
the sensitivity and specificity for fever intersect in this population [15]. Febrile malaria referred 
to episodes of having a significant level of parasitemia and an axillary temperature >37.50C mea-
sured at the time of the visit. All participants with either symptomatic or asymptomatic infection 
were treated with sulfadoxine-pyrimethamine or with parenteral quinine, for cases of severe dis-
ease. Malaria infection, defined as a positive malaria smear, was analyzed in terms of prevalence, 
because chronic, asymptomatic infection is common, and the time of onset of new malaria infec-
tions could not be identified. All case definitions of malaria disease were analyzed as incident 
events, because disease episodes have identifiable times of onset and resolution.
Data analysis. Data were collected and entered into the database at the Blantyre Malaria Project 
facility in Ndirande. The database was in Microsoft Access, and double entry was conducted for 
validation. Data were analyzed using Stata (version 8.0; StataCorp). Months of follow-up were 
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calculated from the date of enrollment until the last recorded visit. Follow-up for participants who 
missed >2 sequential scheduled visits was censored at the last visit they attended. Rates of disease 
were calculated on the basis of person-years of observation (pyo). Except where indicated, CD4 
cell counts were used from the day of the visit or within the 6 months before the visit, so that indi-
viduals contributed events and follow-up time according to this CD4 cell count assignment. World 
Health Organization (WHO) clinical stage of HIV disease was determined on the basis of the WHO 
criteria. To determine the clinical stage as accurately as possible, clinical stage classification for 
analysis was based on the history provided by the participant, as well as on the first 2 months of 
assessment in the study. Poisson regression was used to compare malaria incidences by CD4 cell 
count stratum (<200, 200–500, and >500 cells/mm3) after age and sex were controlled for. CD4 
cell count was used as a continuous variable to measure the association with prevalence of malaria 
infection. A Poisson goodness-of fit test was assessed for over dispersion [16]. 
When malaria incidences for the 3 CD4 cell count groups are compared, the P value for the com-
parison between the lowest group and the highest group is reported. Episodes from the enrollment 
visit were included in the overall incidence but not in the routine or follow-up visit categories. The 
lack of independence of observations from the same individual was controlled for with the Huber/
White/sandwich estimator of variance. χ2 analysis was applied to test the association between CD4 
cell count and the diagnosis of pneumonia, sepsis, or tuberculosis; malaria infection prevalence; 
and clinical malaria with significant parasitemia, reported in number of cases per 1000 visits. Geo-
metric mean parasite density was compared among episodes of parasitemia, using linear regression 
analysis to assess the relationship between parasite density and CD4 cell count. The association 
between fever and parasite density, with CD4 cell count controlled for, was assessed by logistic 
regression. A parasite density–by–CD4 cell count interaction term was considered in the regres-
sion model.
Results
Demographics, losses, and withdrawals. From September 2002 through December 2003, 660 adults 
were enrolled in the study. Passive and active surveillance continued through August 2004, for 591 
pyo. This included 87, 259, and 238 pyo for CD4 cell counts of ≤500 cells/mm3, 200–499 cells/mm3, 
and >200 cells/mm3, respectively. The remainder did not have known or recent CD4 cell count data 
at the time of follow up. The mean age of participants was 31.7 years (range, 16–66 years; SD, 8.9 
years). Four hundred fifty-seven (66%) of the participants were female. Eighty-six (13%) of the 
participants died during the study, and 37 (6%) were withdrawn from the study because the inves-
tigators placed them on lifelong TS prophylaxis after a suspected case of Pneumocystis jirovecii 
pneumonia or because they were prescribed TS prophylaxis by a nongovernmental organization 
that distributed antiretroviral therapy in a neighboring region. Sixty-three (9.5%) of the participants 
migrated out of the area, 20 (3%) withdrew consent, and 119 (17%) were lost to follow-up.
CD4 cell counts. At enrollment, the mean CD4 cell count was 268 cells/mm3 (range, 0–1228 cells/
mm3; SD, 201 cells/mm3). Table 1 summarizes the distribution of CD4 cell counts and WHO clini-
cal stages at enrollment.
Parasitemia and clinical malaria. The rates of clinical malaria with any parasite density, clinical 
malaria with a significant parasite density, and febrile malaria were 0.35, 0.17, and 0.06 cases/pyo, 
respectively. Only 3 participants had severe malaria according to the WHO definition [17], and all 
3 had CD4 cell counts <200 cells/mm3.
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One case was associated with hyperparasitemia (120%), and the other 2 cases were associated 
with anemia that required transfusion. In one of these cases, the participant had concomitant 
Salmonella typhimurium bacteremia and died. Table 2 shows the crude malaria incidence and the 
adjusted rate ratios of malaria disease for each visit type. Increasing incidence of clinical malaria, 
clinical malaria with significant parasitemia, and febrile malaria were associated with decreasing 
CD4 cell counts. The difference was not found when routine and sick visits were analyzed sepa-
rately. CD4 cell count was not associated with prevalence of malaria infection (P=0.23; data not 
shown).
CD4 cell count and parasite density. Geometric mean parasite density for all episodes of infection 
was inversely related to CD4 cell count (regression coefficient, -0.001; P=0.005). This relationship 
was restricted to episodes of clinical malaria (P=0.001) and was not seen among participants with 
asymptomatic infection (P=0.67).
Parasite density and fever threshold. To determine whether individuals with lower CD4 cell counts 
develop symptoms at a lower parasite density, we used a model to determine the probability of 
fever with increasing parasite density (asexual parasites per cubic millimeter) for the 3 CD4 cell 
count groups (figure 1). In this model, CD4 cell count and parasite density did not have a statisti-
cal interaction in the prediction of fever. As expected, the more-immunosuppressed groups always 
had a higher incidence of fever. After CD4 cell count was controlled for, the odds of fever increased 
proportionately with increasing parasite density.
Non-malarial illnesses. Sepsis, pneumonia, and tuberculosis were more strongly associated with 
immunosuppression than was malaria. These illnesses are rare in less immunosuppressed adults, 
whereas all adults in this cohort remained susceptible to clinical malaria (table 3). Of 325 docu-
mented episodes of parasitemia, 22 episodes were associated with additional diagnoses that could 
have symptoms that overlap with those of malaria and require specific therapy (table 4).
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Figure 1. Probability of fever with increasing parasite density. 
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Discussion 
In this urban population of African adults living with HIV infection in a malaria-endemic area, 
immunosuppression had a modest effect on malaria disease. Consistent with other recent studies 
of African adults, participants with CD4 cell counts <200 cells/mm3 had a higher annual incidence 
of malaria disease than did those with CD4 cell counts >500 cells/mm3. However, unlike recog-
nized opportunistic infections—including bacterial sepsis, pneumonia, and tuberculosis, which 
were infrequent in relatively more immunocompetent adults - malaria disease was common in all 
CD4 cell count strata. Severe disease was rare: there were only 3 cases of severe malaria in 591 pyo; 
2 of these cases were categorized as severe malaria on the basis of anemia, which, in adults living 
with HIV infection, is a common condition that may not be related to malaria. The third case was 
defined as severe malaria on the basis of a high parasite density only. No cases of cerebral malaria 
were seen. Compared with other cohort studies of malaria–HIV infection interactions in Afri-
can adults [12, 13], the present study had more-intensive active surveillance, had more-thoroughly 
investigated non-malaria causes of fever, and included a higher proportion of persons with low CD4 
cell counts. Therefore, the failure to find more-pronounced clinical or parasitological interactions 
between HIV infection and malaria is unlikely to be due to study design.
The accurate diagnosis of uncomplicated malaria disease in malaria-endemic areas is difficult 
because of the frequent occurrence of asymptomatic malaria infection. In this study, 3 increasingly 
specific case definitions were applied. We previously used this approach to document an associa-
tion between HIV RNA concentration and clinical malaria [18]. In the present study, the consis-
tent association between lower CD4 cell counts and malaria incidence when increasingly rigorous 
definitions of malaria were used corroborates previous findings of the relationship between HIV-
associated immunosuppression and uncomplicated malaria disease. This form of analysis, how-
ever, does not eliminate the possibility of detection bias. If more-immunosuppressed individuals 
had more fevers and were subjected to more medical evaluations that included malaria smears, the 
incidence of malaria disease episodes may have been falsely elevated. To control for detection bias, 
we also reported the incidence of malaria disease by visit and found no association with immuno-
suppression. Although more immunosuppressed individuals appear to be somewhat more suscep-
tible to malaria, they are even more vulnerable to other opportunistic infections that may occur 
coincidentally with malaria infection. Calculating the incidence of disease by visit demonstrates 
that, even with more-frequent visits by more-immunosuppressed participants, much higher rates of 
sepsis, pneumonia, and tuberculosis were seen in those with lower CD4 cell counts. In contrast, the 
inverse relationship between the per-visit incidence of clinical malaria with significant parasitemia 
and CD4 cell count was not significant. In addition, nearly 1 in 10 episodes of parasitemia among 
participants with the lowest CD4 cell counts was associated with another clinically important diag-
nosis. In at least some cases, illness episodes that occur in the presence of malaria infection may be 
caused not by malaria but by other infections.
We have previously hypothesized that HIV-associated immunosuppression and the lack of acquired 
immunity to malaria may lower the threshold of parasite density that causes symptoms, particu-
larly fever [19, 20]. Parasite density and CD4 cell count increased the risk of fever independently. 
Although individuals with lower CD4 cell counts are more likely to have fever - regardless of the 
presence or density of parasites -as parasite density increased, those who were more immunosup-
pressed had an increase in the odds of fever, relative to baseline, that was similar to the change from 
baseline seen in those who were less immunosuppressed. Most parasite density calculations were 
derived from thick smears on the basis of an assumed total white blood cell count of 8000 cells/
mm3. Individual white blood cell counts may have differed substantially from this estimate. Since 
leukopenia is common in advanced HIV infection [21], we may have overestimated the parasite 
density of participants with lower CD4 cell counts.
080356 Oosterhout BW.indd   52 11-11-2008   15:48:47
53
The results of the present study may not accurately reflect the general experience of patients and 
clinicians in regions of HIV infection and malaria coexistence. Because of a tendency for people 
with illness to seek HIV testing and because of the natural decline in CD4 cell count, the study pop-
ulation was skewed toward more-immunosuppressed participants, with only 87 (15%) of 591 pyo of 
the follow-up time accrued among individuals with a CD4 cell count >500 cells/mm3. The partici-
pants were followed very closely. Low-level, asymptomatic parasitemia was treated with antima-
larial medication, so that we were not able to observe the natural history of asymptomatic infection 
in our population. Participants had free and expeditious access to medical attention and may have 
sought medical attention at an earlier stage in their illness than they would have under non-study 
conditions. The intensity of surveillance, however, was applied equally to all participants, regard-
less of CD4 cell count; thus, any important differences between groups should have been detectable 
in this study. In addition, as community-based antiretroviral therapy clinics develop in regions 
of malaria endemicity, closer surveillance and more-frequent therapy for malaria episodes may 
become more common. The 17% rate of loss to follow-up, although relatively low for a longitudinal 
cohort study in an urban African population, may have affected the study findings, if those lost 
to follow-up had significantly different rates of malaria. Malaria kills people who lack specific, 
naturally acquired immunity, including infants, young children, and pregnant women in malaria-
endemic areas; travelers; and people of all ages in areas without enough malaria transmission to 
stimulate protective immunity. HIV-associated immunosuppression does not obliterate immunity 
to malaria. Adults in endemic areas do not return to having the same risk for severe disease and 
death that they had when they were young. Although uncomplicated P. falciparum malaria will be 
diagnosed and treated approximately twice as frequently in profoundly immunosuppressed adults 
living with HIV infection in malaria-endemic areas, these adults do not appear to be at a high risk 
of progressing to severe disease, even when treated with an antimalarial drug whose efficacy is 
compromised [22].
The impact that HIV infection–malaria interactions in African adults has on the diagnosis and 
treatment of uncomplicated P. falciparum malaria has important public health implications. Where 
malaria is common, the high incidence of fever found among adults with lower CD4 cell counts 
may lead to misclassification of illness episodes as malaria disease. The high incidence of fever 
associated with lower CD4 cell counts makes evaluation and diagnosis of malaria more likely, but 
this does not imply a causal relationship. Without a means to determine whether malaria parasites 
are innocent bystanders or the cause of illness, treatment is warranted for anyone with symptoms 
and a positive malaria smear. However, clinicians who diagnose malaria in HIV-infected adults 
with fever and parasitemia should take care not to overlook potentially life-threatening infections 
with bacteria, fungi, or other parasites.
Acknowledgments
We are grateful to the residents of Blantyre, Malawi, for their participation in this study, and to Neil 
French for helpful discussions.
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO). 
AIDS epidemic update: December, 2005. UNAIDS/05.19E. Geneva: UNAIDS/WHO, 2005. 
Available at:http://www.unaids.org/epi/2005/doc/EPIupdate2005_pdf_en/epi-update2005_en.pdf. 
Accessed 26 January 2006.
2. World Health Organization (WHO). World malaria report 2005. Geneva: WHO, 2005. Available at: 
http://www.rbm.who.int/wmr2005/pdf/adv_e.pdf. Accessed 26 January 2006.
080356 Oosterhout BW.indd   53 11-11-2008   15:48:47
54
3. Greenberg AE, NsaW, Ryder RW, et al. Plasmodium falciparum malaria and perinatally acquired 
human-immunodeficiency-virus type-1 infection in Kinshasa, Zaire—a prospective, longitudinal 
cohort study of 587 children. N Engl J Med 1991; 325:105–9.
4. Nguyendinh P, Greenberg AE, Mann JM, et al. Absence of association between Plasmodium falci-
parum malaria and human immunodeficiency virus-infection in children in Kinshasa, Zaire. Bull 
World Health Organ 1987; 65:607–13.
5. Kalyesubula I, MusokeMudido P, Marum L, et al. Effects of malaria infection in human immuno-
deficiency virus type 1-infected Ugandan children. Pediatr Infect Dis J 1997; 16:876–81.
6. Leaver RJ, Haile Z, Watters DAK. HIV and cerebral malaria. Trans Roy Soc Trop Med Hyg 1990; 
84:201.
7. Niyongabo T, Deloron P, Aubry P, et al. Prognostic indicators in adult cerebral malaria—a study in 
Burundi, an area of high prevalence of HIV-infection. Acta Trop 1994; 56:299–305.
8. Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus 
and Plasmodium falciparum? Int J Epidemiol 1998; 27:296–301.
9. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. HIV infection as a cofactor 
for severe falciparum malaria in adults living in a region of unstable malaria transmission in South 
Africa. AIDS 2004; 18:547–54.
10. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. Childhood malaria in a 
region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect 
Dis J 2003; 22:1057–63.
11. Ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunode-
ficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 
2004; 71:41–54.
12. Whitworth J, Morgen D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on 
malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 
356:1051–6.
13. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JAG, Gilks CF. Increasing rates of malarial 
fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15:899–
906.
14. van Oosterhout JJG, Laufer MK, Graham SM, et al. A community based study of the incidence 
of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. J 
Acquir Immune Defic Syndr 2005; 39:626–31.
15. Smith T, Schellenberg JA, Hayes R. Attributable fraction estimates and case definitions for malaria 
in endemic areas. Stat Med 1994; 13:2345–58.
16. StataCorp. Stata statistical software release 8 manual, vol 3. College Station, TX: StataCorp LP, 
2003:204.
17. Beales PF, Brabin B, Dorman E, et al. Severe falciparum malaria. Trans Roy Soc Trop Med Hyg 
2000; 94(Suppl 1):S1–90.
18. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration 
of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 
365:233–40.
19. Taylor TE, Hoffman IF. Can HIV-1 infections in Africa provide insights into acquired immunity to 
malaria? Lancet 2000; 356:1046. 
20. Coulibaly D, Diallo DA, Thera MA, et al. Impact of preseason treatment on incidence of falciparum 
malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop 
Med Hyg 2002;67:604–10.
21. Zon LI, Groopman JE. Hematologic manifestations of the human immune-deficiency virus (HIV). 
Semin Hematol 1988; 25:208–18.
22. Plowe CV, Kublin JG, Dzinjalamala FK, et al. Sustained clinical efficacy of sulfadoxine-
pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treat-
ment: five year prospective study. BMJ 2004; 328:545.
080356 Oosterhout BW.indd   54 11-11-2008   15:48:47
080356 Oosterhout BW.indd   55 11-11-2008   15:48:47
080356 Oosterhout BW.indd   56 11-11-2008   15:48:47
Chapter 5
Malaria treatment efficacy among 
people living with HIV: the role 
of host and parasite factors
Miriam K. Laufer1, Joep J.G. van Oosterhout2, Philip C. Thesing3, Fraction Dzinjalamala4, 
Teresa Hsi1, Lorraine Beraho1, Stephen M. Graham4, Terrie E. Taylor3,5, Christopher V. Plowe1
1. Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, 
2. Department of Medicine, University of Malawi College of Medicine 
3. Blantyre Malaria Project, University of Malawi College of Medicine 
4.  Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of 
Medicine
5. College of Osteopathic Medicine, Michigan State University, East Lansing              
American Journal of Tropical Medicine and Hygiene 2007, 77:627–632
080356 Oosterhout BW.indd   57 11-11-2008   15:48:48
58
Abstract
Identification of an effect of HIV-associated immunosuppression on response to antimalarial ther-
apy would help guide management of malaria infection in areas of high HIV prevalence. Therefore, 
we conducted an observational study of people living with HIV infection in Blantyre, Malawi. 
Participants who developed malaria were treated with sulfadoxine–pyrimethamine (SP) and fol-
lowed for 28 days. Molecular markers for SP resistance were measured. One hundred seventy-eight 
episodes of malaria were assessed. The 28-day cumulative treatment failure rate was 29.1%. In 
univariate analysis, CD4 cell count was not associated with treatment failure (hazard ratio 0.6, 
95% confidence interval 0.3–1.2). Among children, the risk of treatment failure increased with 
infection with SP-resistant parasites and anemia. Decreased CD4 cell count was not associated 
with impaired response to antimalarial therapy or diminished ability to clear SP-resistant parasites, 
suggesting that acquired immunity to malaria is retained in the face of HIV-associated immuno-
suppression.
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Introduction
Clear evidence of a clinically important impact of HIV infection on malaria infection and disease 
has been difficult to demonstrate, despite the overlapping distribution of these pathogens in sub-
Saharan Africa. Among adults living in areas of high malaria transmission who have acquired 
semi-immunity to malaria, HIV infection has been shown to increase modestly the frequency with 
which clinical episodes of malaria are diagnosed (1–3). Severe malaria is rare in adults living in 
malaria-endemic areas and HIV infection does not appear to increase its incidence. Another impor-
tant aspect of the potential interaction between HIV and malaria is the effect of HIV-associated 
immunosuppression on response to antimalarial therapy. Case series and retrospective reviews 
comparing the antimalarial drug efficacy among HIV-infected and HIV-uninfected patients have 
reported mixed results (4–7) Two recent clinical studies have been conducted in Africa to assess 
antimalarial efficacy in an HIV-infected population. In Zambia, treatment with sulfadoxine–
pyrimethamine (SP) or artemether–lumefantrine was followed by a small increased risk of recur-
rent parasitemia in HIV-infected individuals with CD4 cell count <300/mm3 compared with those 
with CD4 counts >300/mm3, when participants were followed for 45 days, but not after polymerase 
chain reaction (PCR) correction to exclude new infections (8). In Kenya, the risk of treatment 
failure after treatment with SP was 3.4-fold greater for HIV-infected adults with CD4 cell counts 
<200/mm3 compared with HIV-uninfected adults, only in the presence of anemia (9). None of the 
previous studies considered the intrinsic resistance of the parasites to the study treatment.
The ability to clear drug-resistant parasites is a model for acquired immunity to malaria (10). As 
children get older and develop immunity, they have an improved ability to resolve parasitemia 
despite treatment with a drug to which the parasites are resistant. We hypothesized that if HIV-
associated immunosuppression interferes with malaria immunity, then lower CD4 cell counts 
would be associated with an impaired ability of SP treatment to cure infections with SP-resistant 
parasites.
To identify both host and parasite factors that contribute to antimalarial drug efficacy, we studied 
HIV-infected adults and children enrolled in a longitudinal study in Blantyre, Malawi. When par-
ticipants developed symptomatic malaria, they were treated with SP, according the Malawi national 
policy, and were followed for 28 days to assess the efficacy of the drug. Molecular analyses of 
infecting parasites were carried out to identify the presence of genetic mutations associated with 
resistance to SP.
Study participants and methods
Study participants and site. In collaboration with the National AIDS Control Program and the 
Ndirande District Health Office, we established a Voluntary HIV Counseling and Testing Center 
at the Blantyre Malaria Project Research Clinic at the Ndirande Health Center, on the outskirts of 
Blantyre, the largest city in Malawi. Adults and children 2 years of age and older who were found 
to be infected with HIV were invited to participate in a cohort study of the incidence of HIV-associ-
ated illnesses, as described elsewhere (11). Individuals taking trimethoprim–sulfamethoxazole pro-
phylaxis (which was not the national policy at the time) were excluded from the study. Participants 
who volunteered for the cohort study were evaluated on the day of enrollment and every 4 weeks 
thereafter and were instructed to return to the study clinic for evaluation any time they were ill.
Specimen collection. CD4 cell counts were measured at enrollment and every 4 months during 
participation in the study. Malaria smears and hemoglobin measurements were obtained at enroll-
ment, at every scheduled 4-weekly visit regardless of symptoms, and at any sick visits when the 
participant had fever or any other signs or symptoms of malaria disease. Malaria thick smears were 
stained with Field stain, and parasites were counted against 200 white blood cells. Parasite density 
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was calculated on the basis of an estimated white blood cell count of 8,000 cells/mm3 For smears 
with parasite density too high to measure on a thick smear, thin smears were obtained to measure 
the percentage of parasitized red blood cells, and parasite density was calculated on the basis of the 
measured hemoglobin level.
Case definitions. A diagnosis of clinical malaria was made at the time of the clinic visit if any level 
of parasitemia was present, accompanied by symptoms associated with malaria. These symptoms 
included fever documented on physical examination or history of fever in the previous 48 hours, 
myalgia, weakness, pallor, or headache, and without signs or symptoms of severe malaria (12). Par-
ticipants who had clinical or laboratory evidence of an acute bacterial infection were not included 
in the assessment of SP efficacy. However, 1 adult and 1 child with concurrent otitis media were 
included because the study physician determined that the clinical symptoms were most consistent 
with malaria. A second episode in 1 individual was only included if episodes were a minimum of 2 
months apart with documentation of at least 1 negative malaria smear between episodes.
Malaria management. Participants who were diagnosed with uncomplicated malaria were treated 
with SP. The dose for adults was 75 mg of pyrimethamine and 1500 mg of sulfadoxine, and for 
children the dose was ≈ 1.25 mg/kg pyrimethamine and 25 mg/kg sulfadoxine. All participants 
who experienced treatment failure were treated with either halofantrine or quinine and followed to 
ensure resolution of symptoms and parasitemia.
Outcomes. Participants were followed according to the standard 28-day assessment of efficacy, 
with outcomes classified according to the WHO protocol (13). Participants returned for follow-up 
on days 1, 2, 3, 7, 14, and 28 and were also encouraged to return on other days if they were unwell. 
Early treatment failure could occur on days 0–3, and late clinical failure could occur on days 4–28. 
For participants who had parasitemia at day 28, but never had signs of severe disease or fever, 
the outcome was classified as late parasitological failure. Collectively, early treatment failure, late 
clinical failure, and late parasitological failure were classified as treatment failure.
Molecular analysis. Drops of blood were collected on filter papers at every visit during the study. 
After DNA had been extracted from dried filter papers from the day of enrollment, nested PCR 
followed by mutation-specific restriction endonuclease digestion was used to detect the molecu-
lar markers for SP resistance: dihydrofolate reductase (DHFR) Cys→Arg at codon 59 and dihy-
dropteroate synthetase (DHPS) Lys→Glu at codon 540. We have previously demonstrated that 
these 2 mutations accurately predict the presence of the most SP-resistant parasites commonly 
found in Malawi, i.e., those containing DHFR mutations Ser→Asn at codon 108, Asn→Ile at codon 
51, and Cys→Arg at codon 59 and DHPS mutations Ala→Gly at codon 437 and Lys→Glu at codon 
540 (14). Infections in which only parasites containing mutations at DHFR 59 and DHPS 540 
were detected were considered to be resistant infections. Genotyping for resistance mutations was 
performed on all infections in which the clinical outcome was known and on randomly selected 
infections for which the clinical outcomes were unknown. Episodes of recurrent parasitemia from 
14 to 28 days after therapy underwent analysis of the polymorphic region of merozoite surface 
protein-2 (MSP-2) from the original and the recurrent infection, according to established methods 
(15). Polymorphic fragments were considered the same if their measured molecular weights were 
within 15 base pairs. Recrudescent infection was defined as the presence of alleles in the recurrent 
episode that were also found in the original infection.
Data analysis. Information was entered into a database in Microsoft Access (Microsoft, Redmond, 
WA), and the data were analyzed in Stata 8.2 (StataCorp, College Station, TX). Participants <16 
years of age were considered children. Anemia was defined as hemoglobin <10 g/dL. CD4 cell 
counts were used from the day of the diagnosis of malaria if they were available or within the 
prior 6 months. Frequencies were compared using Fisher’s exact test. Student’s t-test was used to 
compare normally distributed variables, and the Wilcoxon rank sum test was used for other con-
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tinuous variables. The primary outcome measure was the cumulative treatment failure rate, with 
comparisons using Cox proportional hazards. The variables were tested to exclude co-linearity. 
Huber–White robust estimates of variance were applied for multiple measurements from a single 
individual for all survival analyses. The role of each independent variable of interest was analyzed 
in both univariate and multivariate models. All variables were included in the final model because 
of their biologic interest. We explored the possibility of interactions between all combinations of 
CD4 cell count, hemoglobin, age, and resistant infections in the model. Kaplan–Meier survival 
curves were generated using the time to the first episode of recurrent parasitemia and compared 
using the log rank test.
Ethical review. This study was approved by the University of Malawi College of Medicine Research 
and Ethics Committee, as well as the institutional review boards of the University of Maryland and 
Michigan State University. Informed consent was obtained from all participants prior to enrollment 
in the cohort study
Results
Study participants. From September 2002 until January 2005, SP efficacy was assessed in 178 
episodes of malaria in 128 individuals. The mean age of the 14 children was 6.9 years, and the 
mean age for the adults was 31.2 years. One participant was receiving anti-retroviral therapy. One 
hundred twenty-seven (71%) clinical malaria episodes were followed until a study endpoint was 
reached. The most common reason for failing to complete the study was having left the study area 
(25/51, 49%); other reasons included unable to locate the residence (8), non-malarial hospitalization 
(4), schedule misunderstanding (2), employment conflict (1), excessive delay due to presidential 
election (1), and unknown (10). Individuals who failed to complete 28 days of follow-up were older 
than those who completed follow-up, but the 2 groups were otherwise similar (Table 1).
Clinical outcomes. Thirty-eight episodes met the criteria for treatment failure. All 21 episodes of 
early treatment failure occurred in adults. The late failures included 7 late treatment failures (5 
among children) and 10 late parasitological failures (4 among children). Using the data from all 
participants, including those with censored outcomes, the 28-day cumulative treatment failure rate 
was 29.1% (95% confidence interval [CI] 20.3–35.8). As shown in Table 2, the failure rate was not 
statistically different for episodes occurring in individuals with CD4 cell counts <200/mm3 com-
pared with ≥200/mm3, but children had a much higher failure rate than adults (71.4% compared 
with 20.9%, P <0.001). No episodes of severe malaria developed during the study. Recurrent para-
sitemia in cases of late clinical or parasitological failure was due to recrudescent infection in 10/12 
(83%) cases in which MSP-2 genotypes were known.
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Molecular analysis. Sixty-five (51%) of the 127 infections that were successfully genotyped with 
respect to the markers for SP resistance were found to be SP-resistant infections. SP-resistant infec-
tions were equally distributed among adults and children (50% versus 57%, respectively, P = 0.4) 
and among those with CD4 counts <200 and ≥ 200 cells/µL (56% versus 48%, P =0.5). Eleven 
infections were wild type with respect to at least one of the codons of interest, and the remaining 
51 infections contained a mixture of SP-susceptible and resistant parasites.
Univariate analysis. In the analysis of host and parasite risk factors, children had a 3-fold increased 
risk of treatment failure compared with adults, and anemia was associated with a 2-fold increase 
relative risk of failure. The log-transformed parasite density at the initial infection was not asso-
ciated with a change in risk (hazards ratio 1.1, CI 0.8–1.6, P = 0.6). Neither CD4 cell count nor 
infection with resistant parasites was associated with increased risk of treatment failure (Table 2). 
We examined early treatment failure and late clinical and parasitological failure separately. The 
relative risk for early treatment failure comparing malaria episodes in individuals with CD4 count 
<200 cells/mm3 to ≥200 cells/mm3 was 0.5 (CI 0.2–1.6, P =0.2), and for late clinical and parasito-
logical failure the relative risk was 0.9 (CI 0.4–2.0, P =0.7). Results were similar when age and CD4 
count were included as continuous variables and when a CD4 cell count cutoff of 300/μL was used 
instead of 200/μL (data not shown). 
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Multivariate analysis. We detected an interaction between age and infection with resistant para-
sites (P =0.04), but we found no interaction between CD4 cell count and infection with resistant 
parasites, CD4 count and anemia, or anemia and infection with resistant parasites on the outcome 
of treatment failure. Age and categorization of child or adult were both included in the multivariate 
model to fulfill the assumptions of proportional hazards. The variables were not co-linear. Because 
age modified the effect of resistant infections on treatment outcome, we analyzed adults and chil-
dren separately (Table 3). In the pediatric population, increasing age was protective against treat-
ment failure. Anemia and infection with resistant parasites were associated with 2-fold and 11-fold 
increased risk of treatment failure, respectively (Table 3). Among adults, none of the proposed 
factors was associated with risk of treatment failure. We conducted the same analysis but restricted 
it to cases in which the parasite density was >2,000/μL, which is a more specific case definition 
and is also the population recommended for study in the WHO protocol for assessing antimalarial 
therapeutic efficacy (13). The results were similar except for a statistically significant increased risk 
of treatment failure with higher parasite density of the initial infection.
An exploration of a possible interaction between CD4 count and ability to clear a resistant infection 
was conducted in the age-stratified analysis, and no statistically significant interaction was found 
(P =0.8 among adults and P =0.2 among children). These analyses were repeated, classifying infec-
tions that contained only SP-resistant parasites as well as those with a mixture of both SP-resistant 
and susceptible parasites as “SP resistant infection”. Relationships between the risk factors of inter-
est and treatment failure were similar (data not shown).
Time to first recurrent parasitemia. Figure 1 shows the relative risk of recurrent parasitemia for 
the lower versus higher CD4 count groups and for children versus adults. The difference between 
CD4 cell count groups was not statistically significant (P=0.1), but between adults and children the 
curves differed (P =0.003).
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Discussion
In this longitudinal study of adults and children living with HIV, we found that increasing immu-
nosuppression had no effect on malaria treatment efficacy. This held true when examining the 
effect of CD4 cell count alone and also after controlling for known factors that influence treat-
ment outcome. To our knowledge, this is the first study to measure antimalarial drug efficacy that 
documented outcomes among infections with both susceptible and resistant parasites. The lack of 
statistical interaction between CD4 count and infection with resistant parasites indicates that more 
severely immunosuppressed individuals did not have an impaired capacity to clear resistant infec-
tions. We confirmed that this finding was not due to our liberal case definition of clinical malaria; 
the same associations were detected when a higher threshold of parasitemia was used to define clin-
ical episodes. Clearance of resistant parasites was impaired in children, but this was independent 
of the degree of HIV-associated immunosuppression. Among children, increasing age was associ-
ated with improved SP efficacy, attributable to the exposure-dependent acquisition of antimalarial 
immunity. Once adults have achieved semi-immune status, this immunity appears to remain stable 
despite increasing duration of exposure with age. Thus, when analyzing adults separately, age was 
not a risk factor for treatment failure.
A small effect of CD4 count may have been undetected due to the sample size. Malaria infection is 
becoming less frequent among individuals identified as being HIV-infected due to trimethoprim–
sulfamethoxazole prophylaxis. Large clinical studies of the interaction between the 2 infections are 
therefore unlikely to be possible in the future. The point estimates of the risk of treatment failure 
among adults suggest an increased risk of treatment failure in the group with the higher CD4 cell 
count, although the confidence intervals were overlapping. It has been suggested that malaria may 
transiently decrease CD4 cell counts in adults with HIV infection 16. We and others have demon-
strated associations between low CD4 cell count and increased susceptibility to malaria based on 
CD4 cell counts that were measured both during and prior to the episode of malaria, as was done 
in the present study, so it is unlikely that the timing of the CD4 cell count measurements obscured 
an important association between immunosuppression and treatment outcome in this study. Incom-
plete follow-up of some participants that inevitably occurs in this mobile, urban population may 
have obscured significant differences. However, the individuals who did not complete the study 
had similar demographic, parasitological, and immunologic characteristics to those who did reach 
a study endpoint. 
The poor efficacy of SP in the HIV-infected pediatric population was expected based on the gradual 
increase in parasitological resistance that occurred at this site from 1998 to 2002 (17). In a recent 
study from 2005, we found a cumulative treatment failure rate of 79% among children of unknown 
HIV status with uncomplicated malaria who were treated with SP (18). Antimalarial drug effi-
cacy is not usually assessed in the adult population in areas of intense malaria transmission where 
acquired immunity aids parasite clearance. Because of SP’s loss of efficacy, Malawi is changing its 
first-line therapy to an artemisinin-based combination therapy. 
These results are consistent with a recent study from Uganda in which no association between the 
presence of HIV infection and PCR-adjusted treatment failure was found in a retrospective analysis 
of specimens from >3,000 participants from drug efficacy trials from 2002 to 2004 (7) Similarly, 
in a prospective trial in Zambia, a trend was noted toward an increased risk of treatment failure 
among individuals with CD4 counts <300/mm3 compared with those with CD4 counts >300/mm3, 
but this difference did not achieve statistical significance (8). Both of these studies found increased 
rates of re-infection in participants with HIV-associated immunosuppression, but we found too few 
cases of re-infection to conduct such a subgroup analysis in this study. The finding that recurrent 
infection was almost always due to recrudescence is probably a result of the post-treatment prophy-
lactic effect provided by the very long action of SP compared with some of the artemisinin-based 
combination therapies used in the previous studies (7,8). 
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The study of SP efficacy conducted by Shah and colleagues in Kenya was the most analogous to 
ours, as only a single therapy was studied in the setting of high levels of parasite resistance. An 
increased risk of treatment failure among adults with low CD4 cell counts was detected only among 
those with anemia. Although anemia at the onset of the malaria episode was an important risk fac-
tor for treatment failure among children, we did not find an interaction between CD4 cell count and 
anemia in this study. Only a small number of participants in the Kenyan study reported the use of 
antifolate drugs in the preceding week (S. Shah, personal communication). Because the investiga-
tors did not provide comprehensive care for the participants in this study, the authors admit that 
their ability to accurately determine previous exposure to SP and antibacterials with antimalarial 
activity was limited (9). The distribution of resistant parasites may have been uneven in the lower 
and high CD4 count strata. 
A key feature that distinguishes our study from previous studies is that all study participants in this 
report were enrolled in a longitudinal cohort study and subjected to close follow-up. Seeking treat-
ment of febrile illness in the informal sector is common in Africa (20,21). It is possible that patients 
who are sick with HIV infection are more frequently exposed to drugs with antimalarial proper-
ties and are more likely to harbor resistant parasites selected by these drugs (19). Our study team 
provided all the medical care for the participants, so we were reasonably confident that none was 
recently exposed to antimalarial medication or antimicrobials that may have antimalarial activity. 
Common HIV-related opportunistic infections, such as bacteremia, may present with symptoms 
that meet the case definition of clinical malaria. If individuals with parasites found on blood smear 
and a second acute illness are treated only for malaria, they are likely to be classified as “treat-
ment failure” because the fever and symptoms are likely to persist or recur. The findings we report 
were derived from a longitudinal cohort study with extensive evaluation of every illness episode. 
Although we could not exclude some causes of fever such as viral co-infection, we were confident 
that the individuals enrolled in the drug-efficacy study did not have concomitant febrile conditions, 
such as bacteremia, pneumonia, meningitis, enteritis, or urinary tract infection. Among the most 
immuno-suppressed people living with HIV infection, up to 10% of those with a positive malaria 
smear may also have a clinically significant additional illness (3). To our knowledge, none of the 
previous studies that examined the relationship between HIV and malaria treatment outcomes so 
thoroughly evaluated the non-malarial etiologies of illness. It is possible that the lack of association 
found between CD4 cell count and treatment failure was due to our ability to identify the concomi-
tant morbidities that occur more frequently among more immuno-suppressed patients and thus 
avoid misclassification of treatment episodes.
This study has key public-health implications. As African countries that grapple with both HIV 
and malaria infection begin to adopt new antimalarial treatment, efficacy trials can focus on HIV-
infected individuals in general and do not require stratification based on CD4 cell count. What may 
appear to be treatment failure among adults with advanced immunosuppression may actually be 
infection with opportunistic pathogens in this population rather than failure to respond to malaria 
treatment. The study of malaria treatment in the context of HIV co-infection provides an opportu-
nity to better understand the development and maintenance of the immune response to malaria.
Conclusion
Although previous studies have demonstrated that HIV associated immunosuppression may 
increase susceptibility to clinical disease with malaria infection, our findings suggest that HIV-
associated immunosuppression does not interfere with a different measure of acquired immunity, 
namely, response to antimalarial treatment. In this setting of intense malaria transmission, only 
children—a population that has not yet developed this immunity—had a diminished ability to clear 
drug-resistant infections. Parasite resistance to SP, as assessed by standard molecular markers, is 
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the strongest predictor of SP treatment failure among young children in a malaria-endemic area. In 
this community-based cohort, the capacity to resolve malaria infection with SP-resistant parasites 
after treatment with SP was not impaired by advanced HIV-associated immunosuppression.
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In the developing world, early mortality, within one month of commencement of anti-tuberculous 
therapy (ATT) is high, particularly with HIV co-infection. In Malawi 40% of those who die are in 
the first month. Reasons remain unclear, and may include delayed diagnosis, opportunistic infec-
tions, IRIS or malnutrition. One possible contributing factor is the described underlying hypoa-
drenalism associated with TB / HIV, exacerbated by rifampicin induction of p450 and glucocotri-
coid metabolism.
Objective:
To assess prevalence of hypoadrenalism in TB patients before and after commencement of ATT 
and relationship to early mortality.
Design: 
Prospective descriptive study assessing hypoadrenalism (prior to and two weeks after commence-
ment of ATT), HIV status and outcome up to 3 months post ATT.
Results: 
Of 51 patients enrolled, 29 (56.9%) were female. Median age was 32 years (range 18-62). Of the 43 
patients HIV tested, 38 (88.3%) were HIV positive. 15.7% died within the first month. Adequate 
cortisol levels were found in 49 of 51 (95.9%) persons before commencing rifampicin. Neither of 
the two with reduced response died. All 34 patients tested at two weeks after start of ATT revealed 
adequate cortisol responses. 
Conclusion: 
The prevalence of hypoadrenalism was low and not associated with early mortality on ATT.
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Introduction and Background
The link between the worsening global tuberculosis (TB) burden and the human immunodeficiency 
virus (HIV) pandemic is well established (1). Worst affected are countries of sub-Saharan Africa. 
Malawi has an HIV seroprevalence rate of 14.2% among 14-49 year olds, while in urban areas such 
as Blantyre this was on average 29% between 1997-2001 (2). Approximately 75% of TB cases are 
co-infected with HIV (3). Case fatality rates of up to 23% and 26% have been reported in sputum 
smear-positive and smear-negative pulmonary tuberculosis patients respectively, at the end of anti 
tuberculosis treatment (ATT) (3). The presence of high mortality rates, despite well organized 
national TB control programmes, is a major concern. The majority of this mortality is described in 
the early phases of ATT, up to 40% of those who die do so in the first month, 60% after two months 
(3). 
The causes of the high early mortality during ATT remain unclear. Suggested risk factors include 
delay in commencing treatment (3), advanced HIV and its associated opportunistic infections, 
a rapid killing of TB bacilli causing adverse immune-mediated (Herxheimer-like) response (4), 
moderate to severe malnutrition (5), and poor absorption of drugs. Another proposed aetiology is 
underlying hypoadrenalism leading to an Addisonian crisis. 
Both TB and HIV can cause hypoadrenalism. While autoimmune disease is the predomi-
nant cause in the developed world, TB remains an important aetiology in developing countries 
(6,7,8,9,10,11,12,13). Studies in the Indian sub-continent and sub-Saharan Africa described TB as 
the cause of 32% to 55% of hypoadrenalism cases (7,8,13,14,15).
Rifampicin is the backbone of current short course ATT regimes. It is also a recognized potent 
inducer of hepatic cytochrome P450 enzymes, which may result in increased clearance of endog-
enous glucocorticoid hormones produced by the adrenal cortex. Kyriazopolou and colleagues (16) 
have previously reported rifampicin-induced adrenal crises in patients with underlying hypoad-
renalism receiving glucocorticoid replacement therapy. Clinical symptoms and biochemical abnor-
malities of hypo-adrenalism resolved within 7 days of stopping rifampicin.
In the present study, we examined the relationship between the state of the adrenal cortex and early 
mortality during treatment for sputum smear-positive TB in Malawian adults. We hypothesized 
that TB and/or HIV infection can both cause sub-clinical hypoadrenalism, which may be exacer-
bated by rifampicin. We postulated that hypoadrenalism would be more severe in patients who died 
during the first month of ATT than in patients who survived. Furthermore, we looked for clinical 
symptoms or signs that correlated with biochemical hypo-adrenalism. Glucocorticoid supplemen-
tation during the intensive phase of anti-tuberculosis treatment could be the important therapeutic 
implication of the confirmation of this hypothesis.
Methods
A prospective, observational study of adults (aged at least 15 years) commencing ATT for spu-
tum smear acid fast bacilli (AFB)-positive pulmonary TB was undertaken at the Queen Elizabeth 
Central Hospital (QECH) in Blantyre, Malawi, a large public tertiary hospital providing free of 
charge medical care. The diagnosis of TB was based on sputum smear microscopy according to the 
Malawi National Tuberculosis Control Programme (NTP) guidelines, which are in keeping with 
the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung 
Disease guidelines (17). The ATT regime followed the NTP guidelines: two months of rifampicin, 
isoniazid, ethambutol and pyrazinamide, followed by six months of daily doses of isoniazid and 
ethambutol.
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Consecutive eligible patients, admitted to the TB ward of QECH during the study period were 
recruited. Those who had received corticosteroids in the last 3 months or were known to have pre-
existing adrenal insufficiency were excluded. Patients were examined for the presence of clinical 
features suggestive of adrenal insufficiency: postural hypotension and hyper/hypo pigmentation 
of skin and mucosa. The presence of other co-morbidities was confirmed using locally available 
diagnostic tools including, where appropriate, basic radiological investigations, blood culture and 
assessment of cerebrospinal fluid. For HIV testing, two rapid HIV-1/2 antibody spot test were used; 
Uni-GoldTM, and DetermineTM. HIV infection was confirmed if both rapid detection tests were posi-
tive and was absent if both tests were negative; in the event of discordant test results, a third rapid 
HIV antibody test, Med Mira RapidTMHIV, was performed as a tie-breaker. Clinical staging of 
HIV-infected patients was in accordance with the WHO expanded case definition for AIDS surveil-
lance of 1993.
Adrenal function was assessed using the short synacthen test prior to, and 2 weeks after com-
mencing ATT to allow sufficient time for induction of cytochrome P450 enzymes by rifampicin. 
Blood samples for serum cortisol measurement were collected before (time 0), and at 30 and 60 
minutes after intravenous administration of 250 micro grammes of synacthen, synthetic adreno-
corticotrophic hormone. Serum cortisol levels were measured after the study follow up was com-
pleted, using an automated analyzer (Roche E170). Hypoadrenalism was defined as a serum cortisol 
below 550nmol/l at 30 minutes. (18,19,20). Early mortality was defined as death before completion 
of one month of ATT. 
After hospitalization, participants were seen by the study clinicians as outpatients for the first 3 
months of ATT. If patients did not turn up for follow up visits, attempts were made to trace them in 
the community. In case this was unsuccessful, outcomes recorded by the district tuberculosis office 
were used to determine the vital status at one, two and three months. 
The sample size was determined to detect an effect size of 0.5, i.e. a change in mean cortisol level 
of half of one (within-subject) standard deviation.  The sample size required to achieve this with 
90% power is 44 if the cortisol levels follow a Normal distribution; this was increased to 50 to allow 
for the likelihood that the cortisol levels would, in fact, have a positively skewed distribution. Cor-
tisol levels did follow an approximate Normal distribution, and were analysed using single-factor 
repeated measures analyses of variance. A single missing cortisol reading was estimated using 
maximum likelihood imputation. All analyses were carried out using EPI-info version 3.3.2 and 
SPSS version 14 statistical programmes. Ethical approval for the study was granted by the Univer-
sity of Malawi College of Medicine Research and Ethics Committee. Informed written consent was 
obtained from all study participants.
Results
Fifty-one adult patients starting ATT for sputum smear-positive pulmonary TB were recruited from 
January 10th to June 14th 2005, of whom 29 (56.9%) were female. The main reason for admission 
of all patients was respiratory complaints. In 50 patients symptoms lasted two weeks or more. The 
median age was 32 years (range 18-62). Fifteen (39%) of the 38 patients known to be HIV positive 
were in WHO clinical stage IV. Eight patients (15.7%) declined, self-discharged or died before HIV 
testing. Thirty-eight (88%) of the remaining 43 patients were HIV-positive. The length of time from 
commencement of symptoms to start of ATT ranged from 7 to 365 days, with a median of 48 days. 
The median duration of symptoms was significantly longer in survivors versus those who died (60 
days vs. 30 days; p= 0.023). 
At one month the case fatality rate was 15.7%. (Table 1). Fourteen patients did not turn up for follow 
up study visits. Ten had also declined the second synacthen test. However, the vital status could be 
ascertained from all patients either through follow up or TB registry. Of the eight patients who died 
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in the first month, seven were HIV positive while the other was of unknown status. Five patients 
had signs consistent with sepsis. One also had severe anaemia. Of the other three, one suffered 
with chronic diarrhoea and severe anaemia (this patient had an unknown HIV status), the other 
had Kaposi’s sarcoma. One patient died at home from an unknown cause. The basal cortisol levels 
as well as the levels after synacthen stimulation were normal in all patients who died in the first 
month. During the study period, only two of 217 (<1 %)  in- and outpatients with sputum smear 
AFB positive TB who were registered in QECH, died before the start of ATT.
Hypo-adrenalism was found in only two patients on initial synacthen test and in none on the day 
14 test. Both patients were discharged home. One was alive and well at three month follow-up. The 
other declined further follow-up on discharge, but was known to be alive at three months. A sig-
nificant rise in mean cortisol level was seen in all groups (Table 2). No clinical features suggestive 
of hypo-adrenalism were noted.
Table 1. Outcome after commencement of anti-TB treatment. (ATT)
Time after commencing ATT Alive Dead
2 weeks 46 5
1 month 43 8
2 months 43 8
3 months 43 8
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Discussion 
This is the first prospective study in an African setting with high HIV prevalence to systemati-
cally evaluate adrenocortical function in TB patients at baseline and following enzyme induction 
by rifampicin. The high HIV prevalence (88%) amongst smear positive TB patients in this study 
is consistent with national Malawian co-infection rates (3). The mortality of 15.7% we recorded in 
the first month is in keeping with the high early mortality rates earlier found in Malawi. With two 
exceptions before treatment, all patients revealed a 30-minute serum cortisol level >550 nmol/L, 
adequate cortisol responses were therefore found in 96.1% of those commencing ATT. Further-
more, repeat sampling at two weeks showed no evidence of hypo-adrenalism in the 34 subjects of 
whom we were able to undertake a repeat sample. We used a widely accepted criterion to signify 
adequate adrenal reserve. (18,19, 20). In support of the findings at synacthen testing were basal 
cortisol concentrations indicating adequate adrenal reserve in all but one patient before rifampicin 
and in all patients post treatment. 
Neither of the two patients with hypoadrenalism died. Seven of the eight deaths in the first month 
appeared to have severe immunosuppression and the causes of death were common complications 
of advanced HIV infection. Despite a large range in time from presentation, the median delay in 
commencing ATT was only 6 weeks at QECH. 
Our study was limited by relatively small numbers, lack of knowledge of HIV status in a number 
of patients who refused testing and the fairly high proportion of patients who were unwilling to 
undergo the 14 day synacthen test. Given the low potential of selection bias and the full follow up, 
we believe our data are sufficiently robust to uphold the main conclusions.
Conclusions
There was a low prevalence of hypoadrenalism in this cohort of pulmonary TB patients with a 
high HIV co-infection rate and mortality was not associated with hypoadrenalism. Furthermore 
we found no evidence to support the hypothesis that rifampicin worsened or induced hypoadrenal-
ism to cause Addisonian crises and early mortality. This study therefore does not provide support 
for the use of steroids to supplement endogenous production in TB patients co-infected with HIV 
who start ATT. Further investigation into the aetiology of early mortality during ATT is urgently 
required.
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Abstract
Objective: We performed a cross sectional study to evaluate treatment results of the paying anti-
retroviral therapy clinic of Queen Elizabeth Central Hospital, a large public and teaching hospital 
in Blantyre, Malawi. The only antiretroviral therapy was a fixed drug combination of stavudine, 
lamivudine and nevirapine. 
Methods: Cross sectional study with interviews, laboratory tests (CD4 count, viral load, nevirapine 
plasma levels, transaminases) and data extraction from files.
Results: 422 (59 %) of the patients who started antiretroviral therapy since 2000 were lost to fol-
low up. The 176 patients enrolled in the study had good virological and excellent clinical treatment 
results. The most common side effect was peripheral neuropathy. Nevirapine plasma levels were 
remarkably high and associated with successful virological treatment results. Two simple adher-
ence questions pertaining to the use of medication in the previous 8 days corresponded well with 
nevirapine levels. The most important reasons for non-adherence were shortage of drugs in the 
hospital pharmacy and personal financial constraints.
Conclusions: 1. Many patients were lost to follow up. 2. High nevirapine levels contributed to good 
therapy results in those studied. 3.  Simple adherence questions predicted sub-therapeutic nevirap-
ine levels. 4. Antiretroviral drug supply needs to be uninterrupted and free of charge, to prevent 
avoidable non-adherence.
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Introduction
Malawi is among the countries with the highest burden of HIV infection in sub-Saharan Africa. 
Of a population of 10.5 million, 900,000 people were estimated to be infected with HIV by 2003 
(National Tuberculosis Control Programme, Ministry of Health HIV/AIDS Unit, Department of 
Clinical Services Ministry of Health, National AIDS Commission 2004). It is also one of the poor-
est countries, with a total annual healthcare expenditure of USD 123.9 million  (USD 11.8 per 
capita) (Malawi Ministry of Health and Population Website. 2004). The Government of Malawi 
introduced antiretroviral therapy (ART) in the central hospitals of the two major cities and the 
Queen Elizabeth Central Hospital (QECH) in Blantyre was the first to start an ART clinic in 2000. 
For the antiretroviral drugs patients paid on average USD 25 per month into a revolving fund, 
which was supported by the Ministry of Health and Population. Apart from the public sector, ART 
was also provided by some private hospitals to an unknown number of patients.
Initial ART activities in Africa generated some scepticism with warnings of “antiretroviral anar-
chy” (Harries AD et al. 2001). Inadequate health infrastructure, unavailability of skilled physicians 
and problems with drug procurement and delivery are considered major limitations to successful 
ART delivery. Other ART providers in Malawi include non-governmental organizations such as 
Medécins sans Frontières, who offer ART free of charge at two government district hospitals in a 
well-funded programme with adequate numbers of trained staff. Encouraging initial results were 
reported from one of these hospitals (Tassie JM et al. 2003). Others have also described favourable 
experience with ART from well-organised programmes in resource-poor settings (Farmer P et al. 
2000, Weidle PJ et al. 2002). However, if successful scaling-up of ART is to be introduced through-
out Malawi as indicated by the WHO 3 x 5 initiative (World Health Organisation. 2004), optimal 
use will have to be made of existing health structures as only limited extra funds and staff will be 
available. Clearly, previous experience from clinics that run under such circumstances may help to 
improve scaling-up activities both in terms of logistics as well as treatment results. To date there are 
few data available from ART clinics that are integrated in an existing hospital infrastructure and 
that run without additional human and financial resources.  We undertook a cross sectional study 
to evaluate treatment results from the Queen Elizabeth Central Hospital ART clinic with emphasis 
on clinical response, adherence, drug side effects as well as drug levels. 
Methods
Site
The Queen Elizabeth Central Hospital is a large public and teaching hospital in the centre of Blan-
tyre, the largest city in Malawi. The ART clinic was integrated in the outpatient department for 
fee-paying patients. We report results from the time patients paid fees for antiretroviral drugs, 
since 2004 the clinic provides free of charge ART. As the clinic expanded with an annual fourfold 
increase in patient numbers, the number of physicians involved increased from 1 to 5. All were 
from the current establishment of the College of Medicine and QECH. The number of half-day 
clinics increased from 2 per week in 2000 to 9 per week in 2003. One nurse and one clerk were 
available to the clinic throughout this period. 
Patients
Inclusion criteria were: age 18 years or older, naïve to antiretroviral drugs at the start of ART, and 
being on highly active ART at QECH for at least 6 months. Patients who had previously been on 
dual therapy were excluded. Patients were recruited at their scheduled visits to the ART clinic 
during a period of twenty weeks, from July to November 2003. All patients who were receiving 
treatment at QECH were expected to visit the clinic during this episode at least once, since the 
maximum number of prescribed tablets was for 3 months. 
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Antiretroviral drug treatment
Double nucleoside reverse transcriptase inhibitor (NRTI) therapy was the only ART available dur-
ing the first months in 2000. Triomune® (Cipla Ltd., Mumbai, India [Cipla website. 2004]), a fixed 
combination of stavudine, lamivudine and nevirapine, was introduced in 2001 and has since been 
the only form of highly active ART prescribed. Triomune® was chosen because it is inexpensive, 
effective (Kumarasamy N et al. 2003), and has a patient friendly dosing schedule of one tablet twice 
daily. No alternative regimens were available in case of treatment failure or side effects. To reduce 
hepatotoxicity and allergic skin reactions, nevirapine, but not the two NRTI’s, should be taken at 
half the dosage during the first 2 weeks (Cipla website. 2004), a schedule Triomune® does not 
allow. Separate NRTI’s were not available until 2003 and the patients in our population therefore 
started ART with a single tablet of Triomune daily, thus receiving only half of the required NRTI’s 
during the first 2 weeks. Drug unavailability was common: Triomune® was regularly out of stock 
from the start of the ART programme. Laboratory monitoring of side effects and treatment results 
was rarely done due to financial constraints of patients and poor laboratory facilities. 
Data collection
The following data were extracted from the ART clinic file of each enrolled patient: age, sex, WHO 
clinical stage of HIV infection (WHO 2004) at the start of ART, duration of ART, CD4 count at start 
of ART and AIDS defining events or pulmonary tuberculosis during ART. Height and weight, travel 
time from home to clinic as well as current medication other than Triomune® were recorded. We did 
not specifically ask for the use of traditional herbs. Laboratory tests and interviews for this study were 
performed only once for each enrolled patient. The study clinician and nurse, who were not members 
of the regular ART clinic staff, conducted interviews concerning side effects and adherence. Patients 
were encouraged to be open about possible non-adherence. They were assured that results of the 
adherence interview would be confidential, would not be communicated to the clinic physicians and 
would not affect their treatment in any way. We asked patients four short questions: did you miss 
a tablet the day before, the week before, the month before and did you never miss a tablet. We also 
asked for reasons for missing tablets. Interviews took place in either the local language or English, 
depending on the patient’s preference. Blood was drawn to measure CD4 count (FacsCount, Becton-
Dickinson, San Jose, CA, USA). Plasma viral load was determined by HIV-1 RNA Retina Rainbow 
Assay TM, from dried plasma spots on filter paper, stored at room temperature (Cassol S et al. 1997, de 
Baar MP et al. 2003). This assay is a single rapid real-time monitored isothermal RNA amplification 
assay that has a lower limit of detection of 50 copies/mm3 (de Baar MP et al. 2001). Further plasma 
samples were stored at –80 0C for subsequent determination of nevirapine levels (Hollanders RM et 
al. 2000) and alanine-aminotransferase (ALT) and aspartate-aminotransferase (AST). The laborato-
ries performed internal quality assurance procedures for viral load tests and CD4 counts.
Virological treatment failure was defined as the presence of a detectable viral load after a minimum of 
6 months of ART, immunological treatment failure as less than 25 % annual increase of the baseline 
CD4 count and clinical treatment failure as the occurrence of an AIDS defining event or pulmonary 
tuberculosis after being on ART for at least 6 months. Sub-therapeutic nevirapine plasma levels were 
defined as levels < 3.0 mg/L (HIV pharmacology Website 2004). Lastly, all files of the clinic were 
reviewed at the end of the study period to evaluate loss to follow up and possible causes thereof.
Statistical considerations
Data were entered and analysed by SPSS version 11.0 and Intercooled STATA 7.0 for Windows. 
Proportions were compared by Chi-square test and means by student-t test (for normally distributed 
data) or Kruskal-Wallis test (for data that were not normally distributed). Spearman’s correlation 
coefficient was used to test for associations with ordinal data. Odds ratios were calculated with 95% 
confidence intervals using the Mantel-Haentzel method. 
Ethical considerations 
The study was approved by the University of Malawi College of Medicine Research and Ethics 
Committee. Written informed consent was obtained from all patients at enrolment.
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Results
A total of 717 patients had visited the ART clinic prior to 1 January 2003, and were therefore 
eligible for the study. However, 453 patients did not attend for a planned visit of the clinic during 
the four months study period. In 31 patient files we found a documented reason: 11 patients died, 
11 patients stopped ART (7 due to side effects, 4 due to financial problems) and 10 patients were 
transferred to another ART clinic. For the remaining 422 (59 %) other patients no explanation was 
available. No detailed addresses or telephone numbers were recorded to trace patients, therefore 
they were considered lost to follow up. Of the 264 patients who started ART before 2003 and vis-
ited the clinic during the study episode, 88 did not fulfil the inclusion criteria (36 were not naïve to 
antiretroviral drugs at the start of ART, 19 were younger than 18 years and 33 did not give consent), 
thus 176 patients were enrolled into the study. Table 1 shows demographic, clinical and immuno-
logical data of the enrolled patients at the start of ART. Our study population had a median age of 
39 years (range: 22 – 71). There was a preponderance of women (55 %).
Twelve patients experienced a WHO stage IV clinical event or pulmonary tuberculosis after the 
start of ART (cryptococcal meningitis 2, oesophageal candidiasis 2, Kaposi’s sarcoma 2, pulmo-
nary tuberculosis 2, extra-pulmonary tuberculosis 2, Non-Hodgkin’s lymphoma 1, chronic diar-
rhoea and wasting 1). In 9 patients these events occurred before the completion of six months of 
ART and therefore clinical ART failure was present in only three cases. Two of the three cases 
also had virological treatment failure; one patient had pulmonary tuberculosis after 1 year of ART 
despite an undetectable viral load at the time of the study. Whether this was due background tuber-
culosis prevalence in the community or inadequate immune reconstitution at the time of diagnosis 
is unknown, since a CD4 count at that point was lacking. Insufficient clinical details were avail-
able to determine if events that happened early during ART were due to immune reconstitution 
disease. We found a low percentage of virological treatment failure: only 20 % of the patients had a 
detectable viral load. There was a significant trend of increasing virological treatment failure with 
increasing duration of ART (p for trend of odds = 0.002) (Table 2). Travel time from home to the 
ART clinic was not significantly associated with virological treatment failure (data not shown).
In 159 patients (90%) a CD4 count at the start of ART was available. Overall there was a mean rise 
of 68 CD4 cells/mm3 (95% confidence interval [CI]: 36 – 99) since the start of ART.   Stratifying by 
treatment duration did not show a significant difference in mean rise in CD4 count in those on treat-
ment <1 year as compared to those who had been on ART >1 year (p=0.58). Eighty-nine patients 
(56 %) had an increase of the CD4 count of more than 25 % per year, 15 patients (9 %) an increase 
of less than 25 % and 54 patients (34 %) had a decrease in the CD4 count. Therefore, 44 % met our 
criteria of immunological treatment failure. 
 
Results of interviews on side effects indicated that 76 % of the patients experienced at least one side 
effect at any time during ART. Numbness and pain in the lower extremities were the most common 
complaints (Table 3). Only 3 patients (3 %) mentioned side effects as a reason for non-adherence. 
There was no statistically significant difference in the frequency of side effects between men and 
women (data not shown). A minority of patients had increased transaminase levels but none had a 
rise of more than 5 times the upper limit of normal  (Table 3). 
During adherence interviews, 92 patients (52 %) reported never having missed a single tablet (and 
one did not know). However when subsequently asked for reasons of interruptions of ART, a total 
of 124 reasons were mentioned by 106 patients. The most frequent reason was unavailability of 
Triomune® in the hospital pharmacy (46 patients [43 %]).  Financial constraints and forgetting to 
take the tablets were mentioned by 34 (32 %) and 29 (27 %) patients respectively. 15 patients (14 
%) gave other causes of non-adherence. 132 patients (75 % of the study population) were unable to 
obtain Triomune® from the pharmacy because of inadequate supplies on at least 1 occasion, but 86 
managed to access alternative sources, as they did not indicate it as a cause for missing tablets.
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Table 1.  Demographic, clinical and immunological data at the start of ART of 176 patients studied   
       
Age groups (years)   n %
 18 - 29   19  (11 %)
30 – 39   70  (40 %)
40 – 49   54  (31 %)
 > 50    33  (19 %)
Sex 
 male   80  (45 %)
 female   96  (55 %)
    
Travel time home – clinic 
< 1 hour   113  (64 %)
 1 – 2 hours   40  (23 %)
 > 2 hours   23  (13 %)
    
WHO stage  
 I   7  (4 %)
 II   40  (23 %)
 III   56  (32 %)
 IV   22  (12 %)
 Unknown   51  (29 %)
CD4 strata (cells/mm3)  
 < 100   46 (26 %)
 100 – 199   49 (28 %)
 200 – 349   47 (27 %)
 > 350    17 (10 %)
 unknown   17 (10 %)
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Table 2.  Viral load in relation to duration of antiretroviral therapy
  total number                  number with    
         non-detectable detectable  
viral load (%) viral load1 (%)
duration of ART 
6 –12 months 95  84 (88 %) 11 (12%)
13 –24 months 79  56 (71 %) 23 (29%)
> 24 months 2   1 (50 %) 1 (50%)
total 176   141 (80 %) 35 (20%)
1 Since all patients had a minimum of 6 months antiretroviral therapy, a detectable viral load indicates viro-
logical treatment failure
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Table 3.  Number (%) of patients who experienced side-effects1 at any time during ART and transaminase 
levels at the time of study enrolment 
       n (%) 
numbness and/or pain of lower extremities    99  (56)
rash       45  (26) 
headache       40  (23)
nausea        26  (15)
vomiting       23  (13)    
  
dizziness       17  (10)
diarrhoea       18  (10)
abdominal pain      14   (8)
jaundice       1   (1)
other        27  (15)
ALT (Units/L)
< 45 (normal)      172    (98)
45 - 134       4      (2)
135 - 224       0      (0)
AST (Units/L)
< 40 (normal)      147    (84)
40 - 119       27    (15)
120 - 199       2     (1)
1 patients may have reported more than one side-effect
ALT = alanine-aminotransferase; AST = aspartate-aminotransferase; 
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Table 4.  Number (%) of patients per nevirapine plasma level group 
      
< 0.15 mg/L   (undetectable)  14  (8 %)
          
0.15 – 2.9 mg/L   (sub-therapeutic)  14  (8 %)
3 – 6 mg/L   (therapeutic)  41  (23 %)  
6.1 – 8 mg/L   (high therapeutic)  47 (27 %)
            
> 8 mg/L   (potentially toxic)   60  (34 %)
total       176  (100 %) 
 
148 (84%) of the study patients had nevirapine plasma levels in the therapeutic range [15] or higher 
(Table 4). From the 4 adherence questions, there was a significant association of sub-therapeutic 
nevirapine levels with having missed a tablet of Triomune® the day before (odds ratio [OR] 15.1; 
CI 4.6 – 50.0; p <0.0001) or the week before (OR 6.5; 95% CI 2.2 – 19.1; p=0.0001). Those with a 
sub-therapeutic nevirapine level had an OR of 6.0 (95% CI 2.4 – 15.3) for virological failure, as 
compared to those with therapeutic or higher levels. There was a borderline significant association 
between a high therapeutic or potentially toxic level and a higher risk of side effects (OR 2.0; 95% 
CI 1.0 - 4.1; p=0.05). There was no difference in the proportion of males and females with sub-
therapeutic nevirapine levels (17.5 % and 14.6 % respectively; OR 1.24; 95% CI 0.55 – 2.80; p=0.60) 
or with high or potentially toxic nevirapine levels (57.5 % and 63.5 % respectively; OR 1.3; 95% CI 
0.7 - 2.4; p=0.42). There was no correlation between body mass index and nevirapine plasma level 
(rs = 0.80; p=0.1).
Discussion
We conducted a cross sectional study to evaluate treatment results of the first government ART 
clinic established in Malawi, which operated in a resource-poor health care setting. The main fea-
tures of this study were the high loss to follow up and the good treatment results in those who were 
adherent, probably due to the higher than expected nevirapine levels. 
Nearly 60 % of the patients who started ART were lost to follow up and could not be evaluated in 
our study. The reasons for this large loss to follow up could not be ascertained.  One quarter of these 
patients never returned after a first visit and we therefore have no confirmation that they actually 
started ART. Financial constraints are likely to have been an important cause of loss to follow up. 
Many patients were dependent on their income as small-scale entrepreneurs for buying antiretro-
viral drugs and they, as well as others who were employed, would have had no source of income 
on becoming chronically ill - in the absence of social security and medical insurance. Others were 
financially dependent on relatives for buying drugs. Another related reason was self initiated trans-
fer to other ART centres. Two well-organised clinics in neighbouring districts hospitals, coordi-
nated by Médecins sans Frontières, offered free ART, which attracted many Blantyre residents (A. 
Jeannin, personal communication). Lastly, a number of people may have died; as there are no death 
registers in Malawi, no information concerning mortality was available. 
The patients enrolled in our study generally started ART when they reached an advanced stage of 
HIV infection: nearly all were symptomatic and had CD4 counts below 350 / mm3. Almost two 
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thirds of those in whom a WHO stage was documented were in stage III or IV. Despite this they 
had good virological and excellent clinical treatment results. Half of the detectable viral loads were 
below 500 copies / mL and since we only had one measurement, some of these patients may have 
had so called blips, temporarily detectable viral loads during otherwise successful ART (Karlsson 
AC et al. 2004). Therefore the virological treatment failure is likely to be lower than the 20 % we 
found. 
There are several explanations for these good results. Clearly, the cross sectional design of our 
study led to selection bias: among those lost to follow up may have been more treatment failures 
and deaths. On the other hand, all our patients were antiretroviral drugs naïve and were treated 
with a simple, effective and adherence promoting ART regimen. Importantly, large numbers of 
patients had higher than expected nevirapine plasma levels. Our study describes nevirapine levels 
in the largest series of African patients to date.  High nevirapine levels have been associated with 
good virological treatment results in developed countries (Veldkamp AI et al. 2001), which was 
confirmed in our study. Nevirapine plasma levels in cohorts in the developed world on average 
showed lower values than in our study population (Donnerer J et al. 2003, Zhou XJ et al. 1999). 
Lower body mass index and a preponderance of females  (Regazzi M et al. 2003) could have 
explained the higher nevirapine levels in our study, but neither was associated with high nevirapine 
levels. We hypothesize that genetic factors involving nevirapine metabolism in the liver may lead 
to higher nevirapine levels, similar to what was recently described for efavirenz in non-Caucasians 
(Ribaudo H et al. 2004). The high nevirapine levels may have implications for nevirapine usage 
during rifampicin containing tuberculosis treatment. If confirmed, it improves the prospect that 
nevirapine in combination with rifampicin, despite their interaction, may still lead to adequate 
nevirapine levels and good ART results in African patients, as was found by others in Europeans 
(Oliva J et al. 2003).
Our good virological and clinical treatment results are in contrast with the immunological find-
ings; one third of the patients had a decrease in CD4 count compared to the start of treatment 
value. These first CD4 count results need to be regarded with caution. They were done in at least 
7 different laboratories; the majority were done by manual CD4 count assays, a group of methods 
more sensitive to subjective interpretation (Crowe S et al. 2003). Furthermore, CD4 counts can 
vary over time and we were only able to compare two measurements, mostly with long intervals 
in between. Our definition of immunological failure was strict and several other definitions are in 
use (Department of Health and Human Services 2004, World Health Organisation 2004), but these 
assume regular CD4 counts or a known peak value on ART and neither was available. In view of 
our results, we do not recommend the use of isolated immunological treatment failure as an indica-
tion for second line ART in resource poor settings, particularly if regular and reliable CD4 counts 
are not available. 
The side effects we observed showed an expected pattern for patients treated with Triomune®. The 
high level of suspected peripheral neuropathy may have been influenced by the fact that 32 % of the 
patients had a bodyweight below 60 kg, while Triomune® containing stavudine 30 mg (the advised 
dosage for persons below 60 kg, instead of 40 mg) was unavailable for most of the study period. 
Having a high nevirapine plasma level appeared to be associated with clinical side effects but this 
did not reach statistical significance. It did not seem to lead to abnormal transaminases levels.
We used a simple questionnaire to assess adherence to ART.   Two questions pertaining to having 
missed a tablet a day before or a week before the clinic visit correlated with sub-therapeutic nevi-
rapine plasma levels. Virological treatment failure was not associated with a positive response to 
any of the four questions. The results of the interviews indicated good adherence in our population, 
but it was not possible to extrapolate the result of the 4 questions into an individual adherence of 
more than 95 %, which is a much quoted target in the literature. Whether this target is as relevant 
in our population is uncertain, since many of the patients in the western cohorts from which this 
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percentage originated, used protease inhibitor-based ART (Turner BJ. 2002). Pill counts and more 
detailed interviews could be used to generate an individual adherence percentage, but these meth-
ods are elaborate, time-consuming and may not be feasible in many African ART clinics. More 
studies are required to validate methods of adherence testing in resource poor ART settings. Mean-
while, we advise the use of the two simple questions mentioned above, to identify persons who 
are more likely to have low antiretroviral drug levels - and are therefore at higher risk to develop 
virological treatment failure - for additional adherence counselling. The reasons for non-adherence 
in our study were very different from those found in developed countries: unavailability of drugs 
and personal financial problems accounted for two thirds of the non-adherence. Despite the fact 
that many patients managed to access Triomune® from an alternative source, more than one third 
of the total reported non-adherence in our study resulted from the unreliable drug supply. 
Our study demonstrates the difficulties encountered in a fee-paying ART clinic in a resource-poor 
setting, largely unsupported by international donors. While it was possible to run the clinic with 
the limited resources available, there was a large loss to follow-up, most likely related to drug 
costs. The high percentage of loss to follow-up does not allow extrapolation of the results to all the 
patients who visited the clinic to start ART. Nevertheless, the patients studied showed good viro-
logical and excellent clinical outcome. Unexpectedly high nevirapine plasma levels in most patients 
may have contributed to this. Provision of free of charge ART with reliable drug supply will result 
in better access to ART, reduction of loss to follow up and promotion of adherence and these are 
prerequisites for successfully scaling-up ART programmes in resource-poor settings.
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Abstract
The antiretroviral therapy clinic of Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi 
was established as a fee paying clinic in 2000. In 2004 a successful transition to free-of-charge 
antiretroviral therapy (ART) provision was made with the introduction of the national ART scale-
up programme. Despite the human resource crisis in the healthcare system, remarkable improve-
ments in quantity and quality of care, a reduction of defaulters, favorable ART outcomes and better 
access to ART for the poor, women and children were achieved. A number of challenges need to be 
overcome to sustain the initial success of the national ART scale-up programme in QECH, the most 
important being the shortage of ART staff in relation to the ever-expanding patient population.
080356 Oosterhout BW.indd   98 11-11-2008   15:48:54
99
Introduction
Malawi, one of the world’s poorest nations, has been hit by a devastating HIV epidemic. It is esti-
mated that, out of a population of 12 million, nearly one million people are infected. In the age 
group of 15 - 49 years the HIV prevalence is 14% and 87,000 die from AIDS each year (Republic of 
Malawi National AIDS Commission, 2004). This resulted in a drop of the average life expectancy 
at birth to less than 40 years in 2004. In the area around Blantyre, the commercial capital of the 
densely populated southern region, HIV prevalence is the highest in the country (Department of 
Nutrition, HIV & AIDS, 2005). The average annual health expenditure is only US$12 per capita 
(Department of Nutrition, HIV & AIDS, 2005). Malawi’s limited healthcare resources make it 
extremely difficult to deal effectively with an HIV epidemic of this magnitude. Particularly cum-
bersome is the human resource crisis in the health sector. Migration to richer countries (‘brain 
drain’) and high morbidity and mortality in healthcare staff (Harries et al., 2002), among other 
factors, have resulted in the availability of one doctor per 64,000 and one nurse per 3,500 persons 
respectively (Department of Nutrition, HIV & AIDS, 2005).
In these challenging circumstances the Ministry of Health and Population (MOHP) developed an 
ambitious national ART scale-up plan that has been implemented since 2004 (Harries et al., 2006). 
We describe the implications of the introduction of this programme in the ART clinic of Queen 
Elizabeth Central Hospital (QECH) and discuss factors that are currently challenging the quality of 
care and further scale-up of ART in this clinic. 
The beginning of ART in the public sector in Blantyre
Queen Elizabeth Central Hospital is the largest hospital in Malawi and the only hospital that pro-
vides a free-of-charge health service in Blantyre. While it should function as a tertiary facility, in 
fact it provides mainly primary and secondary care. In 2000 the MOHP launched the ART clinic 
in QECH, the first in a government healthcare facility in Malawi. There was pressure to start an 
ART programme but, due to restrictions in finance and expertise within the MOHP, preparations 
had been limited. Since antiretroviral (ARV) drugs were not available free of charge, patients had 
to pay into a revolving fund that was subsidized by the government. Dual ARV drug therapy was 
provided to a small group of patients until 2001, when a generic, fixed dose, triple ART combina-
tion (stavudine, lamivudine and nevirapine) became available. 
The Department of Medicine of the College of Medicine (COM), took up the coordination of the 
ART clinic in order to improve clinical care, however the logistics of the clinic (non-clinical staff, 
drug supply, financial administration) remained under the MOHP. During the period from 2001 to 
2004, when the patient population steadily expanded, a number of shortcomings were identified. 
Non-clinical staff was not trained in ART and ART guidelines and standard operating procedures 
were lacking. Determining eligibility, ART counseling and initiation of ART generally took place 
within a single visit. Alternative ARV drugs were not available in case of side-effects or treat-
ment failure. The fixed drug combination did not allow the required nevirapine lead-in phase in an 
appropriate manner. Only a small fraction of the patients were children. For most people ART was 
prohibitively expensive despite subsidization by the government and the gradually decreasing mar-
ket price of generic ARV drugs. Many who managed to start ART could no longer afford it later. 
Irregularities in the financial administration of the revolving fund and logistical problems regularly 
led to interrupted supplies of ARV drugs. An evaluation of the ART clinic in 2003 concluded that 
there was a loss to follow up of 59% of the patients ever started on ART and that the most common 
causes of non-adherence were stock-outs of ARV drugs in the hospital pharmacy and personal 
financial problems (van Oosterhout et al., 2005). While the clinical care had gradually improved, 
the logistical situation in the ART clinic remained problematic until July 2004.
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Introduction of the national ART scale-up programme in QECH
In 2003 an HIV unit was established in the MOHP that developed national ART guidelines, guide-
lines for management of HIV associated illnesses and an ART scale-up plan, in cooperation with 
the coordinators of the existing Malawian ART clinics (the Lighthouse clinic Lilongwe, Medécins 
sans Frontières, faith based organizations and the COM). Funding was obtained through the Global 
Fund to fight AIDS, TB and malaria. A large number of healthcare workers received a theoreti-
cal and practical ART training and were certified and registered as ART clinician, nurse or clerk 
(Makombe et al., 2006). Antiretroviral drugs were provided free of charge. The MOHP gave ART 
scale-up high priority and called healthcare workers away from their stations for three-weeks of 
training. From July 2004 onwards, 60 new ART clinics in government and mission hospitals were 
opened throughout the country and the number of patients ever started on ART in the public sec-
tor increased from 4,000 early 2004 to nearly 70,000 at the end of September 2006 (Ministry of 
Health, Malawi, 2006). 
In July 2004 the transition took place in QECH from its fee-paying system to the free programme 
with the introduction of the new national ART guidelines. An extra nurse and two HIV counselors 
were added to the clinic staff, all of whom received ART training. Clinicians started providing 
ART service five full days per week. In preparation to starting, ART patients attend the clinic to 
determine eligibility and for a separate ART counseling group session. At a third visit, ARV drugs 
are dispensed after individual ART counseling and a clinical review. It is compulsory that a guard-
ian accompanies the patient during these first visits. Although the capacity of the QECH labora-
tory to do CD4 counts gradually increased, the vast majority of patients continue to be enrolled 
on clinical criteria (WHO stage III and IV). A starter pack ARV drug formulation for the first two 
weeks allows a formal nevirapine lead-in phase. Alternative ARV drugs are available: efavirenz for 
patients with clinical hepatitis and severe rash caused by nevirapine; zidovudine for patients with 
peripheral neuropathy, lactic acidosis or pancreatitis caused by stavudine. Recently, a regimen of 
tenofovir, zidovudine, lamivudine and Kaletra was introduced on a small scale for patients with 
ART failure. Monitoring of ART remains largely done by clinical parameters, both for side effects 
(e.g. jaundice to indicate nevirapine induced hepatotoxicity) and treatment failure, i.e. a new WHO 
stage IV events after six months of ART. As before, simple radiology, hematology, biochemistry 
and microbiology investigations are only available for small numbers of selected patients, in partic-
ular those who participate in research studies. Standardized treatment outcomes are registered for 
quarterly reports and discussed during supervision visits by a team from the MOHP HIV Unit.
More than 4,500 patients were registered at the end of August 2006. An overview of the patient char-
acteristics and treatment outcomes is given in Table I and compared to the situation of the fee paying 
ART clinic. A striking difference is the dramatic drop of the number of defaulters (defined as not turn-
ing up for ARV drug collection for three consecutive months). At least two factors are responsible for 
this: the free-of-charge availability of ART and the specific attention to the importance of adherence 
before starting ART. Staff limitations do not allow tracing of defaulters and formal death registers do 
not exist in Malawi, therefore it is likely that a significant number of defaulters have actually died, in 
particular since more had an AIDS diagnosis than non-defaulters (Hartung et al., 2006). Indeed, mor-
tality explained between 30 and 50% of defaulting in two large prospective studies in the ART clinic 
of QECH (E. Moore & M. Ndekha, unpublished data) and in a large urban ART clinic in Lilongwe, 
Malawi (S. Phiri, personal communication), where teams carried out active defaulter tracing. 
We also found that non-adherence to ART (as measured by pill counts) and side-effects were more 
common among defaulters, suggesting that more attention to these problems could reduce the per-
centage of defaulters. The cost of travel to an ART clinic in a central or district hospital may induce 
defaulting (Zachariah, Harries et al., 2006), which could be addressed by decentralization of ART 
to health center level. Measures to minimize defaulting need to be explored as a priority, as the 
prevalence of defaulting is still unacceptably high and increasing with time on ART (Table II), 
which indicates that the overall defaulter rate will rise in the near future.
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The capacity to enroll new patients on ART increased from 375 new patients per year in the old 
clinic to 1,740 patients per year in the new clinic. The percentage of women increased from 45% in 
2002 to 60% in 2005. The Department of Paediatrics of the COM, Blantyre started coordinating 
the rapidly expanding children’s clinic (Ellis & Molyneux, 2006). 
Since UNICEF took over the ARV drug acquisition, delivery and distribution for the national ART 
programme in July 2004, there have been no stock-outs in the QECH pharmacy, in sharp contrast 
to the 2000 - 2003 period. Table II shows a survival analysis of three cohorts starting ART in the 
new QECH clinic at different time points and comparison with national data, indicating favorable 
ART outcomes in QECH. 
Through its affiliation with the COM, the ART clinic of QECH has a teaching function for medical 
under- and postgraduates, clinical officers and nurses. It provides practical training attachments 
for clinicians and nurses in the national ART scale-up programme. It is the referral clinic for ART 
clinics in the southern region of Malawi. Clinicians also offer consultation by telephone and e-mail. 
The Department of Medicine organizes monthly clinical meetings for ART clinics in the region. 
The clinic is involved in a nationwide HIV drug resistance survey and several operations research 
projects.
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Table 1. Comparison of characteristics and cumulative treatment outcomes of the ART clinic of 
QECH before and after the introduction of the National ART scale-up programme.
Old ART clinic New ART clinic
Period 2000 – 2003 2004 – 2006
 (~ 3 years)  (2 ¼ years)
Funding Fee paying Subsidized 
revolving fund ARV’s 
Ministry of Health
Free of charge GFtfATMa Ministry of 
Health
Framework None National ART scale-up programme
Number ever started ~ 1500 4551 (including 700 transfers from old 
clinic)d
Number of women 45%b 2731  60%
Number of children 5%b   467  10%
Indication to start ART:
WHO stage III unknown 2730  60%
WHO stage IV unknown   938  21%
CD4 < 200/mm3 unknown   883  19%
Deaths unknown   252  6% 
Died during first 2 months unknown   123  49%
of ART
Lost to Follow up 59%c   352  8%
Transfer other ART clinic unknown   444  10%
Stopped ART unknown     33   <1%
On alternative first line 
ART (due to side effects)
none     95   2%
Alive and on ART unknown 3470  76%
a. GFtfATM = Global Fund to fight AIDS, Tuberculosis and Malaria
b. Cross sectional survey 2002 (J. van Oosterhout, non-published data)
c. Reference 4
d. Reference 5, also used for other data New ART clinic
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Current challenges
Prior to starting the new ART clinic in QECH, 150 new enrolments per month had been estimated 
to be feasible on the basis of staff and drug availability; further expansion to 250 new patients 
per month was thought to be beyond the current capacity of the clinic. Despite the fivefold rise in 
the capacity to begin ART, demand for free ART was such that the waiting list quickly grew to 
six months. Paradoxically, starting 150 new patients monthly was difficult to achieve, probably 
because many patients died while on the waiting list. This led to debate among the ART clinic staff 
as to whether certain groups, such as pregnant women, children or patients with Kaposi’s sarcoma 
should have an advantage to begin ART over others. After intensive discussions and consultation 
with bioethicists, it was agreed that only health care workers would be exempted from the first-
come-first-served principle, in line with MOHP guidelines. When other ART clinics opened in the 
region during 2005, the waiting list became shorter but has recently increased again, as other clin-
ics developed their own waiting lists.
The staff situation is unstable: the majority of clinicians are from the Departments of Medicine 
and Paediatrics of the COM rather than from the MOHP and many are expatriates with short-
term contracts. Contrary to other large ART clinics in Malawi, the ART clinic of QECH does 
not receive major financial support from non-governmental organizations (NGOs) but expansion 
of the currently small scale support from NGOs may be feasible. Support from the Global Fund 
could not be utilized to create more staff positions. Moreover, providing positions with attractive 
salaries could be at the expense of other equally important programmes. Already, the ART clinic 
requires the input of two Whole Time Equivalents (WTE), for one consultant and one clinical offi-
cer respectively, of which only 0.1 WTE is contributed by the MOHP; the remainder is provided 
by the COM. In comparison, all other QECH medical clinics together require 0.5 and 0.1 WTE, 
respectively. Similar to the situation in most ART clinics in Malawi, clinicians and nurses in QECH 
have accepted the extra responsibility and workload of ART provision, motivated by the clinical 
improvement most patients show. There is, however, a real risk of overburdening that could lead to 
frustration and demotivation. The human resource crisis in Malawi’s healthcare system is profound 
and results from promising initiatives (Palmer, 2006) will probably take many years and may not 
be sufficient.
Limiting the number of patients in the ART clinic of QECH to a certain maximum would be against 
tradition in the Malawi public healthcare system; for example, bed-occupancy rates in the wards of 
QECH and other hospitals are often >100%. If continuing expansion of the ART population occurs 
beyond the staff capacity of the clinic, loss of quality of individual care is likely to ensue. Since 
morbidity, immunological and virological outcomes are not routinely recorded it is likely that any 
negative influence on ART outcome will be reflected late in the standardized treatment outcomes 
of the national ART scale-up programme. It is therefore important that detailed surveys of ART 
results of government funded clinics take place, as performance may not match favorable results 
from ART clinics with extensive NGO funding (Ferradini et al., 2006; Zachariah, Fitzgerald et al., 
2006). Such initiatives are under way in QECH (Moore et al., 2006).
The volume of patient files has grown beyond the capacity of the clerking staff and it has become 
very difficult to manually compile reliable quarterly reports that are required by the national ART 
programme. A pilot project to computerize the administration with touch screen units and specifi-
cally developed software has recently started, funded by an external donor. We observe increasing 
numbers of patients with suspected ART failure. This trend will continue when the honeymoon 
phase of the scale-up programme (the majority of patients being on first line ART for a relatively 
short duration) has passed and thousands of cases of ART failure will require appropriate medical 
care. In this respect, the ART clinic of QECH is increasingly functioning as a secondary and/or 
tertiary referral center, which increases the work burden, as the clinical management of these prob-
lems is relatively complicated and time consuming. In addition, the diagnostic tools at our disposal 
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are insufficient. At the moment we use clinical and immunological criteria to determine eligibility 
for second line ART, while the diagnosis of ART failure is far from straightforward without the 
availability of HIV viral load tests (Bisson et al., 2006). Furthermore, the provision of reliable CD4 
counts is not always guaranteed.
Patients with long-term side effects of stavudine, such as severe peripheral neuropathy, lipodystro-
phy and suspected lactic acidosis and pancreatitis, also claim increasing attention. Solutions for 
diagnosing and management of ART failure and long-term side effects that are adapted to resource-
poor settings are urgently needed.
Training and research projects aim to provide longer-term solutions to current constraints and are 
primary tasks of the majority of the clinicians of the ART clinic of QECH. Research and training 
projects offer opportunities to support the ART clinic by bringing in staff who contribute to ART 
provision. Care has to be taken that an overwhelming patient burden does not interfere with the 
quantity and quality of research and training. Clinicians of the ART clinic of QECH are well posi-
tioned to provide on-site technical support and supervision of ART clinics in the region but such 
activities cannot yet be initiated due to staff shortages.
In 2005 the ART clinic moved to a new, dedicated building, which, due to the rapidly increasing 
number of patients, is already too small and an extension is required. Improvement of the clinic 
logistics and strengthening links with other HIV services (prevention of mother-to-child transmis-
sion, voluntary counseling and testing, tuberculosis treatment) can contribute to a higher efficiency 
of the ART clinic but will require an investment in management capacity. Task shifting of routine 
ART care from highly qualified staff to cadres with limited training can help to relieve the work-
load and save money. Initial steps in this direction have been taken, although evidence that task 
shifting can be introduced without loss of quality in this setting is limited. Several ART clinics 
have recently opened within Blantyre, both in the public and private sector. Decentralization to 
health center level and cooperation with the private sector can relieve the primary care burden on 
the ART clinic of QECH and help to maintain the referral, teaching and research functions. Worry-
ingly, the capacity of these new ART clinics appears to have been saturated within a short period. It 
is unlikely that demand for ART will reduce in the near future as the incidence in Malawi appears 
to have been stable (Bello et al., 2006) and HIV testing campaigns and the wider availability of 
CD4 testing may increase the number of persons identified as eligible for ART.
Conclusion
It is evident that the introduction of the national ART scale-up programme in QECH resulted in a 
sharp increase in the number of patients on ART, improved access to ART for women, children and 
the poor, better documentation and reporting, improved quality of individual care and favorable 
ART outcomes. The clinic has established itself as a regional ART referral center and has important 
academic and research functions. However, in view of the current challenges in QECH and other 
ART clinics in Malawi relying on government funding, it will be difficult to live up to expectations 
to provide ART to all who are eligible, while maintaining an acceptable quality of care. The most 
urgent threat to the early success of the national ART scale-up programme is the shortage of ART 
staff relative to the expanding patient population.
Task shifting of routine ART care, accessing alternative sources of funding for ART staff and bal-
ancing primary and referral care in the context of increasing ART decentralization to health centers 
are measures that can maintain ART care of sufficient quality.
080356 Oosterhout BW.indd   104 11-11-2008   15:48:54
105
References
Bello, G.A., Chipeta, J., & Aberle-Grasse, J. (2006). Assessment of trends in biological and behavioural sur-
veillance data: Is there any evidence of declining HIV prevalence or incidence in Malawi. Sexually Transmit-
ted Infections , 82(Suppl. 1), S9-S13.
Bisson, G.P., Gross, R., Strom, J.B., Rollins, C., Bellamy, S., Weinstein, R., et al. (2006). Diagnostic accuracy 
of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS, 
20, 1613-1619.
Department of Nutrition, HIV and AIDS, Office of the President and Cabinet (2005). Malawi HIV and AIDS 
Monitoring and Evaluation Report 2005. Follow-Up to the Declaration of Commitment on HIV and AIDS 
(UNGASS).
Ellis, J.C., & Molyneux, E.M. (2006). Experience from a public sector antiretroviral treatment clinic for HIV-
infected children in Malawi: The first twelve months. Archives of Child Diseases, 91(Suppl. 1), S23.
Ferradini, L., Jeannin, A., Pinoges, L., Izopet, J., Odhiambo, D., Mankhambo, L., et al. (2006). Scaling up of 
highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet , 367, 
1335-1342.
Harries, A.D., Hargreaves, N.J., Gausi, F., Kwanjana, J.H., & Salaniponi, F.M.L. (2002). High death rates 
in healthcare workers and teachers in Malawi. Transactions of the Royal Society of Tropical Medicine and 
Hygiene , 96, 34-37.
Harries, A.D., Schouten, E.J., & Libamba, E. (2006). Scaling up antiretroviral treatment in resource-poor 
settings. Lancet , 367, 1870-1872.
Hartung, T.K., Nyirongo, G., van Oosterhout, J.J.G., Hofland, H.W., & Zijlstra, E.E. (2006). Retrospective 
description of a defaulter cohort at a large governmental ART clinic in Blantyre, Malawi. XVI International 
AIDS Conference Toronto Canada. Abstract CDB0607.
Kachapilla, R., Nyirongo, G., Mhango, B., Cohen, D., & van Oosterhout, J.J. (2006). ARV therapy Clinic 
QECH Quarterly Report Q3-2006.
Makombe, S., Libamba, E., Harries, A., Phiri, S., Weigel, R., van Oosterhout J., et al. (2006). National Train-
ing and Accreditation for Antiretroviral Therapy scale-up in Malawi. XVI International AIDS Conference 
Toronto Canada. Abstract WEPE0077.
Ministry of Health, Malawi (2006). HIV Unit, ART Quarterly report for September 2006.
Moore, E., van Oosterhout, J.J.G., & Zijlstra, E.E. (2006). A prospective study of treatment outcomes and 
side effects in HIV-1 infected adults commencing TRIOMUNE† (fixed dose combination of nevirapine, sta-
vudine, lamivudine), with and without viral hepatitis coinfection, in Blantyre, Malawi. Research in Progress 
2006 conference, Royal Society of Tropical Medicine and Hygiene, Liverpool, United Kingdom.
Palmer, D. (2006). Tackling Malawi’s human resources crisis. Reproductive Health Matters , 14, 27-39.
Republic of Malawi National AIDS Commission (2004). HIV and AIDS in Malawi 2003: Estimates and 
implications.
van Oosterhout, J.J., Bodasing, N., Kumwenda, J.J., Nyirenda, C., Mallewa, J.,  Cleary, et al. (2005). Evalu-
ation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Tropical Medicine and 
International Health , 10, 64-470. 
Zachariah, R., Harries, A.D., Manzi, M., Gomani, P., Teck, R., Phillips, M., et al. (2006). Acceptance of anti-
retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated 
with cost of transport. Plos ONE, 27, 121.
Zachariah, R., Fitzgerald, M., Massaquoi, M., Pasulani, O., Arnould, L., Makombe, S., et al. (2006). Risk 
factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS, 20, 
2355-2360.
080356 Oosterhout BW.indd   105 11-11-2008   15:48:55
080356 Oosterhout BW.indd   106 11-11-2008   15:48:55
Chapter 9
Nevirapine based antiretroviral  
therapy started early  
in the course of tuberculosis  
treatment in adult Malawians. 
Joep J.G. van Oosterhout1, Johnstone J. Kumwenda1, Michael Beadsworth1,2, 
Gabriel Mateyu1, Temba Longwe1, David M. Burger3, Edward E. Zijlstra1
1. University of Malawi College of Medicine, Department of Medicine, Malawi
2. Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, UK
3. Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, the Netherlands
 
Antiviral Therapy 2007; 12:515-21
080356 Oosterhout BW.indd   107 11-11-2008   15:48:55
108
Abstract
Background: The tuberculosis (TB) mortality rate of registered TB patients in Malawi is 23%, 
and 59% of the deaths occur in the first 2 months of treatment. HIV related complications appear 
to be an important cause. Starting antiretroviral therapy early during tuberculosis treatment may 
improve outcome but problems often arise with drug interactions, adherence, toxicity and immune 
reconstitution disease (IRD).
Methods: We prospectively followed 27 HIV-infected adult Malawians after starting Triomune® 
(a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of 
tuberculosis treatment.
Results: At baseline, 88% had CD4+ T-cell counts <100 cells/ml, all were anemic and 78% were 
malnourished. Five patients (19%) died, two withdrew consent and one stopped all drugs due to 
hepatitis. At 6 months, all but one of the 19 remaining patients had good virological results (16 
patients: <400 copies/ml, two patients: <1,000 copies/ml) and the median CD4+ T cell increase 
was 170 cells/ml. Adverse events were numerous, particularly in the first 2 months. Suspected 
IRD episodes could be managed without treatment interruptions. During the lead-in phase, 59% of 
nevirapine plasma levels were sub-therapeutic despite good adherence, compared with only 14% 
during weeks 4 and 8. 
Conclusion: It is feasible to start Triomune® early during TB treatment with good treatment out-
come. The nevirapine lead-in phase should be avoided when rifampicin-based tuberculosis treat-
ment is started >1 week beforehand.
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Introduction
Malawi is one of the countries most affected by the HIV epidemic in sub-Saharan Africa. The 
prevalence of HIV in adults is estimated at 15% [1]. There is ample evidence that HIV is the driving 
force behind the resurgence of tuberculosis (TB) in the area. The number of reported TB cases in 
Malawi has increased fourfold since 1985 and up to 75% of TB cases are HIV-related. The mortal-
ity during TB treatment is 23%, and 59% of deaths occur within the first 2 months [2]. The causes 
of this high early mortality have not been fully elucidated but HIV-related complications are likely 
to play an important role.
Antiretroviral therapy (ART) can improve the outcome of HIV-infected TB patients [3,4], but the 
best time to start ART in HIV-infected patients presenting with TB has not been fully ascertained 
[5]. Potential problems of combined TB treatment and ART include interactions between rifampi-
cin and antiretroviral drugs that may lead to reduced plasma concentrations of the antiretroviral 
drugs and subsequent development of viral resistance. The number of side effects may increase and 
as the pattern of side effects of antiretroviral drugs and antituberculous drugs overlaps, frequent 
interruptions of both TB treatment and ART can be expected. TB immune reconstitution disease 
(IRD) appears to be common, especially when ART is started early during TB treatment. IRD has 
a diverse clinical picture and can cause diagnostic and therapeutic dilemmas. Lastly, the high pill 
burden is a risk factor for non-adherence, to which ART is particularly vulnerable [6].
The Ministry of Health of Malawi started an ART scaling-up programme in 2004, in which the 
only first line regimen is Triomune®, a fixed drug combination of lamivudine, stavudine and nevi-
rapine (NVP). It is effective, low-priced, has a patient-friendly dosage and a side-effect profile 
well known to local clinicians. With half of the patients on ART being women of childbearing 
age it is important that Triomune® can be used during pregnancy, unlike efavirenz [7], which is 
recommended during rifampicin-containing TB treatment [6]. Efavirenz is also more expensive 
and not available in a generic fixed drug combination tablet. There are no studies assessing clinical 
and pharmacological outcomes of combined use of NVP and rifampicin in Africans. In one study 
from Spain a mean reduction of NVP plasma levels of 31% was observed in 10 patients studied [8], 
another documented adequate NVP plasma levels in 32 patients with good ART clinical efficacy 
[9]. In a Thai study, NVP levels were lower than in controls not taking rifampicin but virological 
results of ART were equally good [10].
Over 40,000 Malawian patients had started Triomune® early in 2006 [11]. Active TB is a common 
indication for ART. Current practice in Malawi is to defer Triomune® for 2.5 months, when rifam-
picin no longer forms part of the TB treatment regimen. However, to have the largest possible effect 
on mortality, ART would need to be started earlier during TB treatment. We explored the feasibility 
of the NVP/rifampicin combination and the early commencement of ART in adult Malawians with 
advanced HIV/TB co-infection.
Patients and Methods
Site description The study took place from April 2005 to June 2006 in the TB ward and outpatient 
ART clinic at Queen Elizabeth Central Hospital (QECH). This is a large public and teaching hos-
pital in Blantyre, the commercial center of Malawi. It is the only hospital that offers free medical 
care in Blantyre, including free ART since July 2004. The medical wards of QECH admit 10,000 
patients per year and 3,000 patients were registered at the ART clinic during the time of the study. 
Study subjects Patients aged 18 years or older, living in the catchment area of QECH who were reg-
istered for treatment of sputum smear acid-fast bacilli (AFB) positive pulmonary TB were encour-
aged to undergo voluntary counseling and testing for HIV. Those who were found to be positive, 
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naive to ART and had a CD4+ T-cell count <200 cells/mm3 and/or were in WHO stage IV, were 
enrolled. Patients with clinically obvious liver disease, jaundice, any transaminase level higher 
than five times the upper limit of normal or who were bedridden were excluded from the study.
Treatment TB treatment was provided according to national guidelines: 2 weeks of daily rifampi-
cin, isoniaside, pyrazinamide and ethambutol, followed by 6 weeks of the same drugs three times a 
week, and 6 months of daily isoniaside and ethambutol (0.5RZHE/1.5R3Z3H3E3/6HE). For relapse 
pulmonary TB the regimen was different: 8 weeks of daily rifampicin, isoniaside, pyrazinamide, 
ethambutol and streptomycin followed by 4 weeks of the same regimen without streptomycin, and 5 
months of rifampicin, isoniaside and ethambutol three times a week (2SRHZE/1RHZE/5R3H3E3). 
Cotrimoxazole prophylaxis was provided at the onset of TB treatment. Patients started Triomune® 
in the second week of TB treatment. The usual 2-week lead-in period for NVP was employed. 
Pyridoxine was not routinely given but prescribed as soon as symptoms of peripheral neuropathy 
developed.
Monitoring and follow up At enrolment, history was taken and physical examination and WHO 
clinical staging of HIV [12] were performed. Blood was taken for full blood count, transami-
nases, creatinine, HIV viral load (Roche Amplicor®; Roche, Basel. Switzerland; detection level 
400 copies/ml) and CD4+ T-cell count (FacsCount, Becton-Dickinson, Franklin Lakes, NJ, USA). 
Transaminases were monitored 1, 2 and 4 weeks after the start of ART. Plasma samples, taken 
1, 2, 4 and 8 weeks after the start of Triomune®, were stored at –80° until transportation to the 
Netherlands for determination of NVP levels, performed using a validated high-performance liquid 
chromatography assay [13]. NVP plasma levels below 3.0 mg/l were considered sub-therapeutic 
[14]. Appropriate laboratory tests and radiological investigations were carried out at intercurrent 
events. Clinical and laboratory adverse events (AEs) were scored according to the AIDS Clinical 
Trials Group criteria, grade I indicating mild, grade II moderate, grade III severe and grade IV life-
threatening events [15]. An AE was recorded in the month it started rather than when it reached its 
highest grade of severity. If several clinical or laboratory abnormalities occurred at the same time 
and were considered to be of the same cause they were scored as a single event. Patients were hos-
pitalized for 2 months and then followed for 6 months as outpatients. They could attend at any time 
for intercurrent problems. In the out-patient phase we undertook standardized AE interviews and 
monitored adherence by pill counts and self report with short structured interviews as previously 
described [16]. Patients were asked if they had missed tablets the day, week, month or ‘ever’ before 
the clinic visit. TB IRD was considered in cases of reappearance of fever, new or worsening pul-
monary infiltrates, pleural effusions, new hepato-splenomegaly, ascites, hepatitis, central nervous 
system disease or gut perforation [17, 18] or new signs of pericarditis, occurring between 1 week 
and 6 months after starting ART. TB treatment failure and drug toxicity as differential diagnoses of 
IRD were excluded in retrospect if resolution followed continuation of drug therapy. It was not pos-
sible to measure CD4+ T-cell count and viral load at the time of the episode. We diagnosed ‘likely 
IRD’ if the clinical picture was characteristic and lasted longer than 1 week and ‘possible IRD’ if 
the duration was shorter than 1 week or an alternative cause was likely. HIV viral load and CD4+ 
T-cell counts were repeated after 6 months of ART. ART failure was defined as a viral load >400 
copies/ml after 6 months of ART. In line with national guidelines, tuberculosis was considered 
cured if a sputum examination did not show acid fast bacilli after 6 months of TB treatment. The 
study was approved by the research and ethics committee of the University of Malawi College of 
Medicine. Written informed consent was obtained from all patients.
Statistical methods The Wilcoxon signed ranks test was used to compare NVP levels at differ-
ent intervals after start of ART, and the chi-square test was used to compare the difference in 
percentage of sub-therapeutic NVP levels between week 1 plus 2 and week 4 plus 8 samples. The 
chi-square and Fisher’s exact test were used to compare ART outcomes and percentage of sub-
therapeutic week 1 and 2 NVP levels, and the Mann–Whitney U test to compare NVP levels of 
week 4 and 8 between different TB regimens. Spearman’s correlation coefficient was used to test 
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for association of time intervals from the last tablet of Triomune® taken to sampling with NVP 
plasma levels.
Results
A total of 27 patients were enrolled in the study. At baseline 48% had CD4+ T-cell counts <50 
cells/ml and 88% <100 cells/ml. The HIV viral load was >105 copies/ml in 81% and >106 copies/
ml in 43%; 14 patients had relapse TB. Significant co-pathology was present in seven patients: 
Kaposi’s sarcoma (2), oesophageal candidiasis (4) and pancytopenia (1). Malnutrition [body mass 
index (BMI) <18.5 kg/m2] was present in 78% and severe malnutrition (BMI <16.0 kg/m2) in 37% 
of the participants. The prevalence of anaemia (Hb <11.7 g/dl in women and <13.2 g/dl in
men) was 100%, while 52% had Hb <8.0 g/dl. Table 1 provides further baseline characteristics.
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Table 2. Description of severe (grade III) or life threatening (grade IV) adverse events
Grade III (n=14)       month of ART
Confusion, inability to speak and lowered consciousness level*  1
Fever (n=2)*       1, 1
Raised transaminases       1
Peripheral neuropathy (n=3)     1, 4, 5
Pneumonia*       2
Anemia       2
New Kaposi’s sarcoma (n=2)     2, 3
Headache       4
Stroke       4
Malaria       6
Grade IV (n=13)       
Renal insufficiency†       1
Pleural empyema and respiratory distress*  1
Hepatitis       1
Anemia       1
Respiratory distress       1
Non-typhoidal Salmonella sepsis    1
Pancytopenia (n=2)       2, 2
Cryptococcal meningitis*      2
Suspected sepsis†       3
Sudden death       4
Pneumococcal meningitis/sepsis†    5
Acute watery diarrhea (suspected cholera)†  6
* indicates suspected immune reconstitution disease; † indicates cause of death
Patients may have experienced more than 1 adverse event
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Table 3. Episodes of suspected immune reconstitution disease
Likely IRD (9 episodes in 9 persons):  Grade month of ART
Cervical lymphadenitis with AFB in fine needle aspiration (n=3) II 1, 2, 5, 
Exudative ascites with strands  II 1 
Pericarditis  II 1
Empyema with respiratory distress  IV 1
New pulmonary consolidation / pneumonia  III 1
Confusion, inability to speak and lowered consciousness level III 1
Cryptococcal meningitis  IV 2
Possible IRD (22 episodes in 15 persons)
Fever (n=9)  II (n=8); III (n=1) 1 
Worsening or new cough, chest pains  
and/or shortness of breath (n=12)  II 1 (n=5), 2 (n=4),
   3, 4 (n=2) 
Worsening Kaposi’s sarcoma lesions  II 1 
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Figure 1. Adverse events, graded according to AIDS Clinical Trials Group tables, during months one to eight 
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Figure 2. Nevirapine levels at 1, 2, 4 and 8 weeks after start of Triomune.
The gridline represents the level (3.0 mg/l) below which the nevirapine concentration is sub-therapeutic.
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Patients started Triomune® after a median (range) of 9 (6–14) days of TB treatment. Two patients 
withdrew consent within 2 weeks after starting Triomune®, another developed hepatitis in the 
second week and TB treatment and Triomune® were stopped. Five patients died, all between the 
3rd and the 6th month of ART. Causes of death were progressive renal failure (unknown cause), 
pneumococcal meningitis and sepsis (in a patient who refused to take cotrimoxazole prophylaxis), 
pancytopenia with suspected sepsis, severe acute watery diarrhea (suspected cholera) and unex-
pected sudden death at home with acute shortness of breath of unknown cause. 
Nineteen patients completed TB treatment on Triomune®. After 6 months of Triomune® the 
median (range) increase of the CD4+ T-cell count was 170 (4–243) cells/ml, the median (range) 
weight gain was 8.4 (0.6–17) kg, the median (range) weight gain percentage was 17 (1–51) % and 16 
had a viral load <400 copies/ml. Fifteen of the 19 patients who completed TB treatment were cured. 
Month 7 sputum results of the four others were unavailable, but they had no respiratory complaints 
after completion of TB treatment. 
Non-adherence to ART was observed in two patients once during hospitalization. During the out-
patient visits all pill counts indicated >95% adherence. Seven patients reported having missed a 
tablet once, one patient twice. 
All patients experienced AEs (Figure 1). Of the 261 AEs, 64% happened in the first 2 months of 
ART. A total of 27 grade III and IV AEs occurred in 16 patients, 63% in the first 2 months. The 
incidence of grade III and IV AEs (including first and subsequent episodes in one individual) was 
1.90/person-year of observation (pyo) during the full period of combined ART and TB treatment 
and 3.89/pyo during the first 2 months of ART. Table 2 describes the grade III and IV AEs. At the 
time of presentation it was often impossible to determine if an AE was a side effect of any of the 
medications used, IRD or a new illness. Eight patients developed a new rash; all were mild and 
did not necessitate interruption of ART or TB treatment. Apart from the patient who developed 
grade IV clinical hepatitis, one other reached grade III transaminases increases that normalized 
after fluconazole was discontinued without interruption of ART or TB treatment. Grade I or II 
transaminase increases (<5 times the upper normal level) occurred in 19 of the 23 other patients 
but they were able to continue all drugs without further hepatic complications. All patients who 
used Triomune® for more than 2 weeks developed symptoms of peripheral neuropathy with one 
exception. These were controlled with pyridoxine and symptomatic treatment without the need to 
change ART or TB treatment. 
Episodes of suspected immune reconstitution disease were documented in 19 patients who had 
one ‘likely’ and one ‘possible’ episode (Table 3). The 22 ‘possible’ IRD episodes were generally 
mild and improved without the use of corticosteroids. Eight of the nine ‘likely’ IRD episodes were 
believed to be paradoxical worsening of TB [18], six of which were treated with corticosteroids. No 
IRD episode resulted in death or interruption of ART. 
NVP levels after 1 and 2 weeks, taken during the NVP lead-in period, were lower than after 4 and 8 
weeks of Triomune® (Figure 2). The NVP levels of week 1 samples (median 2.41 mg/l) were lower 
than those of week 4 (median 6.66 mg/l; P<0.001) and week 8 (median 5.29 mg/l; P=0.001). The 
NVP levels of week 2 samples (median 2.40 mg/l) were also lower than those of week 4 (P<0.001) 
and week 8 (P<0.001). The NVP levels of week 1 and 2 were not significantly different (P=0.88). 
The median interval from the last tablet of Triomune® to the time of sampling for NVP levels of 
week 1 and 2 was 15 h (range: 3–18). Of the week 1 and 2 NVP levels, 59% were sub-therapeutic 
compared with 14% of the week 4 and 8 NVP levels (P<0.001). The median interval from the last 
tablet of Triomune® to the time of sampling for NVP levels of week 4 and 8 was 3 h (range 1–12). 
There was no correlation between the interval from the last tablet of Triomune® to the time of sam-
pling and the week 4 and 8 NVP levels (rs = –0.19; P=0.9). The NVP levels of week 4 and week 8 
samples were not significantly different between those receiving standard or relapse TB treatment 
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(week 4: median 7.68 mg/l versus 6.05 mg/l; P=0.18 and week 8: median 6.42 mg/l versus 4.25 
mg/l; P=0.097, respectively). We found no significant difference in the percentage of sub-therapeu-
tic week 1 and 2 NVP levels between patients with ART failure and those with undetectable viral 
loads (33% versus 66%; P=0.65) and between patients who died or had ART failure and those with 
undetectable viral loads (62% versus 66%; P=0.8).
Discussion
This is the first study on detailed clinical and pharmacokinetic outcomes in sub-Saharan African 
patients taking NVP-containing ART and rifampicin simultaneously.
Due to the lack of safety data in this setting we chose to enroll a small number of patients for inten-
sive clinical and laboratory monitoring. The study population had a high risk of death indicated by 
advanced HIV disease progression and high prevalence of anaemia, malnutrition, co-morbidity and 
frequency of relapse TB. The mortality we observed was comparable with that in all TB patients 
in Malawi [6] and HIV infected TB patients in the region [19] not receiving ART. In cohorts of 
HIV-infected TB patients with CD4+ T-cell counts <200 cells/ml not on ART, the 1-year mortality 
varied widely, from 10% in Ivory Coast [20] to 80% in the Gambia [21]. In sharp contrast to TB 
patients not on ART, deaths in our study all occurred after the first 2 months of TB treatment [19]. 
Theoretically, the package of care we provided could have prevented mortality due to opportu-
nistic infections and insufficient medical care, while deaths due to side effects or IRD could have 
occurred, but this was not substantiated by our data. 
Of the patients, 80% completed their TB treatment successfully and 64% were alive with an HIV 
viral load of <400 copies/ml after 6 months of ART. We may have overestimated ART failure 
because two of the three patients with detectable viral loads had <1,000 copies/ml on a single mea-
surement and may therefore have had ‘blips’ during successful ART. Furthermore, deaths could 
have been unrelated to ART failure, IRD or toxicity. 
Most of the numerous AEs were mild and led to treatment interruption in only one patient. Nearly 
all patients developed new symptoms of peripheral neuropathy, probably caused by combined use 
of isoniazid and stavudine. Pyridoxine should therefore be given preemptively from the start of TB 
treatment. 
There is no widely accepted definition of IRD. Our definition was adapted to clinical circumstances 
in resource-poor settings and did not include a measure of successful ART (indicated by improving 
HIV viral load and/or CD4+ T-cell count). Our ability to exclude other infections was restricted by 
the available microbiological facilities. Exclusion of toxicity and TB treatment failure could only 
be done in retrospect; therefore, diagnosing IRD was difficult. Importantly, despite the diagnostic 
limitations it was possible to manage suspected IRD episodes pragmatically, without TB treatment 
and ART discontinuation. Clinicians judged that treatment with steroids was required in 67% of the 
likely IRD episodes. ART providers in resource poor settings need to be trained to recognize IRD 
and side effects of combined treatment and algorithms for management need to be developed.
The pill load during the initial phase of combined TB treatment and ART was high: patients took 
10–15 tablets (dependent on body weight) per day, to which drugs for symptom relief and antimi-
crobials were often added. During the continuation phase of TB treatment the number of tablets 
dropped by 50%. Despite frequent AEs and a high pill burden we recorded good adherence to ART, 
both during the in-patient intensive phase of TB treatment as well as the outpatient continuation 
phase. 
The majority of steady-state NVP levels (week 4 and 8 samples) were in the therapeutic range, 
adding to accumulating evidence [9, 10] that NVP and therefore Triomune® can be used safely 
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in combination with rifampicin. This is highly relevant as Malawi is currently introducing a new 
6-month TB treatment regimen with daily rifampicin throughout. We are concerned, however, with 
the large percentage of sub therapeutic NVP levels (59%) during the 2-week lead in phase, despite 
good adherence. Few pharmacological studies have addressed the lead-in phase of NVP. A study 
from the Netherlands has shown that NVP levels during the first 2 weeks were associated with the 
rate of decline of the HIV viral load [22], indicating potential clinical relevance. In comparison 
with this population that did not use simultaneous rifampicin, median NVP levels during the first 
2 weeks in our study were substantially lower. Although ART outcomes were not associated with 
sub-therapeutic NVP levels during the first 2 weeks, our study provided inadequate power to detect 
such association if it existed. Our results indicate that, in order to achieve therapeutic NVP levels 
from the start of Triomune®, a NVP lead-in phase should be avoided in patients who are already 
receiving rifampicin, since mutations conferring high-level resistance to NVP develop readily in 
the presence of low NVP levels [14]. A larger study may be required to confirm the implications of 
this strategy.
Limitations of our study and therefore our findings need to be considered. The number of patients 
studied was small. The quality of care was relatively high and patients were hospitalized during 
the first 2 months of treatment, which is not current daily practice in Malawi. It is conceivable that 
AEs, IRD and pill burden will have a greater effect on treatment outcome and adherence outside a 
study context. Due to logistical restrictions we were unable to take NVP trough levels. Regarding 
the week 1 and 2 samples, potentially lower trough levels would strengthen our case to avoid the 
NVP lead-in phase. During steady state the long half life of NVP is expected to lead to minimal 
differences between peak and trough levels. This was supported by our finding that the duration of 
the interval between last Triomune® and sampling was not correlated with the value of the NVP 
levels of week 4 and 8. In addition, the lower limit of the steady-state therapeutic range for NVP 
(3.0 mg/l) is based on a study in which samples were taken at random times [14].
In conclusion, it is feasible to combine NVP with rifampicin and to start Triomune® early during 
TB treatment, with respect to TB treatment and ART outcomes, AEs, IRD and NVP plasma levels. 
In patients on rifampicin for 1 week or more, a NVP lead-in phase should be avoided to prevent 
sub-therapeutic NVP levels. A clinical trial is needed to determine the optimal timing of ART dur-
ing TB treatment in settings with limited healthcare facilities. Based on current evidence, it seems 
prudent to defer ART until the continuation phase of TB treatment, when IRD and other AEs are 
expected to be fewer and the pill burden is lower. 
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Abstract
Background Wasting in HIV/AIDS is associated with a poor prognosis.  This trial tested the hypoth-
esis that among wasted adult Malawians starting antiretroviral therapy (ART), patients who receive 
food supplementation with ready-to-use fortified spread (RUFS) for 3.5 months will have a greater 
increase in body mass index (BMI) and fat free body mass than those receiving corn/soy blend 
(CSB). 
Methods Adults with BMI <18.5 kg/m2 starting ART were randomized to receive iso-energetic 
amounts of RUFS or CSB. Weight, fat-free body mass, clinical outcome, CD4 count, HIV viral load, 
quality of life, and ART adherence were assessed at regular follow up visits. Primary outcomes for 
the study were changes in BMI and the fat free body mass after 3.5 months.  
Findings 491 adults were enrolled. The mean BMI was 16.5 kg/m2. After 3.5 months patients receiv-
ing RUFS had a greater increase in BMI (2.2 ±1.9 vs. 1.7 ± 1.6 kg/m2, p=0.001) and fat-free body 
mass (2.9 ± 3.2 vs. 2.2 ±3.0 kg,  p=0.04) than those receiving CSB.  The mortality rate was high 
and similar for those receiving RUFS and CSB (27% vs. 26%).  No significant differences in the 
CD4 count, HIV viral load, Hb, albumin, quality of life assessment or ART adherence were noted 
between the two groups.   17 (3.5%) subjects were lost to follow-up. 
Interpretation Supplementary feeding with RUFS resulted in a greater increase in BMI and lean 
body mass than feeding with CSB.  Whether this confers clinical or survival benefit to wasted HIV 
infected patients as they continue ART, requires further study. 
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Introduction
The prevalence of wasting, defined as a body mass index (BMI) <18.5 kg/m2, in patients with 
advanced HIV infection in sub-Saharan Africa is around 20-40%.1,2 Wasting can be the result of 
increased metabolic consumption of nutrients, decreased intake from loss of appetite, opportunis-
tic infection, malignancy, diarrhea and malabsorption, and starvation secondary to poverty, the 
latter occurring particularly in sub-Saharan Africa.3  Because food insecurity is common, and an 
adequate diet is believed to be important for adherence with antiretroviral therapy (ART)4, supple-
mentary feeding in conjunction with ART is advocated as the standard of care in the treatment of 
wasted HIV infected adults in Malawi. In addition, mortality during the first months of ART in 
sub-Saharan African settings is very high and a low BMI is an independent risk factor for this early 
mortality.5 Supplementary feeding may therefore be seen as an intervention to improve outcome 
on ART.  However, evidence to support the effectiveness of this practice is limited, and there have 
been no published controlled trials demonstrating the benefit of food supplementation in the treat-
ment of wasted HIV infected adults in resource limited settings, whether on ART or not.6 
The most commonly available supplementary food is corn-soy blend (CSB), an inexpensive cereal 
legume combination that has been widely used in Africa for decades. However, CSB has been 
associated with disappointing results in supplementary feeding programs among children, preg-
nant women and HIV infected adults in sub-Saharan Africa.7,8 In a recent study from urban Malawi 
in HIV-infected adults not receiving ART CSB appeared to have no effect on mortality or clinical 
complications.9 Specialized, energy-dense ready-to-use fortified spreads (RUFS) have also been 
recommended for feeding wasted HIV infected adults. RUFS is a pre-cooked, energy dense, lipid 
paste made from peanuts that resists bacterial contamination.10 RUFS has been associated with bet-
ter outcomes in therapeutic and supplementary feeding of malnourished children with and without 
HIV.11,12
We conducted a randomized controlled supplementary feeding trial in Malawi to test the hypothe-
sis that among wasted HIV infected adults starting ART, patients who receive RUFS for 3.5 months 
will have a greater increase in BMI and fat free body mass than those receiving CSB. 
Subjects and methods
Subjects and study site All HIV infected individuals, aged 18 years or older, meeting the eligibil-
ity criteria for ART according to the Malawian national HIV treatment guidelines (WHO clinical 
stage III or IV or any WHO stage with a CD4 count <250/mm3) and initiating ART with a BMI of 
<18.5 kg/m2 were eligible for this study. Exclusion criteria were pregnancy and lactation, or partici-
pation in another supplementary feeding program. The study took place at the ART clinic of Queen 
Elizabeth Central Hospital in Blantyre, Malawi.
Blantyre is the major commercial city of Malawi, with a population of 1,000,000, and an estimated 
HIV prevalence of 27% in adults.13 Clinical care at this ART clinic is provided by the Department 
of Medicine of the College of Medicine, University of Malawi. The only available first line ART 
regimen is a generic, fixed-dose combination of nevirapine, stavudine and lamivudine. Routine 
cotrimoxazole prophylaxis before and during ART had not been fully implemented at the time of 
the study.
The study was approved by the College of Medicine Research and Ethics Committee, University 
of Malawi, the Human Studies Committee of the Washington University School of Medicine, and 
the Committee for Research on Human Subjects at the University of the Witwatersrand. Written 
informed consent was obtained from all participants. This trial is registered with Current Con-
trolled Trials #ISRCTN67515515.
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Study Design This was a randomized, controlled, investigator blinded effectiveness trial of sup-
plementary feeding with either CSB or RUFS. Randomization took place with sealed, unmarked 
opaque envelopes that were allocated to subjects in an area separate from the research and treatment 
room, using block randomization of 50 numbers. The envelopes contained a card with a unique 
number from 1–500. A designated staff member matched the number with the food assignment, 
and dispensed the appropriate food during the intervention period. All the other staff members, 
including the clinicians managing the ART program and the nutritionist were blinded to the study 
assignment. The food supplements were distributed monthly in conjunction with clinic follow-up 
visits, and each of the study participants remained within the group to which they were assigned for 
the duration of the study. Food supplements were started simultaneously with ART initiation and 
given for a period of 3.5 months. Subjects returned for follow-up two weeks after study initiation, 
and monthly thereafter. 
Participants, who failed to return to the ART clinic for a period exceeding two months, were visited 
at home, and information regarding clinical status, ART compliance, and body weight and compo-
sition was collected.  If the participant had died, date and circumstances of death were ascertained 
by interviewing the closest relatives.  Participants that could not be located were considered to be 
lost to follow-up. 
The primary outcomes of the study were changes in the BMI and the fat free body mass, after 
3.5 months. Secondary outcomes were nutritional status, defined as well nourished (BMI ≥18.5), 
moderately wasted (16 < BMI < 18.5), severely wasted (BMI <16), death, alive nutritional status 
unknown and lost to follow up. Additional secondary outcomes were quality of life, serum albu-
min, hemoglobin, CD4 count, HIV viral load and adherence to the ART regimen. 
A sample size of 450 subjects was chosen to enable detection of a difference in BMI and fat free 
body mass of 0.5 kg between the two groups with 95% specificity and 80% power. This sample size 
calculation allowed for 15% attrition due to pregnancy, losses to follow up and death.
Study procedures Following informed consent, demographic, clinical status, quality of life and 
anthropometric measurements were obtained, including weight, height, mid-upper arm circumfer-
ence, waist circumference and bioelectrical impedance. 
ART and food supplementation were initiated simultaneously. Participants were subsequently seen 
at the clinic on four occasions during the study, after 0.5, 1.5, 2.5, and 3.5 months.  During each 
visit clinical status was assessed, quality of life and ART adherence questionnaires were admin-
istered, and body weight, bioelectrical impedance, and waist and mid-upper arm circumferences 
were measured. Quality of life information was collected using a locally adapted version of the 
14-item CDC Health-Related Quality-of-Life assessment.14 ART adherence was measured with 
a local, previously validated questionnaire that consisted of four questions: did you miss a tablet 
the day, week, month or ever before.15 Bioelectrical impedance measurements were done with the 
Quaatum 2000 device (RJL Systems, Clinton Township, Michigan). All measurements were made 
by trained study staff using standardized procedures.
Blood samples were drawn at enrolment and at 3.5 months for measurement of serum albumin, 
hemoglobin, CD4 count (FacsCount, Becton-Dickinson, Franklin Lakes, NJ, USA), and HIV viral 
load (Roche Amplicor®; Roche, Basel. Switzerland; detection level 48 copies/mL). HIV viral load 
was only measured at 3.5 months.
Open-ended focus group discussions involving an average of eight randomly selected study partici-
pants from both supplementary feeding groups, were conducted to explore the usage, acceptability, 
and sharing of the food supplements. These were led by experienced social scientists from the 
University of Malawi who were not involved in any other aspect of the study. 
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Study foods The nutritional composition of the 2 supplementary foods is compared in Table 1. 
Both supplementary foods provided the same level of energy, neither provided amounts of micro-
nutrients that significantly exceeded the estimated average requirement. The two study foods were 
produced locally in accordance with international food safety specifications. The amounts provided 
were chosen to cover 50% of the daily estimated average energy requirement, based on the WHO 
Nutritional Guidelines that take into account that people living with HIV/AIDS need 30% more 
energy than healthy individuals.16 The advice given to both groups of participants was to consider 
the food supplements a part of their HIV treatment and that the food should not be shared with 
others. 
Statistical analysis The data was doubly entered into an Excel database.  Fat free body mass was 
calculated using the equations developed by Kotler et al. for wasted HIV infected adults.17 Means 
and standard deviations were calculated for continuous parameters. Comparisons between subjects 
receiving RUFS and CSB for dichotomous parameters were made using Fisher’s Exact Test (2 out-
comes) or Chi-Square Test (3 or more outcomes).
Comparisons of continuous parameters were made using Student’s t-test. A value of p <0.05 was 
considered statistically significant for all comparisons. The association between death and demo-
graphic, anthropometric and immunological characteristics of the subjects was assessed by binary 
logistic regression modeling. Covariates that were considered were sex, age, receiving cotrimox-
azole, BMI, fat-free body mass, CD4 count, hemoglobin, and albumin at enrollment. Receiving cot-
rimoxazole as prophylaxis at any time during the study period was considered as having received it, 
in the regression analysis. SPSS version 13.0 (Chicago, IL) statistical software was used. 
Role of the funding agencies The study sponsors, Academy for Educational Development and AIDS 
Community Research Initiative of America (ACRiA), sent the proposal for expert review prior to 
making a funding decision, however after agreeing to fund the study, they played no role in the 
implementation, data collection, data analyses or writing of this report. 
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Table 1. The nutrients provided by the two food supplements, expressed as amount/day and com-






EAR Women EAR Men
Energy (kJ⋅d-1) 5694 5694
Energy (kcal d-1) 1360 1360 3022 3022
Protein (g⋅d-1) 35.5 50 46 56
Calcium (mg⋅d-1) 830 258 1000 1000
Phosphorus (mg⋅d-1) 700 1050 580 580
Magnesium (mg⋅d-1) 240 500 255 330
Potassium (mg⋅d-1) 2880 1700 4700 4700
Selenium (µg⋅d-1) 78 22 45 45
Zinc (mg⋅d-1) 8 8 8 11
Copper (mg⋅d-1) 0.9 2.9 0.9 0.9
Iron (mg⋅d-1) 8 16 18 8
Vitamin A  (µg⋅d-1) 710 1040 700 700
Vitamin C (mg⋅d-1) 90 26 60 75
Vitamin D (µg⋅d-1) 5 6 5 5
Vitamin E (mg⋅d-1) 52 32.5 12 12
Niacin (mg⋅d-1) 14 13 11 12
Folic Acid  (µg⋅d-1) 400 153 320 320
Thiamine (mg⋅d-1) 1.1 1.3 0.9 1.0
Riboflavin (mg⋅d-1) 1.3 0.8 0.9 1.1
Vitamin B6   (mg⋅d
-1) 1.3 1 1.1 1.1
Vitamin B12  (µg⋅d
-1) 1.4 0.5 2.0 2.0
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Results
Four hundred and ninety-one subjects (96% of all eligible individuals during the study period) were 
enrolled from January to December 2006 (Figure 1). After 6 months of enrollment it was decided 
to increase the number of participants due to a larger than expected number of deaths. No adverse 
reactions to either food were reported. There were no significant differences in the demographic, 
anthropometric or clinical characteristics between the two study groups at baseline (Table 2). Sev-
enteen (3.4%) participants were lost to follow-up and 21 (4.3%) were known to be alive, but missed 
their 3.5 months clinic visit and no anthropometric measurements were made. 
Subjects receiving RUFS had a greater increase in BMI and fat free body mass than those receiving 
CSB after 3.5 months of nutritional intervention and ART (Table 3).  There was no difference in 
survival, HIV viral load strata, immune reconstitution as measured by CD4 count or quality of life 
between those receiving RUFS and CSB. 
Mortality was very high in both groups; 124 (25%) subjects died within the first 3.5 months. Male 
gender, not receiving cotrimoxazole prophylaxis, and a lower BMI, hemoglobin and albumin at 
baseline were independent risk factors of death at 3.5 months (Table 4). 
Self reported adherence to the ART regimen was similar in both groups at each follow-up visit. 
Few participants reported missing a dose of ART on the previous day (1.8 vs. 1.2 %, p = 0.5) or at 
least one dose in the previous week (5.0 % vs. 4.6 %, p=0.5) in the RUFS and CSB groups, respec-
tively.
Twelve focus group discussion sessions were conducted, 95 subjects participated, 42 of whom 
received RUFS and 53 CSB.  Both study food supplements were universally highly appreciated. 
Nearly all participants expressed that sharing of both food supplements by dependents and family 
members was common, although CSB was more likely to be shared because it needed preparation 
by caregivers before consumption. 
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Figure 1.  Study Flow Diagram 
 
















































Assessed for eligibility  (n= 1343) 
Excluded  (n = 852) 
 
  Not meeting inclusion criteria, 
  BMI > 18.5         (n =832) 
   
   Refused to participate  (n =11) 
   
   Missed as eligible (n =5) 
   
   Pregnant      (n =4) 
Analyzed  (n = 156) 
 
No one excluded from analysis   
Did not complete 3.5 mo 
follow-up  (n=  89) 
 
  Died (n = 67) 
    
  Alive, nutritional status 
   unknown (n = 11) 
    
  Lost , status unknown  
   (n = 11) 
 
Allocated and received 
ready-to-use fortified 
spread          (n = 245) 
 
Did not complete 3.5 mo 
follow-up  (n=  80) 
 
  Died (n = 64) 
    
  Alive, nutritional status 
   unknown (n = 10) 
    
  Lost , status unknown  
   (n = 6) 
 
 
Allocated and received corn/ 
soy blend            (n = 246) 
 
Analyzed  (n =166) 
 
No one excluded from 
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Age (years) 36.0 ± 11.0 36.0 ± 12.0 




Body Mass Index (kg/m2) 16.5 ± 1.5 16.5 ± 1.5 
Fat Free Mass (% of body composition)  96.0 ± 10.0  95.0 ± 12.0 
Fat free body mass (kg) 40.5 ± 5.8 41.0 ± 7.2 
Arm Circumference (cm) 20.4 ± 2.2 20.8 ± 4.1 




Severely Malnourished, BMI < 16.0 










CD4 Count (cells x 106/L) 131.0 ± 140.0 142.0 ± 319.0 
Albumin (g/L) 24.0 ± 8.0 24.0 ± 4.0 
Hemoglobin (g/L) 96 ± 20 98 ± 57 
Received cotrimoxazole prophylaxis 151 (62%) 137 (56%) 
 
Quality of Life 
 
  
General Health: 1=excellent  5=poor                    4.5  ±  0.7 4.5  ± 0.8 
Physically Unhealthy days per month 17.6  ± 11.8 16.2  ± 11.3 
Mentally unhealthy days per month 6.1   ± 9.4 6.4  ±  10.0 
Mental/ physical limitation days per month 12.7  ± 12.9 13.2 ± 13.1 
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n = 245 
 
CSB 
n = 246 
 
P  Value 
Anthropometric 
 
   
Gain in Body Mass Index (kg/m
2
) 2.2 ± 1.9 1.7 ± 1.7 0.001 
Gain in fat free body mass (kg) 2.9 ± 3.2 2.2 ± 3.0 0.04 
Weight Gain (kg) 5.6 ± 4.8 4.3 ± 4.0 0.001 
Body Mass Index (kg/m
2
) 19.0 ± 2.1 18.4 ± 1.1 0.001 
Fat Free Body Mass  
(% of body composition)  
89.0 ± 8.0 91.0 ± 8.0 0.03 
 
Clinical/ Nutritional Status 
 
   
Severely Malnourished 10 (4%) 12 (5%) 0.48 
Moderately Malnourished 53 (22%) 69 (28%) 0.12 
Well-nourished 93 (38%) 85 (35%) 0.51 
Died 67 (27%) 64 (26%) 0.76 
Alive nutritional status unknown 11 (4%) 10 (4%) 0.83 
Lost to follow-up 11 (4%) 6 (2%) 0.32 
Survivors that were hospitalized in first 
3.5 months 
 
30 (12%) 31 (13%) 0.98 
Laboratory 
 
   
CD4 count (cells x 10
6
/L) 289 ± 185 297 ± 447 0.80 
Increase in CD4 count (cells x 10
6
/L) 168 ± 145 150 ± 139 0.26 
HIV viral load   < 50 copies/ mL 96 (39%) 97 (39%)  
                          50-1000 copies/mL 59 (24%) 62 (25%) 0.98 for trend 
                          > 1000 copies/mL 5 (2.0%) 4 (1.6%)  
Serum albumin (g/L) 32 ± 7 32 ± 10 0.99 
Increase in serum albumin (g/L) 6 ± 7 6 ± 3 0.99 
Hemoglobin (g/L) 112 ± 17 113 ± 15 0.49 
Increase in hemoglobin (g/L) 15 ± 21 13 ± 20 0.28 
 
Quality of Life 
 
   
General Health: 1=excellent  5=poor 3.1  ±  1.0 3.0  ± 1.0 0.27 
Physically unhealthy days/ month 5.5   ±  8.0 5.7  ±  8.4 0.79 
Mentally unhealthy days/ month 2.6  ± 5.5 2.5  ± 5.7 0.84 
Mental/ physical limitation days/ month 4.2  ±  8.8 4.2  ±  8.8 0.99 
 
Values expressed as mean ± SD for continuous parameters, No (%) for dichotomous 
parameters 
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Table 4 Summary of logistic regression modeling of death1
Independent variable Standardized β coefficient P value
Sex male 2.15 0.03
Age -0.98 0.20
BMI -1.47 0.0001
Fat-free body mass 1.00 0.89
Cotrimoxazole prophylaxis2 -3.99 0.0001
CD4 count -1.00 0.95
Haemoglobin -1.22 0.01
Albumin -2.88 0.0001
1 enter mode used, r = 0.61 for the model The standardized β coefficient corresponds to the relative risk by 
which each factor increases the chance of death.  Negative numbers indicate that as the independent variable 
decreases, the risk of death increases.
2 having received cotrimoxazole prophylaxis at any time during the study period
Discussion
We found that in wasted patients initiating ART, food supplementation with RUFS resulted in a 
greater increase in BMI and fat-free body mass, compared to CSB. However, no difference in mor-
tality, immune reconstitution, HIV suppression, adherence to ART, or quality of life was observed 
between the groups. 
The study was limited in that food consumption was not observed in either of the groups, therefore 
the degree of adherence with the dietary recommendations is not known. However, this was an 
effectiveness study, as opposed to an efficacy study, to determine which of the two supplementary 
foods lead to better outcomes in a limited resource, operational setting.  This study did not have a 
control group receiving no supplementary food; it is therefore unknown what the nutritional status 
would have been without supplementary feeding. Although included in the original proposal, such 
a control group was deemed unethical by the review board in Malawi because it is national policy to 
give supplementary food to wasted HIV/AIDS patients. Only 3% of subjects were lost to follow-up, 
which compared to other studies of HIV infected individuals in sub-Saharan Africa is very low.
RUFS may have promoted greater weight gain compared to CSB because of its higher energy den-
sity thereby allowing adequate energy intake in patients with some degree of anorexia. In addition, 
the focus group discussions indicated that RUTS was shared less often.  RUFS is ready to be eaten, 
while CSB needs to be cooked.  Food preparation for ill adults with HIV/AIDS will often be done 
by relatives or dependents, a practice that may be more conducive to sharing of the supplementary 
food. CSB is a component of the traditional diet, while RUFS is regarded as a special supplement for 
patients, a medicinal food. This cultural view of supplementary foods may have encouraged greater 
sharing of CSB. Although there were differences in the micronutrient content between the food 
supplements, we estimate that there were adequate amounts of all macro- and micronutrients in the 
patients’ diets to promote weight gain if the supplements were consumed in addition to a habitual 
diet. Micronutrient supplements have been recently recommended by some researchers to delay HIV 
progression, however an evidenced-based review article concluded that there is insufficient evidence 
for routine micronutrient supplementation in patients on ART.18 Micronutrients could be easily added 
to food supplements in the future if clinical evidence emerges warranting this practice. 
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ART, particularly regimens including stavudine, is associated with metabolic side effects such as 
lipodystrophy, dyslipidaemias and insulin resistance in Africa in individuals with BMI > 25 kg/
m2.19  RUFS is a food with a very high fat content.  We chose to give the supplementary food for a 
short, fixed duration of 3.5 months, to avoid putting patients who would have recovered from their 
wasting at an increased risk of metabolic complications.
Our findings are consistent with some previous observations of supplementary feeding with energy-
dense foods in HIV infected persons. Severely malnourished, HIV-infected Malawian children 
who received RUFS had greater weight-for-height improvement than those receiving CSB.12 Adults 
with AIDS in urban Malawi given vegetable oil and CSB, had greater improvement in BMI than 
those receiving CSB alone.9 Findings from an ART program in rural Malawi that provided CSB as 
a supplementary food in 2003 and RUFS in 2004, indicate that patients receiving RUFS had greater 
weight gain (1.5 vs. 0.8 kg/month; p=0.04).20 No other randomized controlled trials comparing 
supplementary foods for wasted HIV infected individuals were identified in a literature search. 
This study is novel in that it provides conclusive evidence that an energy dense food is associated 
with improved recovery from wasting. 
Our data do not show a survival benefit associated with one of the supplementary foods. As the 
study was underpowered to detect differences in survival smaller than 5%, we may have failed to 
detect a small survival benefit during the intervention period. Furthermore, since low BMI is an 
independent risk factor for death,5,21,22 surviving patients who received supplementary RUFS, and 
who are more likely to have a higher BMI, might have a better prognosis as they continue ART.
In our high-risk study population we observed a mortality rate of 25% in the first 3.5 months of 
ART. High early mortality rates are common in ART programs in sub-Saharan Africa. In a study 
from rural Malawi, the mortality rate in the first 3 months of ART was 26% in patients with severe 
malnutrition.5 In another rural district of Malawi the mortality was 14.6% among all patients in the 
first 6 months and among those with BMI <18.5 kg/m2 the relative risk of death was 3.56.21 The 
3-month mortality among all patients initiating ART in studies from Senegal, Uganda and Zambia 
was 7.6%, 6.4% and 6.3% respectively. Having a low BMI was identified as a risk factor of death in 
all three studies, increasing the risk of death by 2 to 3-fold. 22,23, 24 One noticeable difference between 
our study and the previous reports was the irregular availability of cotrimoxazole prophylaxis in 
Blantyre. A study from Malawi showed that cotrimoxazole prophylaxis can ameliorate early mor-
tality during ART25 and indeed the regression analysis in our study indicated that the absence of 
cotrimoxazole prophylaxis was a strong risk factor of death. This suggests that invasive bacterial 
infections may have been an important cause of mortality, an observation found in other studies of 
early mortality on ART from sub-Saharan Africa.24, 26, 27 We speculate that the high mortality rate 
in our study may also have been due to undiagnosed opportunistic infections present at enrolment. 
Tuberculosis is highly prevalent in Malawi, often presents atypically in patients with advanced 
immune suppression, and can give a clinical picture of wasting syndrome. It is an important cause 
of mortality in the first 6 months of ART in patients in sub-Saharan Africa.28 Emaciated patients 
might benefit from more careful clinical screening for opportunistic infections at the start of ART, 
in particular for tuberculosis.
The CSB provided to each patient in our study cost $5.4/month, while RUFS was three times as 
expensive at $16/month. In comparison the Malawian government obtains the first line ART regi-
men for $15/month. About one-third of all adults initiating ART in Blantyre are wasted, so provi-
sion of supplementary food is a significant expense.  We have demonstrated that an energy-dense 
supplement promotes better nutritional recovery in 3.5 months.  Follow-up over a longer period 
of time is warranted to determine if the anthropometric benefits conferred by specialized energy 
dense supplements will lead to improved outcomes and thus whether RUFS is a cost effective inter-
vention in ART scale-up programs in resource limited settings.
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Abstract
Poverty related malnutrition is considered an important cause of HIV associated wasting in sub-
Saharan Africa. Low body mass index (BMI) is a strong risk factor for mortality occurring early 
during ART. 
In a retrospective study we compared the effect of food supplementation versus no nutritional inter-
vention in adult malnourished Malawians starting antiretroviral therapy (ART) at Queen Elizabeth 
Central Hospital (QECH) in Blantyre. All patients received nevirapine, lamivudine and stavudine 
free of charge. The food-supplemented group included participants of a trial of the effectiveness of 
two different food products, given during the first 14 weeks of ART.  The historical control group 
was part of an observational cohort study of side effects and clinical outcomes of the first line ART 
regimen. 
Baseline characteristics were similar, except cotrimoxazole prophylaxis was more commonly used 
in the food-supplemented group. In the food-supplemented group nutritional recovery was superior 
at 14 and 26 weeks, however mortality and severe morbidity were not improved at 14 weeks and 
worse at 26 weeks. There were no differences in mortality and severe morbidity between recipients 
of either of the food supplements. Low BMI, WHO stage IV and being in the food-supplemented 
group were risk factors for mortality at 14 and 26 weeks in the multi-variate analysis. Differences 
in the study conduct of the two groups, rather than detrimental effects of food supplementation may 
explain the effect on mortality. 
There is need to conduct a randomized controlled food supplementation trial that includes an arm 
without nutritional supplement in wasted adults starting ART in resource poor settings.  
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Introduction
Multiple contributing factors have been identified in the pathophysiology of weight loss and wast-
ing associated with HIV infection [1]. In sub-Saharan Africa food insecurity is common in the gen-
eral population and patients with HIV/AIDS often experience increasing poverty as their disease 
progresses [2]. It is therefore assumed that poverty related malnutrition is an important cause of 
HIV associated wasting in the area.
Few studies have evaluated the effects of food supplementation provided to adult patients with HIV/
AIDS. A recent observational study in Malawi before the introduction of ART scale-up indicated 
disappointing results [3]. ART alone can prevent and reduce weight loss and wasting [4] and many 
countries in Sub-Saharan Africa, including Malawi, have started ambitious ART scale-up pro-
grammes. Results of ART outcome in sub-Saharan Africa have been encouraging [5], but in com-
parison to western settings the mortality during the first months of ART is high [6], for which a low 
BMI at the start of ART is a strong and independent risk factor [7]. As one of the possible means 
to reduce this early mortality several countries in the area have implemented food supplementation 
during the early phases of ART. This intervention has not been studied, and it has been considered 
unethical to conduct placebo controlled studies of food supplementation in wasted patients with 
HIV/AIDS.
We compared nutritional and clinical outcomes in two different cohorts starting ART at the same 
clinic, one a clinical trial of two food supplements (food supplemented group [FSG]), the other an 
observational cohort study of the safety and efficacy of the first line ART regimen without food 
supplements (non-food supplemented group [NFG]).
Methods
Both studies took place at the outpatient ART clinic of Queen Elizabeth Central Hospital (QECH) 
in Blantyre, the largest city of Malawi, that has an estimated HIV prevalence of 27% among adults 
[8]. QECH is the only government hospital in Blantyre and provides primary, secondary and ter-
tiary health care. Since 2004 the ART clinic of QECH has offered ART free of charge. All patients 
receive the same first line regimen: a generic, fixed-dose combination of nevirapine, stavudine and 
lamivudine. Routine cotrimoxazole prophylaxis during ART had not yet been fully implemented at 
the time of both studies, due to irregular availability in the hospital pharmacy. 
The FSG consisted of patients in a clinical trial comparing the effectiveness of two different food 
supplements, corn-soy blend (CSB) and ready-to-use food spread (RUFS), a peanut butter based 
product, introduced at the start of ART and continued for 14 weeks. Food supplements were forti-
fied with minerals and vitamins and the amounts provided were designed to cover 45% of the daily 
estimated average requirement for energy, in line with World Bank recommendations [9]. It was 
considered unethical to include a control group in this clinical trial that took  place during 2006-7, 
and has been described in more detail elsewhere [10]. 
The NSG include patients from a prospective cohort study of clinical outcomes and side effects of 
the first line ART regimen during 2005-6; food supplements were unavailable for these patients 
[11]. In the NFG, but not in the FSG, it was policy to interrupt ART when tuberculosis was diag-
nosed, because of fear of drug interactions.
Patients in both groups were ART naive, and started ART when found eligible according to the 
National ART guidelines: WHO clinical stage III or IV or any WHO clinical stage with a CD4 
count <250 cells/ml. Patients in the FSG were 18 years and older, in the NFG16 years and older, 
but for this analysis patients aged 16 and 17 were excluded. Patients in the FSG were enrolled if the 
body mass index (BMI) was <18.5 kg/m2 and similarly only patients from the cohort study whose 
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BMI at the start of ART was <18.5 kg/m2 were included in the NFG. Exclusion criteria were the 
same for both studies (inability to follow ART instructions and clinical evidence of active liver 
disease), except that pregnancy was an additional reason for exclusion in the clinical trial; we there-
fore also excluded pregnant women enrolled in the cohort study from the NFG. Follow-up visits 
were at identical intervals in both studies; 2, 6, 10, 14, 18, 22, and 26 weeks after ART initiation. In 
both groups active tracing of patients at home was done in case they did not turn up for scheduled 
visits.
Early mortality was defined as death during the first 14 weeks of ART. WHO criteria were used to 
define malnourishment (BMI <18.5 kg/m2) and severe malnourishment (BMI <16 kg/m2). The vital 
status of patients who stopped ART was ascertained and used for analysis of mortality, but not for 
anthropomorphic outcomes, as weights had not been recorded.  Reasons for stopping ART were 
side effects, poor adherence or patients choice in both groups, and tuberculosis only in the NFG. 
Patients who were transferred out to another ART clinic were assumed to remain alive on ART. 
Outcomes were BMI increase, weight increase, percentage with BMI <18.5 kg/m2, percentage with 
BMI <16 kg/m2, mortality, severe clinical events (defined as having experienced a hospitalization, 
death or both), and percentages of losses to follow up and stopped ART, at 14 and 26 weeks. 
For comparisons at baseline, 14 weeks and 26 weeks, t-tests and Chi-squared tests were used for 
continuous and categorial variables respectively; Fisher’s exact test was used to compare the per-
centages of lost to follow up and stopped ART. For the determination of risk factors of early mortal-
ity crude odds ratios (OR’s) were calculated and adjusted OR’s were determined using multivariate 
logistic regression, p-values were obtained using the Wald test. Factors and covariates used were 
sex, age, BMI, CD4 count and WHO clinical stage at enrollment, and receipt/not of any cotri-
moxazole prophylaxis and receipt/not of food supplementation in the first 14 weeks. All reported 
p-values are two sided and we considered a p-value <0.05 as significant. All analyses were done 
with SPSS software version 11.0 (Chicago, IL). Both studies were approved by the Research and 
Ethics Committee of the University of Malawi College of Medicine and written informed consent 
was obtained from all participants.
Results
Three hundred patients were enrolled in the cohort study, 104 were eligible for the NFG. Of 491 
patients enrolled in the trial, 489 were included in the FSG, of whom 245 received CSB and 244 
RUFS. 
Baseline charateristics were similar in boths groups (Table 1), except for a lower useage of cotri-
moxazole prophylaxis in the NFG, since the availability gradually improved over time.
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Table 1. Baseline characteristics
Characteristic no food supplement food supplements p-value
Number 104 489
Female sex: n (%) 50 (50.0%) 294 (60.1%) 0.06
Mean age (range) 36.3 (20-58) 36.2 (18-80) 0.93
WHOa stage n (%) 0.07
III: 61 (58.7%) 320 (65.4%)
IV: 37 (35.6%) 127 (26.0%)
Mean CD4 (sdb) 112.5 cells/ml (110.5) 136.7 cells/ml 
(151.6)
0.12
CD4 < 100: n (%) 56 (53.8%) 256 (52.4%) 0.97
Mean weight (sd) 44.6 kg (5.7) 42.8 kg (5.8) 0.003
Mean BMI (sd) 16.6 kg/m2 (1.50) 16.5 kg/m2 (1.42) 0.77
BMIc <16 kg/m2: n (%) 28 (26.9%) 161 (32.9%) 0.23
Cotrimoxazole 
prophylaxis
33 (31.7%) 286 (58.5%) <0.0001
a. WHO = World Health Organization
b. sd = Standard Deviation
c. BMI  = Body Mass Index
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Table 2. Outcomes at week 14 and 26
Outcome    no food supplement  food supplements  p-value
Week 14
Mean (sdc) weight increase  3.3 kg (4.7)   5.0 kg (4.6)  0.006
Mean (sd) BMId increase 1.2 kg/m2 (1.8)   1.9 kg/m2 (1.8)  0.003
BMI <18.5 (kg/m2)  63.4%    44.4%   0.004
BMI <16 (kg/m2)  12.7%    6.6%   0.13
Mortality n (%)a  18 (17.5%)   126 (26.1%)  0.065
Severe eventa, b  n (%) 35 (33.7%)   192 (39.3%)  0.285
Lost to follow up n (%) 1 (1.0%)    7 (1.4%)   1.0
Stopped ART  10 (9.6%)    4 (0.8%)   <0.0001
Week 26
Mean (sd) weight increase 5.5 kg (5.6)   6.9 kg (5.5)  0.07
Mean (sd) BMI increase 2.1 kg/m2 (2.1)   2.7 kg/m2 (2.1)  0.04
BMI <18.5 (kg/m2)  46.3%    29.2%   0.007
BMI <16 (kg/m2)  7.5%    3.6%   0.28
Mortality n (%)a  20 (19.8%)   152 (32.0%)  0.015
Severe eventa, b  n (%) 39 (37.9%)   234 (49.5)  0.033
Lost to follow up  2 (1.9%)    14 (2.9%)   1.0
Stopped ART  11 (10.7%)   4 (0.8%)   <0.0001
a. Losses to follow up not considered as dead or alive
b. The percentage that experienced at least one hospitalization, death or both
c. sd = standard deviation
d. BMI  = Body Mass Index  
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Weight and BMI increases were higher in the FSG and the percentage with malnutrition was lower 
at 14 weeks (Table 2). These effects were still present at 26 weeks (three months after the end of the 
intervention), although the difference in weight increase was no longer significant.
 Mortality at 14 weeks was high in both groups with a lower mortality in the NFG, although the 
difference was not significant. The percentage of patients who experienced a severe clinical event 
was similar in both groups. At 26 weeks a significant difference in mortality and severe clinical 
events appeared, with lower rates in the NFG group. In the univariate analyses low BMI and WHO 
stage IV were associated with early mortality. Low BMI, WHO stage IV and being in the FSG were 
independent risk factors for death within 14 weeks, after adjustment for BMI, CD4 count, WHO 
stage, cotrimoxazole prophylaxis, sex, age and food supplementation (Table 3). The multivariate 
analyses at 26 weeks gave comparable results, the adjusted odds ratio (OR) of death of being in the 
FSG was 2.3 (CI: 1.28 - 4.21; p=0.006); male gender had also become an independent risk factor 
of death (adjusted OR 1.69; CI: 1.10 – 2.62 ; p=0.017).   The losses to follow up were very low in 
both groups at both time points. Within the FSG there were no differences between those receiv-
ing RUFS and CSB with respect to mortality (29.0 vs. 25.5%; p=0.38), severe clinical events (41.4 
vs. 38.8%; p= 0.55) and losses to follow up (1.6 vs. 0.8%; p=0.45), despite significant advantage 
of RUFS over CSB in nutritional recovery (BMI increase: 2.2 vs. 1.7 kg/m2 ; p=0.009, and weight 
increase: 5.6 vs. 4.4 kg; p=0.014 respectively).
 
Discussion
Our findings demonstrate benefit of short term food supplementation on nutritional recovery that 
was still evident 3 months after the end of the intervention. Paradoxically, survival and severe mor-
bidity in the early phases of ART were not improved and after six months follow up results suggest 
that the strategy of food supplementation could be harmful. 
Early mortality in both study groups was high. Several studies have highlighted the problem of 
early ART mortality in sub-Saharan Africa. In populations similar to ours, overall early ART 
mortality varied between 5 and 8%, and a low BMI increased the risk of death two to three fold [7, 
12, 13, 14]. In comparison with these studies the mortality in the FSG was at the higher end of the 
spectrum. Few studies have addressed causes of death during the early phases of ART in Africa. 
One study reported the importance of tuberculosis [15], another suggested relevance of asymptom-
atic cryptococcal infection [14]. Comprehensive analysis of etiology of early ART mortality has not 
been published as far as we know. Detailed data on causes of death in our study were not available 
either. 
Our results need to be interpreted with caution due to important limitations. Firstly, a major dis-
advantage of historical control groups is that factors other than those measured are often different 
between the groups. Although many circumstances in the two groups we compared were the same, 
the study aim in the NFG is likely to have led to more thorough clinical assessment at baseline and 
during follow up after ART initiation. A reflection of this may be the higher number of clinician 
initiated interruptions of ART. Better individual clinical care could have prevailed in the NFG to 
explain the lower mortality at 14 and 26 weeks. 
Could the food supplements have been harmful? The food products were fortified with a small 
amount of vitamin A, that was recently shown to be potentially harmful in a meta-analysis of stud-
ies generally using a higher dose over a longer period [16]. Food supplements might have negative 
effects on glucose tolerance and serum lipids, although this has not been studied. We believe it is 
very unlikely that the short food supplementation increased mortality for either of these reasons. 
It could have been detrimental if instructions the study team gave for the food supplements would 
have reduced emphasis on individual ART counseling. However the study setting in the FSG was 
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designed to prevent this.  A likely explanation for the discordant effect of food supplementation 
on anthropmetric outcomes and severe clinical events is that a low BMI at the start of ART in a 
number of patients reflected presence of active, undiagnosed opportunistic infections, in particular 
tuberculosis [17;18]. The high mortality in the patients with higher CD4 counts may be a reflection 
of this. The policy to interrupt ART during TB treatment in the NFG could have been beneficial, 
although there is no convincing literature to support this, but the impact cannot be large since it 
occured in only three patients. 
A second limitation of this study is that adherence to the food supplements was not measured, since 
the aim was to compare effectiveness of food supplements in operational circumstances. Lack of 
individual clinical benefit could therefore be attributed to non-adherence to the food supplement. 
Thirdly, we were unable to compare other known risk factors for mortality in HIV infected persons 
such as anemia and hypo-albuminaemia, since these data were not available in the NFG. We could 
not compare adherence to ART between the groups and if nutritional support improved ART adher-
ence [19], better virological and immunological results could have been found in the FSG, however 
we did not have viral load and CD4 count results from both groups at the same time points. 
We have provided the first comparison of food supplementation versus no nutritional intervention 
in patients with a low BMI at the start of ART in resource limited settings. Despite important 
limitations of this study, we have shown that food supplementation improves nutritional recovery 
but our results also cast doubt on overall clinical benefit in this setting. These discordant results 
underline the need for a randomized controlled trial of food supplementation, including an arm 
without a food product. However implementation of a control arm could pose practical problems, 
as participants highly appreciate food supplements when available [10]. 
In conclusion, despite a positive effect on nutritional recovery, food supplementation during the 
first 14 weeks of ART did not improve early ART mortality and severe morbidity, while at 26 weeks 
the non-food supplemented group appeared to have a survival benefit. More evidence is required 
for this relatively expensive intervention to improve ART outcome in resource limited settings.
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Abstract
We describe the evaluation of the HIV post exposure prophylaxis (PEP) programme for occupa-
tional injuries in Queen Elizabeth Central Hospital, Blantyre, Malawi. An audit was performed 
one year after introduction, by reviewing files of all clients who sought advice regarding PEP. In 
addition, the incidence of occupational injuries and awareness of the programme were assessed 
through interviews with nurses.
The logistics of the programme were adequate. Of 29 clients who reported occupational injuries, 19 
started PEP. Only double antiretroviral drug therapy was available; side-effects were common but 
generally mild. Attendance of scheduled follow-up visits was poor, and few HIV test results after 
completion of PEP were obtained. Interviews with nurses revealed a high incidence of occupational 
injuries, but many did not report for advice about PEP; mostly because of unawareness of the pro-
gramme and a reluctance to be tested for HIV.
080356 Oosterhout BW.indd   152 11-11-2008   15:49:02
153
Introduction
Post-exposure prophylaxis (PEP) for HIV transmission through occupational injuries in health-
care workers in Africa has received little attention. This is in spite of surveys in several African 
countries reporting that these injuries occur frequently and that, in combination with high HIV 
prevalence, risk of HIV transmission is significant.[1–3] Data from developed countries indicate 
that the risk of HIV transmission from a single percutaneous exposure is approximately 0.3%. 
Specific risk factors include injury with a large-bore hollow needle, deep injury, presence of visible 
blood on the sharp device, prior use of the sharp device in a blood vessel and terminal illness in the 
source person.[4] 
No randomized controlled studies have been carried out into the use of PEP to prevent HIV trans-
mission. However, a case control study of health-care workers in France, the UK, Italy and the USA 
indicated that zidovudine reduced the risk of HIV infection following occupational exposure by 
80%.[5] Further support for the efficacy of HIV-PEP is derived from animal experiments and the 
analogy with mother-to-child vertical transmission prophylaxis. Zidovudine is recommended in 
PEP regimes, as it is the component for which most data is available regarding efficacy and safety. 
It is generally used in combination with lamivudine and, if the risk of transmission is felt to be high, 
a third drug, usually a protease inhibitor, is added.[4] Current guidelines recommend initiation as 
soon as possible, but cut-off times have not been strictly formulated, as early pathogenesis of HIV 
remains unclear.[4] The advised treatment duration is 28 days, based on animal studies.
There is no information on the incidence of occupational injuries in hospital workers in Malawi. 
HIV infection in patients admitted to Queen Elizabeth Central Hospital (QECH) in Blantyre, 
Malawi, is common, and the prevalence among adult medical inpatients is 70–76% [6, 7].
As patients often present with advanced disease, a high HIV viral load is likely and occupational 
injuries therefore carry a relevant risk of HIV transmission for workers at QECH. No prevention 
programme for occupational transmission of blood-borne infections was available within govern-
ment health institutions in Malawi up to 2003, with the exception of hepatitis B vaccination of 
medical students. 
We describe the evaluation of the HIV–PEP programme for occupational injuries in QECH 1 year 
after its introduction and also the results of interviews with nurses regarding occurrence of occu-
pational injuries, as well as awareness and utilization of the programme. 
Methods
Site. The QECH is a large public and teaching hospital in Blantyre, the biggest city in Malawi, and 
provides free primary, secondary and tertiary medical care. Physicians of the Department of Medi-
cine (DoM) of the College of Medicine, the only medical school in Malawi, run the antiretroviral 
(ARV) therapy clinic of QECH, various other adult medical outpatient clinics, as well as the adult 
medical wards of QECH, with 13,000 admissions per year. QECH has on average 250 nurses and 
85 clinical staff, while approximately 60 medical students and interns per year rotate through the 
departments.
Set up of the PEP programme in QECH. We introduced the PEP programme according to national 
guidelines for the treatment of HIV,[8] with some local adaptations. Duovir® (Cipla Ltd, Mumbai, 
India), a fixed dose preparation of zidovudine and lamivudine, was the only PEP regimen avail-
able and was provided free of charge. Initially it was donated, later it became available through the 
national ARV therapy programme of the Ministry of Health, supported by the Global Fund to fight 
AIDS, malaria and TB. Prior to commencement, all departments were informed, posters were pro-
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vided, lectures were organized and all clinical officers were trained in the principles of PEP. This 
allowed a 24-h per day PEP service, with rapid HIV testing for clients and source persons. In line 
with national guidelines, we insisted that the client was HIV tested before receiving PEP, because 
PEP is not indicated for those who are already HIV infected, and double ARV therapy is poten-
tially harmful as it can readily induce drug resistance. Any client seen outside office hours had a 
follow-up visit with an ARV physician within 24 h. Clients received information about the risk of 
HIV transmission, the HIV testing procedure, the nature and risks of side effects, the importance 
of adherence and the need for appropriate contraception. After a risk–benefit analysis, the client 
and the ARV physician came to a decision on whether or not to start a course of PEP. For those who 
started PEP, follow-up visits were scheduled.
File reviews. Files of all the clients who sought advice after an occupational injury between Novem-
ber 2003 and November 2004 were reviewed. Demographic data, details concerning the injury, the 
decision to start PEP and side effects were retrieved.
Interviews. Because of the lower-than-expected notifications of occupational injuries, in particu-
lar, in the group of nurses and clinical officers, we interviewed nurses of three different clinical 
departments of the QECH. A research nurse from the DoM, who was not involved with the PEP 
programme or the ARV therapy clinic, conducted the interviews. Nurses were approached during 
working hours at their place of work. It was explained that accepting the interview was entirely on 
a voluntary basis, and that any information provided would remain confidential.
Results
Clients. During the first year of the PEP service, 29 clients sought advice after an occupational 
injury. The majority (20=69%) had a needle stick injury. The mean age of the clients was 32 years, 
with a range of 22–61 years; 55% were men. Among the clients were 10 (35%) doctors and five 
(17%) medical students, two (7%) clinical officers, seven (24%) nurses and five others. The time of 
presentation was outside office hours in nine (31%) of the cases. PEP was started in 19 (66%) cases, 
but in two, it was stopped the next day after the source person was tested HIV negative. In 69% of 
those who received PEP, it was started 4 h or sooner after the injury and all started within 48 h (in 
three cases, no time was indicated). In 10 cases, PEP was not started, in five because the source 
person was found to be HIV negative, in three, because the estimated risk for HIV transmission 
was too low and, in one, the event was notified after much delay. All clients were HIV tested, except 
one, who came after a very long delay and did not receive PEP. One client was HIV positive. When 
PEP was started, seven of the 19 reported side-effects that were generally mild; however, one client 
had to stop Duovir® due to severe nausea and vomiting. Clients were advised to attend four follow-
up visits, but only one client did so. Most did not report their HIV test result after 3 and 6 months. 
We did not test for hepatitis B and C, because no interventions for these were available.
Interviews with nurses. In January 2005, we interviewed 37 nurses from the departments of medi-
cine, surgery and obstetrics and gynaecology. This represented a response of 61% of the nursing 
establishments of those wards. Nurses were approached during working hours at their place of 
work. The main reasons for being unable to obtain an interview were absence from work due to 
illness or leave, and lack of a financial compensation. Questions included the number and type of 
occupational injuries sustained in 2004 (Table 1). Twenty-eight (76%) nurses reported a total of 56 
injuries in 2004, which translates into an incidence rate of 1.5 occupational injuries per person-
year, assuming all worked throughout 2004. Only one of the 28 nurses who had an occupational 
injury sought advice for PEP. In the majority (20=74%), the reason for not seeking help was being 
unaware about the PEP programme; four (15%) did not want a HIV test, while three thought the 
event was not serious enough.
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Discussion
We found an alarmingly high reported incidence of occupational injuries among nurses in the clini-
cal departments of QECH. Moreover, this is likely to be an underestimation of the true incidence, 
as nurses may not have recalled injuries sustained several months earlier, particularly if these were 
considered to be minor. Severe understaffing, a high patient burden and poor medical-technical 
facilities are likely to have contributed to this high incidence. 
Our data need to be approached with some caution as not all nurses were interviewed; it is, how-
ever, reasonable to assume that the sample of nurses was representative for all clinical departments 
at QECH.
The other major group of paramedical staff at risk are clinical officers. They undertake similar and 
more invasive procedures with limited resources. We did not interview clinical officers but expect 
a situation similar to that of the nurses.
It was feasible to introduce a programme of HIV PEP in a resource-poor setting. The organization 
of our programme was adequate. Clients were given prompt advice and PEP, if indicated. Trained 
clinicians and rapid HIV testing were available 24 h per day. There was an uninterrupted supply 
of PEP medication that was, generally, well tolerated. In our experience, HIV testing of the source 
person was not problematic, in all but two cases clients were able to obtain results of the source 
person, if identifiable, within 24 h after the injury. 
Despite these adequate logistics, there were clear shortcomings: 
(1) The uptake was limited, and many nurses reported to be unaware of the programme. The pub-
licity campaign at the start of the PEP programme had clearly been insufficient. It is worrying that 
several nurses were reluctant to undergo an HIV test. The HIV prevalence in adults in Malawi is 
as high as 15% [8], and the possibility of a positive test result may have caused fear of stigmatiza-
tion. The recent introduction in Malawi of free-of-charge ARV therapy may remove some of the 
resistance against HIV testing, but other concerns, in particular pertaining to the confidentiality of 
the HIV test result, also have to be addressed.
(2) The attendance of clients to scheduled follow-up visits after PEP was poor and, therefore, the 
effectiveness of the programme is unknown. 
Based on experience in the first year of our PEP programme and the results of the interviews, we 
have the following recommendations for the introduction of HIV PEP in resource poor settings: (a) 
an intensive and continuous publicity campaign is required. A PEP management team in which all 
the potential benefiting groups are represented should be established, as this is likely to improve 
ownership and uptake of the programme. (b) Emphasis needs to be given to the value of reporting 
post–PEP-HIV test results back to the clinician, to advise clients in case of HIV transmission and 
to properly evaluate the effectiveness of the PEP strategy. (c) Where the incidence of occupational 
injuries is high, injury-prevention measures need to be reviewed. (d) In many developing countries, 
hepatitis B prevalence among hospital patients is very high and, since the infectivity of hepatitis B 
is far higher than that of HIV, routine hepatitis B vaccination should be available for all nursing and 
clinical staff. (e) A PEP programme can be used as a tool to give attention to other aspects of HIV 
infection to staff members of medical institutions, such as voluntary counseling and testing, the use 
of condoms and antiretroviral therapy. With the increasing availability of ARV drugs in resource 
poor settings, it is important that hospitals provide an HIV-PEP service for occupational injuries to 
their staff. As we described, more than a good logistical organization is required for a satisfactory 
uptake of an HIV-PEP programme.
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Abstract
The objective of this study was to investigate the utility of finger-prick blood samples for CD4 cell 
counting. We estimated agreement between CD4 cell counts in paired finger-prick and venous 
samples from 110 HIV-infected adults from Malawi. Bias was 6.6 cells/ml (limits of agreement 
-50.7 and 63.7 cells/ml) for absolute counts and 0.71% (limits of agreement -2.07 and 3.48%) for 
%CD4/lymphocyte suggesting that finger-prick blood samples can be used interchangeably with 
venous samples for CD4 cell counting.
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Introduction
There is currently a rapid scaling up of antiretroviral therapy (ART) in resource-poor settings, espe-
cially in Africa. World Health Organization (WHO) clinical staging is usually employed to assess 
whether an individual should start ART in such settings [1], but clinical staging does not always 
correspond to the degree of immunosuppression [2], and patient management could be improved 
by increased availability of CD4 lymphocyte counts (CD4 cell counts) [3]. The main reasons why 
CD4 cell counts are not widely used are the high cost of flow cytometry, the ‘gold standard’ method 
of CD4 cell counting, and a lack of skilled laboratory staff [4,5]. 
To overcome these problems, a number of simplified non-flow cytometric CD4 cell counting meth-
ods have been developed [6–9]. There have been problems with the accuracy of such methods 
[10], but they have the potential to make affordable CD4 cell counts available for use by staff with 
minimal training away from major medical centers. Rapid tests for CD4 cell counts are currently 
under development [11] and could increase the availability of CD4 cell counting. Such tests could 
be performed on finger-prick blood samples, enabling them to be conducted where trained phle-
botomists are not available or when difficulties are encountered with venous sampling. Finger-prick 
blood samples are commonly used in resource-poor settings for rapid HIV tests and malaria para-
site slides, and so may be more acceptable than venesection. Studies comparing CD4 cell counts in 
finger-prick and venous blood are currently lacking. Previous studies of full blood counts in healthy 
adults using haematological analysers have found mean leukocyte counts that are 7.82% [12] and 
8.34% [13] higher in finger-prick blood samples compared with venous blood. The differences were 
greatest among the large leukocyte subpopulations (principally neutrophils) and were least among 
small leukocytes (principally lymphocytes).
We therefore conducted a study in HIV-infected adults to estimate the agreement between results 
obtained using finger-prick and venous blood for absolute CD4 cell counts and CD4 cell counts as 
a percentage of the total lymphocyte count (%CD4/lymphocyte). 
Methods
The study was conducted in the ART clinic, Queen Elizabeth Central Hospital, Blantyre, Malawi. 
After informed consent was obtained, simultaneous venous and finger-prick blood samples were 
taken by three study nurses, experienced in finger-prick and venous blood sampling, from 111 
consecutive HIV-infected Malawian adults during September and October 2006. There were no 
exclusion criteria.
Blood samples were taken simultaneously from the pad of the middle finger and an antecubital 
vein of the opposite arm. Finger-prick samples were taken using BD Genie lancets (2.0mm×1.5 
mm; Becton Dickinson, San Jose, California, USA) according to the manufacturer’s recommended 
procedure [14]. This produced a free flow of blood with minimal squeezing of the finger. Venous 
sampling was performed using a 21G needle and syringe. Finger-prick and venous samples were 
collected in separate BD Microtainer ethylenediamine tetraacetic acid capillary blood tubes (250 
μl per tube). The first drop of finger-prick blood was discarded. One set of samples was rejected, 
because the finger-prick sample clotted. Paired blood samples were tested in parallel for CD4 cell 
counts within 6 h of collection using Multitest CD3/8/45/4 kits with TruCount tubes (TruCount; BD 
Biosciences, San Jose, California, USA) and full blood counts on a HMX haematological analy-
ser (Beckman Coulter, Fullerton, California, USA). Full blood counts were not obtained on two 
samples because of insufficient blood. No other data are missing. TruCount is an established flow 
cytometric CD4 cell counting assay that generates both an absolute CD4 cell count, %CD4/lym-
phocyte and total lymphocyte count and has excellent repeatability and quality assurance scores 
[15]. Data were acquired on a FACSCalibur flow cytometer (Becton Dickinson) and analysed using 
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MultiSet software, blinded to the paired result for each sample. 
The main outcome measure was agreement between finger-prick and venous samples assessed 
by estimating bias and limits of agreement (bias ±1.96 SD) with 95% confidence intervals (CI) as 
described by Bland and Altman [16].
Results
The median age of the 110 participants with analyzable samples was 33 years (range 20–64). Sixty-
nine per cent were women, 5% were pregnant, 26% were taking ART, 14% were on treatment 
for current bacterial, fungal or tuberculous infection and 15% were febrile (axillary temperature 
>37.50C). At the time of sampling or when started on ART, 21% of participants had WHO clini-
cal stage I HIV/AIDS, 31% stage II, 30% stage III and 18% stage IV. No participants complained 
about either blood sampling procedure and no adverse events were reported. The median CD4 cell 
counts on venous blood samples were 277 cells/ml (range 2–1121) for absolute counts and 13.28% 
(0.16–38.31%) for %CD4/lymphocyte. Agreement between paired CD4 cell counts was good, with 
little bias and narrow limits of agreement (Fig. 1).
Finger-prick CD4 cell values were higher than venous CD4 cell counts by an average of 6.6 cells/ml 
(95% CI 1.0, 12.0), with limits of agreement -50.7 cells/ml (95% CI -60.3, -41.2) and 63.7 cells/ml 
(95% CI 54.2, 73.3). Total lymphocyte counts (by TruCount) were higher in finger-prick blood with 
a bias of 183 cells/ml, resulting in higher venous compared with finger-prick %CD4/lymphocyte 
values with a bias of 0.71% (95% CI 0.44, 0.97) and limits of agreement -2.07% (95% CI -2.53,-1.61) 
and 3.48% (95% CI 3.02, 3.95). Total leukocyte counts were also higher in finger-prick blood com-
pared with venous blood, with a mean difference of 949 cells/ml.
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Fig. 1. Comparison of CD4 cell counts determined for finger prick blood and venous 
blood samples from 110 HIV-infected patients.  
 
Solid horizontal lines depict bias and upper and lower limits of agreement. Dashed lines 
denote 95% confidence intervals for these values. Mean counts are the average of the finger-
prick and venous CD4 cell counts for each individual. (a) Absolute CD4 cell counts; (b) CD4 
cell count as percentage of the total lymphocyte count. 
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Discussion
When expressed as a percentage of the mean value for each cell type count, the biases for the CD4 
lymphocyte, total lymphocyte and total leukocyte counts are 2.2, 8.2 and 15.2%, respectively. As 
previously observed [12,13], these figures suggest that the difference between leukocyte counts in 
venous and finger-prick blood samples is largely caused by large leukocytes rather than lympho-
cytes.
The study was conducted under optimum blood sampling conditions. The use of lancets with smaller 
blades might necessitate excessive finger squeezing to produce a blood sample, leading to dilution 
of the sample with tissue fluid. Rapid diagnostic tests are, however, likely to require less than the 
250ml blood collected from each finger prick in this study so this may not be a major issue.
Conclusion
These data indicate that provided a careful sampling technique is followed, finger-prick blood sam-
ples could be used in place of venous blood samples in HIV-infected African adults for both abso-
lute CD4 cell counts and %CD4/lymphocyte values. This potentially increases the accessibility for 
CD4 cell counting in resource-poor settings, especially once rapid tests become widely available.
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Summary
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In this thesis an overview of several aspects of HIV management in Malawi is provided.
In chapter 2 we described the results of a large prospective cohort study of HIV infected adults, 
in which we addressed the questions of the potential impact of trimethoprim-sulfamethoxazole 
(TS) prophylaxis in HIV infected persons in Malawi and the bacterial resistance among pathogenic 
bacterial strains cultured during disease episodes in this population. Because none of the persons 
received TS prophylaxis and very few antiretroviral therapy (ART), which was not available free 
of charge at the time, the study provided a good insight into the natural history of HIV infection in 
Malawi. Firstly we confirmed the extremely high morbidity and mortality that occurs in patients 
with advanced HIV infection: those with WHO clinical stage III and IV and those with a CD4 count 
<200/μl. This indicates the high potential benefit of TS prophylaxis and ART in those groups. 
As expected, the incidence rates of severe bacterial infections, in particular bacterial pneumo-
nias and sepsis, and of tuberculosis and oral candidiasis were high. The incidence of uncompli-
cated malaria was very high. Other differences from the HIV associated disease pattern in western 
settings were low rates of Pneumocystis jiroveci pneumonia (PcP), Toxoplasma encephalitis and 
isosporiasis. Despite having relatively extensive diagnostic capacity in the research center, a spe-
cific diagnosis could not be made for many of the disease episodes. More than 75% of the cultured 
pathogenic bacteria were resistant to TS, which was similar to a previous report from Blantyre 
[1]. This fact and the concern that introduction of TS prophylaxis to a large population could lead 
to widespread cross-resistance to sulfadoxine-pyrimethamine (SP), the first line anti-malarial in 
Malawi and many countries in sub-Saharan Africa, were the reasons why local policy makers had 
not yet introduced TS prophylaxis in Malawi in 2002. 
Originally we had planned to do a randomized placebo controlled clinical trial of TS prophylaxis to 
establish whether TS prophylaxis is beneficial in holo-endemic malaria areas where bacterial resis-
tance to TS is high. However international research review boards, mindful of the results of the two 
studies from Ivory Coast [2, 3] that had demonstrated benefit of TS prophylaxis (in circumstances 
of low TS resistance), decided that a placebo group was unethical. Instead, we were advised to do 
the cohort study of chapter 2 first, to provide more data in support of a placebo-controlled study. 
This was an interesting ethical paradox because in the cohort study effectively all the patients were 
in “placebo group” not receiving TS. In the end we were overtaken by developments as increasing 
evidence emerged of the benefit of TS prophylaxis in circumstances in countries from the region 
[4, 5, 6, 7] and a programme of TS prophylaxis was finally introduced by the Ministry of Health 
in 2006. It was not until the end of 2007 before sufficient stocks of TS were available to actually 
implement provision of TS prophylaxis to all eligible persons.
Because PcP was uncommon in the cohort and previous reports had given conflicting data about the 
importance of PcP in sub-Saharan Africa, we investigated the PcP incidence in chapter 3 in more 
detail. Having follow-up data of patients after disease episodes and with the availability of post-hoc 
Pneumocystis PCR results from induced sputum samples we could reliably distinguish between 
PcP and Pneumocystis colonization. This made it possible to use the PCR results to increase the 
sensitivity of induced sputum results and to confirm or reject cases we had initially labelled as 
probable PcP (those patients with a negative immune-fluorescence stain of an induced sputum, but 
with clinical suspicion of PcP strong enough to warrant PcP treatment). We confirmed that PcP was 
a rare diagnosis in the cohort as a whole, but the incidence was substantial in the population at risk, 
those with a CD4 count <100/ml. Clinicians may have the impression that PcP occurs infrequently 
because even in this group with very advanced immune suppression bacterial pneumonia and pul-
monary tuberculosis are much more common than PcP.
Malaria was the most common specific diagnosis in HIV infected adults in the cohort.  In chapter 
4 we wanted to study aspects of malaria related to HIV immune suppression. We found that clinical 
malaria was common in all CD4 strata, but severe malaria was very rare. Clinical malaria had a 
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moderately higher incidence in persons with lower CD4 counts, although it was much less strongly 
associated with HIV immune suppression than opportunistic infections such as sepsis, bacterial 
pneumonia and tuberculosis. It appears that in persons with HIV infection in malaria endemic 
areas immunity to malaria is largely preserved. The more HIV immune suppression progresses, 
the more likely it is that when patients present with parasitemia and fever, another infection than 
malaria is the cause of the febrile illness. This can lead to misclassification of the disease episode 
as malaria whereby the clinican may be overlooking a potentially life-threatening illnesses.
The question of the efficacy of malaria treatment was the topic of the fourth paper from the cohort 
study in Ndirande in chapter 5. Earlier studies had suggested that there is a higher chance of 
malaria treatment failure in patients with more advanced HIV immune suppression. We looked at 
the ability of HIV infected persons in various CD4 strata to clear malaria infection with SP, a drug 
to which there is widespread resistance in Malawi. We found that CD4 count was not associated 
with SP treatment failure. Anemia and infection with SP-resistant parasites were factors associated 
with SP failure, but only in children. The fact that in adults with advanced HIV immune suppression 
SP failure is not more common than in HIV infected persons with high CD4 counts suggests that 
acquired immunity to malaria is maintained during HIV infection in areas with intensive malaria 
transmission. This supports the observations of chapter 4, namely that the malaria incidence only 
moderately increases with declining CD4 counts and that malaria very rarely progresses to severe 
disease.
Chapter 6 reports about a prospective study undertaken among tuberculosis patients in Queen 
Elizabeth Central Hospital. The hypothesis that adrenal insufficiency is an important contribu-
tor to early mortality during TB treatment, and that adrenal insufficiency may be exacerbated 
by enhanced metabolism of cortisol through enzyme induction in the liver by rifampicin was not 
confirmed. Fifty-one patients were screened for adrenal insufficiency with a synacthen stimula-
tion test, first at the start of TB treatment and then repeated two weeks later. Only two patients 
had (asymptomatic) adrenal insufficiency and both survived the first 3 months of TB treatment, 
while the patients that died all had adequate adrenal reserve and the causes of death appeared to be 
HIV-associated opportunistic infections and Kaposi’s sarcoma. Adrenal insufficiency therefore is 
unlikely to be associated with early mortality during tuberculosis treatment in Malawi.  
In chapter 7 we wanted to evaluate the results of the ART clinic of QECH during the time this was 
a fee-paying clinic. Only 41% of all patients who had ever started ART from 2000 to 2003 were 
retained in care. Those who were still being followed up showed good clinical, immunological and 
virological results. Nevirapine levels were relatively high compared to most previous (western) 
studies and high nevirapine levels were associated with good virological outcome. The most com-
mon reasons patients reported for non-adherence were personal financial problems and drugs being 
out of stock in the hospital pharmacy. The attrition rate in QECH was similar to the other large 
urban fee-paying ART clinic in the capital Lilongwe and contrasted with the much lower losses to 
follow up in the ART clinic in Chiradzulu district, coordinated by Médecins sans Frontières, where 
antiretroviral drugs were provided free of charge and drug supply was rarely interrupted. 
In chapter 8 we investigated the impact of changes that occured at the ART clinic of QECH after 
the introduction of the national ART scale-up programme in 2004, in particular that ART became 
free of charge and that the drug logistics improved.  Alternative antiretroviral drugs were intro-
duced for patients with side effects on the standard first line regimen and a second line regimen 
became available – on a small scale – for patients with ART failure. Results of ART are reported in 
standard treatment outcomes (alive on ART, death, defaulter, transfer out to other ART clinic, stop 
ART) and produced quarterly. The results indicate that the defaulter rate is much lower than before 
the national ART scale-up programme. Deaths and stopping ART are at acceptable levels, although 
early mortality (in the first 3 months after starting ART) was identified in QECH as an important 
problem similar to elsewhere in sub-Saharan Africa. Women and children found increased access 
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to ART. No stock outs of antiretroviral drugs occurred between 2004 and 2007. Challenges were 
also noted, in particular the ever increasing patient load, the human resource crisis in the health 
care sector (shortages of clinicians and nurses), a long waiting list before ART initiation, inad-
equacy of existing infrastructure (ART clinic building and equipment), file management and record 
keeping, and management of the long term side effects of stavudine.
In chapter 9 a detailed clinical study is presented of 27 patients who initiated ART with the national 
first line regimen (stavudine, lamivudine and nevirapine), in the second week after they had started 
treatment for AFB smear positive TB. This study was done in preparation of a larger trial of the 
timing of ART during TB treatment. In this high risk group with advanced HIV infection, and 
other risk factors of mortality (anaemia and malnutrition) the mortality during TB treatment was 
19 %; virological and immunological results of the survivors were good. Suspected immune recon-
stitution inflammatory syndrome was common but could be managed with corticosteroids and 
symptomatic therapy, without interruption of ART or TB treatment. Side effects occurred fre-
quently especially during the first two months of ART. Only one patient interrupted ART and 
TB treatment, due to drug induced hepatitis. Nevirapine levels were low in the first two weeks of 
ART, when the normal nevirapine lead-in phase was used, suggesting that when enzyme induction 
by rifampicin has taken place, this lead-in phase should be avoided, to prevent risk of resistance 
development. The majority of nevirapine levels at 4 and 8 weeks of ART were in the therapeutic 
range, adding to existing evidence that when rifampicin and nevirapine are used together, sufficient 
nevirapine levels and adequate ART results can be achieved.
In chapter 10 we present a randomized clinical trial that questioned which  the most effective of 
two different food supplements was when given during the first 14 weeks of ART to wasted Mala-
wian adults. This was an effectiveness study in an operational setting. Use of ready to use food 
spread (RUFS) resulted in significantly better nutritional recovery than corn-soy blend (CSB), and 
several reasons for this are suggested. There were no differences in survival, severe morbidity (as 
measured by hospitalizations), adherence to ART and quality of life between users of the tradi-
tional CSB and the newer, more expensive and more energy dense RUFS. Mortality in both groups 
was at the higher end of the spectrum compared to other ART cohorts described from sub-Saharan 
Africa. This clinical trial was originally written to contain a control group without nutritional 
intervention, but this was considered unethical, as food supplementation had become the standard 
of care for wasted HIV infected patients in Malawi. 
The question therefore remained if food supplementation, that carries a relatively high cost in this 
population is clinically beneficial compared to no nutritional intervention. To get more insight into 
this problem we did a retrospective study (chapter 11) comparing patients from the clinical trial of 
chapter 10 with wasted patients from a prospective observational study of the outcomes and side 
effects of the first line ART regimen. The cohort study had been done around one year earlier, also 
at the ART clinic of QECH and none of the participants had received food supplements.. Partici-
pants in both groups had similar baseline characteristics. The food supplemented group had a better 
anthropometric recovery. Unexpectedly they had a trend to a higher mortality at 14 weeks and a 
significantly worse survival at 26 weeks. The difference in the study populations and the treatment 
of the patients in the two groups, may have been diufferent due to the use of a historical control 
group. It is unlikely that the short-term food supplementation caused a negative effect on mortality. 
The main value of these results is that they should stimulate further studies of food supplements 
added to ART that include a control group without nutritional intervention.
Chapter 12 is a short report of the challenges we faced when we introduced a programme of post-
exposure prophylaxis for occupational injuries in health care workers in QECH in 2003. Despite an 
adequate logistical organization, and the availability of free of charge medication, uninterrupted 
drugs supply and around the clock HIV testing, the uptake of the service was far from optimal. This 
was mainly due to inadequate publicity on the one hand and unwillingness of staff to undergo HIV 
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tests on the other. This is worrying since interviews with nurses had indicated that occupational 
injuries occurred frequently. A number of reccomendations were made to avoid the problems that 
we had experienced.
In chapter 13 we showed that blood obtained from a finger prick can be used in place of venous 
blood for the determination of CD4 counts. Capillary and venous samples were taken for CD4 count 
testing at the same time from 110 adults with varying degrees of immune suppression. Agreement 
between values of venous and capillary samples was excellent for both absolute CD4 counts as well 
as CD4 percentages. Since finger prick sampling is easier to  perform and more acceptable to local 
patients than venous punctures, because they are done for malaria tests, our results are promising 
for the use of finger prick samples for rapid CD4 tests that are being developed.
Many questions and challenges concerning TS prophylaxis and and even more concerning ART 
in sub-Saharan Africa remain. The benefits and potential harms of continued TS prophylaxis after 
immune reconstitution on ART is an important issue that needs to be addressed in a clinical trial. 
While TS prophylaxis can be safely stopped in western patients on stable, successful ART if the 
CD4 count has increased above 200 cells/ml, however this can not simply be extrapolated to sub-
Saharan Africa, where the benefit of TS is mostly in preventing severe bacterial infections and 
probably malaria, to a larger degree than PcP and Toxoplasma encephalitis. Such a trial is being 
prepared in Malawi. 
Knowledge of ART in resource limited settings still has many gaps. High priority for further study 
has the high early mortality on ART, the causes of which have not been accurately established. 
Additionally data are still sparse on problems associated with long-term first line ART, in particu-
lar ART failure and mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. The evi-
dence base of appropriate diagnostic tools and management options for these increasingly common 
conditions needs to be improved urgently. The very large and ever increasing patient population 
on ART and the strong limitations in health care human resources in Malawi and the rest of sub-
Saharan Africa make the challenges for local scientists in this field urgent, attactive and difficult 
at the same time. 
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In dit proefschrift komt een aantal aspecten van de behandeling van HIV in Malawi aan de orde.
In hoofdstuk 2 worden de resultaten van een grote prospectieve cohort studie beschreven, die als 
doel had de potentiële invloed van cotrimoxazol profylaxe voor HIV geïnfecteerde personen te 
bepalen en tevens de antibiotische resistentie te meten in pathogene bacteriën die gekweekt werden 
tijdens ziekte perioden. Omdat geen enkele persoon in het cohort cotrimoxazol profylaxe gebruikte 
en vrijwel geen enkele antiretrovirale therapie (ART), hetgeen op dat moment nog niet gratis ver-
strekt werd, bood deze studie een goed inzicht in het natuurlijk beloop van HIV infectie in Malawi. 
Op de eerste plaats werd de extreem hoge morbiditeit en mortaliteit bevestigd die optreed tijdens 
vergevorderde HIV infectie, in het bijzonder bij hen in WHO klinisch stadium III en IV en/of met 
een CD4 getal kleiner dan 200 cellen/μl. Juist in deze groepen bestaat een groot potentieel voordeel 
van cotrimoxazol profylaxe. 
Zoals verwacht waren de incidentie getallen van bacteriële infecties, in het bijzonder bacteriële 
pneumonie en sepsis, en van tuberculose en orale candidiasis hoog. Ongecompliceerde malaria 
kwam ook erg vaak voor. Andere verschillen ten opzichte van het in westerse landen optredende 
HIV geassocieerde ziektepatroon waren de geringe aantallen Pneumocystis jiroveci pneumonie 
(PcP), Toxoplasma encephalitis en isosporiasis. Ondanks de relatief uitgebreide diagnostische 
capaciteit in het onderzoekscentrum kon voor veel ziekte episoden geen specifieke diagnose wor-
den vastgesteld. Meer dan 75% van de gekweekte pathogene bacteriën waren resistent tegen cotri-
moxazol, hetgeen overeen kwam met een eerdere melding uit Blantyre [1]. Deze bevinding en 
de bezorgdheid dat weid verbreid gebruik van cotrimoxazol zou kunnen leiden tot kruisresisten-
tie tegen de eerste lijn malaria behandeling (sulfadoxine-pyrimethamine [SP]) in Malawi en vele 
andere landen in Afrika bezuiden de Sahara, leidden ertoe dat de lokale gezondheidszorg autoritei-
ten in 2002 nog niet besloten hadden cotrimoxazol profylaxe in te voeren.
In eerste instantie was deze studie opgezet als een gerandomiseerde, placebo-gecontroleerde kli-
nische studie om eenduidig vast te stellen of cotrimoxazol effectief zou zijn in holo-endemische 
malaria gebieden met een hoge graad van cotrimoxazol resistentie onder bacteriële pathogenen. 
Echter geconsulteerde internationale ethische commissies vonden dat een placebo groep niet 
ethisch verantwoord was, gezien de resultaten van twee studies uit Ivoorkust, die hadden aange-
toond dat cotrimoxazol profylaxe een gunstig effect heeft in omstandigheden waar lage resistentie 
tegen cotrimoxazol aanwezig was. We werden geadviseerd om eerst een cohort studie te doen 
om meer ondersteuning voor een placebo gecontroleerde studie te verkrijgen. Dit leidde tot een 
interessante ethische paradox omdat de cohort studie die we vervolgens uitvoerden feitelijk een 
studie was waarin alle patiënten (in plaats van de helft) in de placebo groep – zonder cotrimoxazol 
profylaxe - zaten. Uiteindelijk werden wij ingehaald door andere groepen in omringende landen 
met vergelijkbare omstandigheden tot Malawi [4, 5, 6, 7], die samen voldoende bewijs verschaften 
om over te gaan tot introductie van cotrimoxazol profylaxe in Malawi, wat uiteindelijk gebeurde in 
2006. Aan het einde van 2007 waren er pas voldoende voorraden om routinematige cotrimoxazol 
profylaxe ook daadwerkelijk uit te voeren.
Omdat we weinig PcP gevallen hadden gediagnosticeerd in de cohort studie en eerdere studies 
contrasterende resultaten hadden opgeleverd over het belang van PcP in Afrika, onderzochten we 
de incidentie van PcP in meer detail in hoofdstuk 3. Met de beschikbaarheid van follow-up gege-
vens na de ziekte episoden en met achteraf bepaalde Pneumocystis PCR resultaten, verkregen van 
geïnduceerd sputum, konden we betrouwbaar onderscheid maken tussen Pneumocystis kolonisatie 
en PcP. Vervolgens gebruikten we de PCR resultaten om de sensitiviteit van de geïnduceerde spu-
tum resultaten te vergroten en gevallen die we aanvankelijk hadden geregistreerd als “mogelijke 
PcP” te verwerpen of bevestigen (gevallen met een geïnduceerd sputum met een negatief immuno-
fluorescentie resultaat, maar een zodanig sterke klinische verdenking dat over gegaan was tot PcP 
behandeling). We bevestigden dat PcP in het cohort als geheel een zeldzame diagnose was maar 
dat de incidentie substantieel was in de groep met de laagste CD4 getallen (<100 cellen/μl). Voor 
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clinici in Afrika wordt de indruk dat PcP niet vaak voorkomt mogelijk versterkt doordat zelfs in 
de groep met de meest geavanceerde immuun suppressie, bacteriële pneumonie en tuberculose een 
veel hogere incidentie hebben.
Malaria was de meest voorkomende ziekte in HIV geïnfecteerde volwassenen in het cohort. In 
hoofdstuk 4 bestudeerden we aspecten van malaria in relatie tot HIV immuun suppressie. Hoe-
wel klinische malaria zeer frequent voorkwam in alle CD4 strata was ernstige malaria zeldzaam. 
Klinische malaria had een matig verhoogde incidentie in diegenen met een lagere CD4 getal, maar 
malaria was veel minder sterk geassocieerd met HIV immuun suppressie dan opportunistische 
infecties zoals sepsis, bacteriële pneumonie en tuberculose. Het lijkt dus dat in personen met HIV 
infectie in endemische malaria gebieden de immuniteit tegen malaria niet sterk wordt aangetast. 
Hoe verder de immuun suppressie voortgeschreden is, des te waarschijnlijker is het dat wanneer 
een patiënt zich presenteert met koorts en malaria parasieten in het bloed, een andere infectie dan 
malaria de oorzaak van de koorts is. Dit kan leiden tot misclassificatie van de ziekte episode als 
malaria, waardoor een belangrijke, mogelijk levensbedreigende andere diagnose wordt gemist.
De effectiviteit van malaria behandeling bij HIV geinfecteerden was onderwerp van het vierde 
artikel van de cohort studie in Ndirande in hoofdstuk 5. Eerdere studies hadden gesuggereerd dat 
de kans op malaria therapie falen toeneemt met voortschrijdende immuun-suppressie. We bestu-
deerden de capaciteit van HIV geïnfecteerde personen in verschillende CD4 strata om malaria 
infectie te klaren met SP, waarvan het bekend was dat er een hoge graad van resistentie onder mala-
ria parasieten bestond in Malawi. We stelden vast dat de graad van immuun suppressie niet was 
geassocieerd met falen van SP behandeling. Anemie en infectie met SP resistente parasieten waren 
geassocieerd met SP falen maar alleen in kinderen. Het feit dat in volwassenen met geavanceerde 
immuun suppressie SP falen niet vaker voor kwam dan bij hen met hogere CD4 getallen suggereert 
dat verworven malaria immuniteit tegen malaria behouden blijft tijdens HIV infectie, in gebieden 
met hoge malaria transmissie. Dit ondersteunt de bevindingen van hoofdstuk 4, namelijk dat de 
malaria incidentie maar gering toeneemt bij progressieve immuun progressie en dat klinische ern-
stige malaria zelden voor komt onder HIV geinfecteerden.
In hoofdstuk 6 beschrijven we een prospectieve studie van volwassen tuberculose patiënten in 
Queen Elizabeth Central Hospital. De hypothese was dat bijnier insufficiëntie een belangrijke bij-
drage levert aan de mortaliteit die gezien wordt tijdens de eerste fase van de tuberculose behande-
ling in Malawi en dat bijnier insufficiëntie kan worden verergerd door enzym inductie van rifam-
picine in de lever waardoor het metabolisme van cortisol wordt versterkt. Deze hypothesen wer-
den echter niet bevestigd. Eenenvijftig patiënten werden getest op bijnier insufficiëntie met een 
synacthen stimulatie test, voor het begin van de tuberculose behandeling en nog eens twee weken 
later. Slechts twee patiënten hadden asymptomatische bijnier insufficiëntie en beiden overleefden 
de eerste drie maanden van de tuberculose behandeling. Alle patiënten die overleden hadden een 
adequate bijnier reserve en de doodsoorzaken leken in alle gevallen HIV geassocieerde infecties en 
Kaposi’s sarcoma te zijn. Het is daarom onwaarschijnlijk dat bijnier insufficiëntie een belangrijke 
bijdrage levert aan de vroege mortaliteit tijdens tuberculose behandeling in Malawi.
In hoofdstuk 7 beschreven we de resultaten van de ART kliniek van QECH in de periode dat in 
deze kliniek betaald moest worden voor de antiretrovirale therapie. Slechts 41% van alle patiënten 
die ooit in de kliniek gestart waren met ART tussen 2000 en 2003 waren nog steeds onder behan-
deling. Degenen die nog onder behandeling waren hadden goede klinische, immunologische en 
virologische resultaten. Nevirapine plasma spiegels waren relatief hoog vergeleken met de meeste 
westerse studies en hoge nevirapine spiegels waren geassocieerd met goede virologische resultaten. 
De meest voorkomende redeneren die patiënten noemden als oorzaak voor verminderde therapie 
trouw waren persoonlijke financiële problemen en het afwezig zijn van medicatie in de ziekenhuis 
apotheek. Het hoge percentage patiënten dat na de start van de behandeling niet meer kwam opda-
gen was in overeenstemming met een andere grote ART kliniek in de hoofdstad Lilongwe waar ook 
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betaald moest worden voor de medicatie maar in sterk contrast met de kliniek van Artsen Zonder 
Grenzen in Chiradzulu District, waar gratis ART werd verstrekt en nauwelijks onderbreking van 
de medicatie bevoorrading optrad.
In hoofdstuk 8 onderzochten we de gevolgen van de veranderingen die optraden in de ART kliniek 
van QECH door de introductie van het nationale ART programma in 2004, in het bijzonder met 
betrekking tot het gratis beschikbaar komen van antiretrovirale medicijnen en de verbetering van 
de logistiek van de geneesmiddelen voorziening. Verschillende nieuwe middelen werden geïntro-
duceerd voor het geval van bijwerkingen van de eerste lijn ART en een tweede lijn behandeling 
kwam beschikbaar in geval van therapie falen. Van de resultaten van de behandeling wordt elk 
kwartaal een verslag geschreven met vermelding van standaard uitkomstmaten: percentages in 
leven op ART, overleden, transfer van zorg naar andere kliniek, stop ART en uitvallers. Meer 
vrouwen en kinderen kregen toegang tot ART. Na de introductie van het nationale ART programma 
werd het percentage uitvallers beduidend lager. De mortaliteit en het percentage dat ART stopt zijn 
acceptabel, hoewel de vroege mortaliteit (sterfte tijdens de eerste 3 maanden na de start van ART) 
een belangrijk probleem is, vergelijkbaar met andere ART programma’s in Afrika bezuiden de 
Sahara. Gedurende de periode tussen 2004 en 2007 was er geen enkele onderbreking van de voor-
ziening van antiretrovirale medicijnen. Belangrijke uitdagingen hebben zich echter aangediend: 
het steeds toenemende aantal patiënten, het gebrek aan gezondheidszorg staf (vooral clinici en ver-
pleegkundigen), een lange wachtlijst voordat ART gestart kan worden, inadequate infrastructuur 
(het polikliniek gebouw en de medische apparatuur), de administratie van de patiënten gegevens en 
behandeling van de lange termijn bijwerkingen van stavudine.
In hoofdstuk 9 presenteren we een gedetailleerde klinische studie van 27 patiënten die intensief 
vervolgd werden nadat zij startten met de standaard eerste lijn ART bestaande uit stavudine, lami-
vudine en nevirapine, in de tweede week van de behandeling voor sputum positieve long tuber-
culose. Deze studie was een voorbereiding voor een grotere klinische vergelijkende studie betref-
fende de juiste timing van ART gedurende tuberculose behandeling. In onze groep patiënten die 
een hoog risico had, gezien de vergevorderde HIV infectie en andere risicofactoren voor mortaliteit 
zoals anemie en vermagering, was de sterfte 19% gedurende de tuberculose behandeling. De viro-
logische en immunologische resultaten van de overlevenden waren goed. De waarschijnlijkheids-
diagnose immuun reconstitutie inflammatoir syndroom werd vaak gesteld, maar deze episoden 
konden worden behandeld met corticosteroïden en symptomatische therapie zonder onderbreking 
van ART of tuberculose behandeling. Bijwerkingen kwamen frequent voor, vooral tijdens de eerste 
twee maanden na de start van ART. Slechts een patiënt moest ART en tuberculose behandeling 
onderbreken ten gevolge van medicatie geinduceerde hepatitis. Nevirapine spiegels waren te laag 
tijdens de eerste twee weken van de ART, tijdens welke periode wij de gebruikelijke halve dosering 
van nevirapine toepasten. Dit suggereert dat wanneer enzym inductie door rifampicine heeft plaats 
gevonden, het beste meteen met de volledige nevirapine dosis gestart kan worden om het risico op 
resistentie tegen nevirapine te vermijden. De grote meerderheid van de nevirapine spiegels na 4 en 
8 weken ART vielen binnen de gewenste waarden, en de observaties in deze studie dat adequate 
nevirapine spiegels en klinische resultaten bereikt werden, geven steun aan het beleid om nevira-
pine en rifampicine te combineren. 
Hoofdstuk 10 is het verslag van een gerandomiseerde klinische studie waarbij twee verschillende 
voedingssupplementen werden vergeleken, die gegeven werden gedurende de eerste 14 weken van 
de ART aan vermagerde volwassen patiënten. De studie was erop gericht om de effectiviteit van de 
voedingssupplementen in operationele omstandigheden te vergelijken. Zogenaamde “ready to use 
therapeutic food spread” (RUFS), resulteerde na 14 weken in een beter herstel van de voedingstoe-
stand dan een maïs soja mengsel (“corn-soy blend” [CSB]), een bevinding waarvoor verschillende 
verklaringen worden aangevoerd. Er waren echter geen verschillen in mortaliteit, ernstige ziekte 
gevallen (gemeten aan het aantal ziekenhuis opnames), therapie trouw van ART, en kwaliteit van 
leven tussen de gebruikers van de traditionele CSB en de nieuwere, duurdere en meer energie 
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geconcentreerde RUFS. De mortaliteit in beide groepen lag, vergeleken met andere ART studies 
uit de regio, aan de hoge kant van het spectrum. Deze studie was aanvankelijk opgezet met een 
controle groep die geen voedingssupplentatie zou krijgen, maar dit werd ethisch gezien onverant-
woord geacht in verband met het feit dat voedingssuppletie in Malawi als standaard behandeling 
was geïntroduceerd voor vermagerde HIV patiënten. 
De vraag blijft echter bestaan of voedingssuppletie, die gepaard gaat met relatief hoge kosten, 
in deze populatie klinische voordelen biedt. Om hier meer inzicht in te krijgen voerden wij een 
retrospectieve studie uit, in hoofdstuk 11, waarbij we de patiënten uit de studie van hoofdstuk 10 
vergeleken met een historische controle groep bestaande uit vermagerde patiënten uit een prospec-
tieve observationele cohort studie van de bijwerkingen en behandelingsresultaten van de eerste lijn 
ART. Deze cohort studie was een jaar eerder uitgevoerd in dezelfde ART kliniek en geen van de 
patiënten ontving voedingssuppletie. Patiënten hadden dezelfde kenmerken aan het begin van de 
ART als de patiënten uit de voedingssuppletie studie. Patiënten die voedingssuppletie ontvingen 
hadden een beter herstel van de voedingstoestand na 14 en 26 weken. Echter er was een onverwachte 
trend in verschil in mortaliteit bij 14 weken en een significant verschil bij 26 weken ten nadele van 
de patiënten die voedingssuppletie ontvingen. Mogelijke verschillen in de patiënten populaties en 
verschillen in de behandeling van patiënten, als gevolg van het gebruik van een historische controle 
groep zouden de verklaring kunnen zijn voor het verschil in mortaliteit. Het is niet waarschijnlijk 
dat de voedingssuppletie zelf hiervoor de oorzaak is. Het belang van deze studie ligt vooral in het 
stimuleren van vervolg onderzoek dat wel een controle groep zonder voedingsinterventie bevat.
Hoofdstuk 12 is een kort verslag van de problemen die we ondervonden bij de introductie van een 
HIV post-expositie profylaxe programma voor ziekenhuis staf in QECH in 2003. Ondanks een 
goede logistieke organisatie en de gratis beschikbare medicatie, die ononderbroken beschikbaar 
was, en de aanwezigheid van 24-uur per dag HIV test mogelijkheden was de acceptatie van het 
programma matig. Dit had te maken met een blijkbaar onvoldoende succesvolle publiciteitscam-
pagne en de geringe bereidwilligheid van ziekenhuis staf een HIV test te ondergaan in hun eigen 
ziekenhuis. Dit geeft aanleiding tot zorg, omdat bleek uit interviews met verpleegkundigen dat 
beroepsmatige verwondingen frequent voorkwamen. Wij gaven een aantal aanbevelingen om deze 
problemen aan te pakken of te voorkomen.
In hoofdstuk 13 toonden we aan dat bloed verkregen door afname middels een prik in de vingertop 
gebruikt kan worden in plaats van bloed van een venepunctie, voor de bepaling van het CD4 getal. 
Dit bewezen we door van 110 volwassen patiënten met verschillende graden van immuun deficiën-
tie capillair bloed en veneus bloed tegelijkertijd af te nemen voor CD4 bepaling. De CD4 waarden 
vertoonden uitstekende overeenkomst zowel wat betreft absoluut CD4 getal als CD4 percentage. 
Aangezien in vergelijking met een venepunctie, een prik in de vingertop makkelijker te verrich-
ten is en meer acceptabel voor lokale patiënten, die deze methode gewend zijn voor malaria tests, 
lijkt dit een geschikte manier voor bloedafname voor snelle CD4 tests die op dit moment worden 
ontwikkeld.
Er blijven veel vragen en uitdagingen bestaan met betrekking tot cotrimoxazol profylaxe en nog 
veel meer aangaande ART in Afrika bezuiden de Sahara. De voor- en nadelen van het continueren 
van cotrimoxazol profylaxe na immuun reconstitutie gedurende ART is een belangrijk onderwerp 
voor een toekomstige klinische studie. Hoewel cotrimoxazol profylaxe veilig gestopt kan worden 
in het westerse patiënten, wanneer tijdens succesvolle ART het CD4 getal stabiel boven de waarde 
van 200 stijgt, kan dit niet zonder meer naar Afrika worden geëxtrapoleerd, aangezien cotrimoxa-
zol profylaxe daar vooral belangrijk is voor het voorkomen van ernstige bacteriële infecties en 
waarschijnlijk malaria (ziekten die ook bij hogere CD4 getallen vaak voorkomen), meer dan voor 
de preventie van PcP en Toxoplasma encephalitis. Een dergelijke studie wordt op dit moment in 
Malawi voorbereid.
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De kennis op het gebied van ART in ontwikkelingslanden heeft nog veel lacunes. Een aantal onder-
werpen heeft hoge prioriteit voor verder onderzoek: ten eerste de vroege mortaliteit gedurende 
ART, waarvan de oorzaken nog onvoldoende bekend zijn. Problemen die optreden tijdens langdu-
rige ART moeten meer aandacht krijgen, op de eerste plaats de diagnose van ART falen en op de 
tweede plaats de problematiek rond mitochondriele toxiciteit ten gevolge van nucleoside reverse-
transcriptase remmers. Diagnostische methoden die zowel kwalitatief goed, goedkoop en lokaal 
toepasbaar zijn, dienen te worden ontwikkeld. Ook de tweede lijn ART en mitochondriele toxiciteit 
behandeling zijn vrijwel niet wetenschappelijk onderbouwd op basis van gegevens uit de regio. 
Gezien de enorme toename van het aantal patiënten op ART en de zeer gebrekkige situatie wat 
betreft de hoeveelheid werknemers in de gezondheidszorg in Malawi en de rest van Afrika bezui-
den de Sahara zijn de uitdagingen voor lokaal werkende wetenschappelijk onderzoekers zowel 
urgent, aantrekkelijk als moeilijk uitvoerbaar.
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